GLP-1 receptor agonists and methods of use

Abstract

The present invention relates to GLP-1 receptor agonists compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, n, p, A, X, Y and B are as defined herein. The present invention also relates to compositions which comprise a GLP-1 receptor agonist compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating obesity or non-insulin-dependent diabetes mellitus (Type 2 diabetes) comprising administering to a patient a therapeutically effective amount of a compound of the invention.

Description

GLP-1 RECEPTOR AGONISTS AND METHODS OF USECROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to and benefit of U. S. Provisional Application Nos. 63 / 712.726, filed October 28, 2024, and 63 / 873,205, filed August 29, 2025, the disclosures of which are hereby incorporated by reference in their entireties.FIELD

[0002] This disclosure relates generally to compounds which are GLP-1 receptor agonists and their uses. A preferred use of GLP-1 receptor agonists is for the treatment of obesity.BACKGROUND

[0003] Glucagon-like peptide- 1 (GLP-1) is a hormone secreted by L cells in the small intestine. GLP-1 consists of 30 or 31 amino acids and acts through the GLP-1 receptor to exert its effects. These effects include promotion of glucose dependent insulin secretion, inhibition of glucagon secretion, delay of gastric emptying, and suppression of feeding. As a result, GLP-1 analogs have been developed as effective therapeutic agents for diabetes and obesity, showing significant benefits in reducing lib Ale levels and promoting weight loss.

[0004] There is a need for small molecule GLP-1 receptor agonists for treating various disorders, including obesity.SUMMARY

[0005] The present invention is directed to compounds which are GLP-1 receptor agonists. The compounds, and their pharmaceutically acceptable salts, are useful, for example, for the treatment of obesity. More particularly, the present invention provides in one embodiment (embodiment no. 1) compounds of Formula I:Ior a pharmaceutically acceptable salt thereof,wherein:R1is halogen, CN, OH, aminoalkyl, hydroxyalkyl, diaminoalkyl, dihydroxy alkyl, Ci-C alkyl, heteroalkyl, Ci-Cg heteroalkyl, Cs-Cs cycloalkyl, 3-10 membered heterocycloalkyl, -C=C-(3-10 membered heterocycloalky l), -C=C-(C3-Cs cycloalkyl), or -phenyl-fCs-Cs cycloalkyl), wherein R1is substituted with 0 to 5 substituents independently selected from halogen, CN, OH, Ci-Cg alkyl. 3-10 membered heterocycloalkyl or Cs-Cs cycloalkyl, wherein the C1-C6 alkyl, 3-10 membered heterocycloalky l or C3-Cs cycloalkyl is substituted with one or more halogen atoms, C1-C2 alkyl, or Ci-Cg alkyloxy;R2is H or methyl;R3is H or methyl;R4is hydrogen or Ci-Ce alkyl;R5is hydrogen or Ci-Cg alkyl; orR4and R5, together with the atom which they are attached, or R4and R6, together with the atom which they7are attached, fomi a bridged C7-C8 heterocyclic ring fused to the pyrazole;each R6is independently H, halo, or Ci-Cg alkyl and each R7is independently' H, halo, or Ci-Cg alkyl, orR° and R' together with the atom to which they are attached, form a Cs-Cg cycloalkyl ring or a 3-6 membered heterocycloalkyl ring, wherein the C<-Cg cycloalky7! ring or the 3-6 membered heterocycloalkyl ring is substituted with 0 or 1 instances of R9, provided that if there are two R6and R7then only one set forms a ring and the other R6and R7is each independently H or Ci-Cg alkyl;R9is H, Ci-Co alkyl, -SO2-(Ci-C alkyl), -((Ci-Cg alkylenyl)OXCi-Cg alkyl), -(Ci-Ce alkylenyl)(C3-C8cycloalkyl), -(C)(O)(Ci-Cg alkyl), -(CH2)aryl, C3-C8cycloalkyl, -(CH2)(C3-Cs cycloalkyl), C(O)Ci-Cg alkyl, -((Ci-Cg alkylenyl)O)t(Ci-Cg alkyl), or S(O)2(Cj-C6 alkvl) whereinone or more of the hydrogen atoms of the Ci-Ce alkyd may be substituted with fluoro or hydroxyl, and 0 or 1 of the carbons of the Ci-Ce alky l form a cyclopropyl ring, and wherein t is 1, 2, 3, 4 or 5;n is 1 or 2;p is I, 2, 3. 4 or 5;R4, R5, R6and R7are each independently substituted with 0 to 2 substituents independently selected from halogen, NH2, aminoalkyd, diaminoalkyl, Ci-Cs alkyl, and Ci-Cs alkyl substituted with one or more halogen atoms, C1-C6 alkoxy, hydroxy, oxo, CONRwlRw2, SO2N Rw3Rw4, SO2R'”'5, N(Rw6)CORw7, NRW8SO2RW9, wherein Rwl, Rw2, Rw3, R'v4, R"'5, Rw6, R'v7. Rw8, and R"'9, are each individually selected from H and Ci-Cg alkyl;A is 5-10 membered heteroaryl or C&-CJO aryl;X is O, S, orNR^ wherein Rxxis H or C1-C3 alkyl, wherein C1-C3 alkyl is substituted with 0, 1, or 2 substituents selected from halogen and C3-C6 cycloalkyl;pyrazole moiety and the right A on Y is bound to B,Z is C, CRxorN;Rxis H. halo, hydroxy, Ci-Cs alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, or -O(C3-Ce cycloalkyl); Ry, and Rz, together wath the atom which they are attached and optionally Rx, form a 5-8 membered heterocycloalkyl ring or a 5-6 membered heteroaryl; orRy, and Rzare each independently H, halo, Ci-Ce alkyl, or C3-C6 cycloalkyl; orRxand Ry, together whh the carbon to which they are attached, form a spiro C3-C6 cycloalkyl ring and Rzis H, halo, or Ci-Ck alkyd; orRxand Rz, together with the carbon to which they are attached, form a spiro Cs-Ce cycloalky l ring and Ryis H, halo, or C1-C6 alkyl; andB is C3-C8 cycloalkyl, 5-13 membered heterocycloalkyd, and or heteroan 4, and B is substituted by 0, 1, 2, or 3 substituents, each independently selected from C1-C3 alkyl, -O(Ci-Ce alkyd), -(Ci-C<; a1kylenyl)-O(Ci-C3 alkyl), -(Ci-Ce alkylenyl)-O(Ci-C6 alkylenyl)-O(Cj-C3 alkyl), halogen, heteroalkyl, hydroxyl, 5-9 membered heterocycloalkyl, -O(C3-Ce cycloalkyd), C3-C6 cycloalkyL 5-9 membered heteroaryl, 5-9 membered aryl, -0(C6-Cio aryl), and phosphorus atom substituted with oxo and / or C1-C3 alkyl, wherein one or more of the hydrogen atoms of the C1-C3 alkyd, Ci-Cfi alkyl or heteroalkyl may be substituted with deuterium or fluoro and wherein the 5-9 membered heterocycloalkyl, 5-9 membered heteroaryl or 5-9 membered aryl is substituted with 0, 1, 2, or 3 substituents independently selected from -C1-C3 alkyl, -C1-C3 haloalkyl, -C -C6 cycloalkyl, and oxo;R8is Ci-Cg alkyl, 5-6 membered heterocycloalkyl, heteroaryl, or aryl, and R8is substituted by 0.1, 2. or 3 substituents, each independently selected from C1-C3 alky L C3-C6 cycloalkyl, (MC3-C6 cycloalkyl), phenyl, halogen, SO2CII3 and oxo, wherein one or more of the hydrogen atoms of the C1-C3 alkyl or C3-C6 cycloalkyl may be substituted with fluoro or chloro; oraryl, heteroaryl, 4-10 membered heterocycloalkyl, C3-C10 cycloalkyd, wherein R8bis substituted by 0, 1, 2 or 3 substituents, each independently7selected from C1-C3 alkyl, halogen, and oxo, wherein one or more of the hydrogen atoms of the C1-C3 alkyl may be substituted with fluoro or ochloro; optionally, wherein if R8ais I, then R8bis heteroaryl or 4-10 membered heterocycloalkyl with at least one nitrogen, and R8aforms abend with the nitrogen of the heteroaryl or 4-10 membered heterocycloalkyl;wherein R8c, when present, is Ci-Ce alkyl, substituted with 0, 1, 2, or 3 substituents independently selected from halogen, Cs-Cg cycloalkyl, phenyl or 3-8 membered heterocycloalkyl;optionally, wherein at least one of (a)-(h) is true:(a) R8is other than optionally substituted Cg-io ary l and optionally substituted or 5 to 10 membered heteroaryl;(b) Y is other than, wherein the left Y on Y is bound to the pyrazole moiety and the right Y on Y is bound to B;(c) R1is other than optionally substituted 3 to 10 membered heterocycloalkyl and 5 to 10 membered heteroaryl;(d) n is 1 and R6is Ci-Cg allyd and R7is C1-C0 alkyd, or(e) n is 1 and R6and R7together with the atom io which they are attached, form a Cs-Cg cycloalkyl ring or a 3-6 membered heterocycloalkyl ring;(f) n is 2;wherein the lefton Y is bound to the pyrazole moiety’ and the right T on Y is bound to B; andpyrazole moiety' and the right is bound to B and R20is selected from C1-C3 alkyl or cyclopropyl.

[0006] The invention also includes compositions comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further includes methods for treating obesity by administration of a compound of Formula I, or a pharmaceutically acceptable salt thereof, to a patient in need thereof, or by administration of a pharmaceutical composition comprising a compound of Formula I or its salt and a pharmaceutically acceptable carrier.

[0007] The summary of the technology described above is non-limiting and other featur es and advantages of the technology' will be apparent from the following detailed description, and from the claimsDETAILED DESCRIPTION

[0008] As noted above, the present invention includes compounds of Formula I, wherein the compounds are GLP-1 receptor agonists suitable for use for the treatment of obesity.

[0009] Unless otherwise designated, reference to a compound of the Formula I, as used herein, includes compounds of the Formulas 1, la, II, Ila, III, IV, IV a, IVb, V, Va, Vb, VI, Via, VIb, VII, Vila, VIII, IX, IXa, IXb, X, Xa and Xb.

[0010] The present invention encompasses for each of the various embodiments of the compounds of the invention described herein, including those of Formula I, and the various embodiments thereof and the compounds of the examples, all forms of the compounds such as. for example, any solvates, hydrates, stereoisomers, and tautomers of said compounds and of any pharmaceutically acceptable salts thereof, unless otherwise indicated. Additionally, in the examples described herein, the compounds of the invention may be depicted in the salt form. In such cases, it is to be understood that the compounds of the invention include the free acid or free base forms of such salts, and any pharmaceutically acceptable salt of said free acid or free base forms. In addition, in instances where an acidic group such as tetrazole and a basic group such as an amine are present within the same compound, these compounds may be drawn herein for convenience as the free acid and base forms but it should be understood that these can also be alternatively depicted in their zwitterionic forms in which the tetrazole bears a negative charge and the amine bears a positive charge, which are also included as compounds of the invention.

[0011] In one aspect, the present invention includes compounds of Formula I:Ior a pharmaceutically acceptable salt thereof, wherein R1, R2, RJ, R4, R3, R6, R7, R8, n, p. A, X, Y and B are as defined herein for the compounds of Formula (I) in embodiment no. 1 (i.e., as defined in the Summary of the Invention): wherein the compounds may be suitable for use for the treatment of obesity,

[0012] In embodiment no. 2, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:R1is halogen, CN, OH, aminoalkyl, hydroxyalkyl, diaminoalkyl, dihydroxyalkyl, Ci-Ce alkyl, heteroalkyl, C?.-Cs cycloalkyl, 3-10 membered heterocycloalkyl, -C=C-(3-I0 memberedheterocycloalkyl), -C=C-(C3-Cs cycloalkyl), or -phenyl-(C3-Cs cycloalkyl), wherein R1is substituted with 0 to 5 substituents independently selected from halogen, CN, OH, Ci-Cs alkyl, Ci-C'6 alkyl substituted with one or more halogen atoms, or Ci-Ce alkyloxy;R2is II or methyl;R3is H or methyl;R4is hydrogen or Ci-Ce alkyl;R5is hydrogen or Ci-Ce alkyl; orR4and R5, together with the atom which they are attached, or R4and R6, together with the atom which they are attached, form a bridged C?-Cs heterocyclic ring fused to the pyrazole;each R6is independently H, halo, or Ci-Ce alkyl and each R7is independently H, halo, or Ci-Ce alkyl, orR6and R' together with the atom to which they are attached, form a C3-C6 cycloalkyl ring or a 3-6 membered heterocycloalkyl ring, provided that if there are two R6and R7then only one set forms a ring and the other R6and R7is each independently H or Ci-C'6 alkyd;n is 1 or 2;p is 1, 2, 3. 4 or 5;R4, R5, R6and R7are each independently substituted with 0 to 2 substituents independently selected from halogen. M b. aminoalkyl, diaminoalkyl, Ci-C& alkyl, and C1-C& alkyl substituted with one or more halogen atoms, Ci-Ce alkoxy, hydroxy, oxo, CONRwlRw2, SO? N Rw3Rw4, SO2Rw5, N(RW6)CORW7, NRW8SO2R"9, wherein Rwl. Rw2, Rw3, Rw4, Rw5, Rw6, Rw7, Rw8, and R*9, are each individually selected from H and Ci-Ce alkyl;A is 5-10 membered heteroaryl or C5-C10 an. 1.X is O, S. or NR® wherein Rxxis H or C1-C3 alkyl, wherein C1-C3 alkyl is substituted with 0, 1, or 2 substituents selected from halogen and C3-C6 cycloalkyl;pyrazolopyridine structure and the right X is bound to B,Z is C, CRxorN;Rxis H, halo, or Ci-Ce alkyl;Ry, and Rz. together with the atom which they are attached and optionally Rx, form a 5-8 membered heterocycloalkyl ring or a 5-6 membered heteroaryl; orRy. and Rzare each independently H, halo, or Ci-Cs alkyl; orRxand Ry, together with the carbon to which they are attached, form a spiro C -C6 cycloalkyl ring and Rzis H, halo, or Ci-Cs alky l; orRxand Rz, together with the carbon to which they are attached, form a spiro C3-C6 cycloalkyi ring and Ryis H. halo, or Ci-Ce alkyl; andB is C3-C8 cycloalkyl, 5-13 membered heterocycloalkyl, aryl or heteroaryl, and B is substituted by 0, 1, 2, or 3 substituents, each independently selected from C1-C3 alkyl, halogen, heteroalkyl, 6-9 membered heterocycloalkyl, -O(C3-C6 cycloalkyl), C3-C6 cycloalkyi, 5-9 membered heterocycloalkyl, -0(C6-Cio aryl), and phosphorus atom substituted with oxo and / or C1-C3 alkyd, wherein one or more of the hydrogen atoms of the C1-C3 alkyl or heteroalkyl may be substituted with fluoro and wherein the 5-9 membered heterocycloalkyl may be unsubstituted or substituted with 1, 2, or 3 substituents independently selected from -C1-C3 alkyl, -C1-C3 haloalkyl, -C3-C6 cycloalkyi, and oxo;Rsis Ci-Ce alkyl, 5-6 membered heterocycloalkyl, heteroaryl, or aryl, and R8is substituted by 0.1, 2, or 3 substituents, each independently selected from C1-C3 alkyl, Cs-Ce cycloalkyi, O / Cs-Ce cycloalkyi), phenyl, halogen, SO2CH3 and oxo, wherein one or more of the hydrogen atoms of the C1-C3 al kyl or C3-C6 cycloalky i may be substituted with fluoro or chloro; oraryl, heteroaryl, 4-10 membered heterocycloalkyl, C3-C10 cycloalkyi, wherein R8bis substituted by 0, 1, 2 or 3 substituents, each independently selected from C1-C3 alkyl, halogen, and oxo, wherein one or more of the hydrogen atoms of the C1-C3 alkyl may be substituted with fluoro orchloro; wherein if R8ais, then R8bis heteroary l or 4-10 membered heterocycloalkyl with at least one nitrogen, and Rsbforms a bond with the nitrogen of the heteroaryl or 4-10 membered heterocycloalkyl;wherein R80, when present, is Ci-Cs alkyl, substituted with 0. 1, 2, or 3 substituents independently selected from halogen, C3-C6 cycloalkyi, phenyl or 3-8 membered heterocycloalkyl;optionally, wherein at least one of (a)-(f) is true:(a) R8is other than optionally substituted Ce-io aryl and optionally substituted or 5 to 10 membered heteroaryl;structure and the right A is bound to B, andnxl is an integer of 1 to 3;nx2 and nx3 are independently an integer of 1 to 10;Rlxis hydrogen, Ci-Cr, alkyl, or (Ct-Cs alkyl)carbonyl;R2Xand R3Xare independently hydrogen or Ci-Cs alkyl;(c) R1is other than optionally substituted 3 to 12 membered heterocycloalkyl and 5 to 10 membered heteroaryl;(d) n is 1 and R6is Ci-C, alkyl and R7is Ci-C& alkyl, or(e) n is 1 and R6and R7together with the atom to which they are attached, form a C.v-Cs cycloalkyl ring or a 3-6 membered heterocy cloalkyl ring; and(f) n is 2,

[0013] In embodiment no. 3, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula la,and R1, R4, R5, R6, R7, Rs, n, p, A, X, Y and B are as defined in embodiment no. 1.

[0014] In embodiment no. 4, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula 1 has the Formula 11IIand R1. R2. R3, R4, R5, R6, R7, R8, n, p, X, Y and B are as defined in embodiment no. 1.

[0015] In embodiment no. 5, the present invention provides a compound of Formula Ila, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula Ila,and R1, R2, R3, R’, R5, R6, R7, Rs, n, p, X, Y and B are as defined in embodiment no. 1.

[0016] In embodiment no. 6, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula III,and R1. R4. R5. R6. R7, R8, n. X, Y and B are as defined in embodiment no. 1 and Rzland Rz2are as defined below.

[0017] In embodiment no. 7, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula IV.and R1, R2, R3, R4, R5, R6, R7, R8, n, p, X, and B are as defined in embodiment no. 1.

[0018] In embodiment no. 8. the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula IVa,and R1, R4. R3, R6, R7, R8, and B are as defined in embodiment no. 1.

[0019] In embodiment no. 9, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula IVb,and R1. R4. R5. R6. R7, R8, and B are as defined in embodiment no. 1.

[0020] In embodiment no. 10, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula V,and R1, R2, R3, R4, R5, R6, R7, R8, n, p, X, and B are as defined in embodiment no. 1.

[0021] In embodiment no. 11, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula Va.and R1, R4, R5, R6, R7, R8, and B are as defined in embodiment no. 1.

[0022] In embodiment no. 12, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula Vb,and R1. R4. R5. R6. R7, R8, and B are as defined in embodiment no. 1.

[0023] In embodiment no. 13, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formulaand R1, R2, R3, R4, R5, R6, R7, R8, n, p, X, and B are as defined in embodiment no. 1.

[0024] In embodiment no. 14, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula Via,and R1, R4, R5, R6, R7, R8, and B are as defined in embodiment no. 1.

[0025] In embodiment no. 15, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula VIb,and R1, R4, R5, R6, R7, R8, and B are as defined in embodiment no. 1.

[0026] In embodiment no. 16, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula VII,and R1, R2, R3, R4, R5, R6, p, A, X, Y and B are as defined in embodiment no. 1.

[0027] In embodiment no. 17, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula Vila,and R1, R2, R3, R4, R5, R8, p, A, X, Y and B are as defined in embodiment no. 1.

[0028] In embodiment no. 18, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula VIII.and R1, R2, R3, R4, R5, R6, R7, R8, Y and B are as defined in embodiment no. 1.

[0029] In embodiment no. 19, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula IX,and R1, R2, R3, R4, R5, R6, R7, R8, n, p, X, and B are as defined in embodiment no. 1.

[0030] In embodiment no. 20, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula IXa,and R1, R4, R5, R6, R7, R8, and B are as defined in embodiment no. 1.

[0031] In embodiment no. 21, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof wherein the compound of Formula I has the Formula IXb,and R1, R4, R5, R6, R7, R8, and B are as defined in embodiment no. 1.

[0032] In embodiment no. 22, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula X,and R1, R2, R3, R4, R5, R6, R7, R8, n, p, X, and B are as defined in embodiment no. 1.

[0033] In embodiment no. 23, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula Xa,and R1, R4, R5, R6, R7, R8, and B are as defined in embodiment no. 1.

[0034] In embodiment no. 24, the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula Xb,and R1, R4, R5, R6, R7, R8, and B are as defined in embodiment no. 1.

[0035] In embodiment no. 25, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-3, or a pharmaceutically acceptable salt thereof, wherein A is 6-9 membered heteroaryl or C5-C7aryl.

[0036] In embodiment no. 26, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-3 or a pharmaceutically acceptable salt thereof, wherein A is

[0037] In embodiment no. 27, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-5 and 7-24, or a pharmaceutically acceptable salt thereof, wherein

[0038] In embodiment no. 28, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-5 and 7-24, or a pharmaceutically acceptable salt thereof, wherein A is

[0039] In embodiment no. 29, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-5 and 7-24, or a pharmaceutically acceptable salt thereof, wherein A is

[0040] In embodiment no. 30, the present invention provides a compound of Formula I as set forth in embodiment no. 28, or a pharmaceutically acceptable salt thereof, wherein

[0041] In embodiment no. 31, the present invention provides a compound of Formula I as set forth in embodiment no. 29, or a pharmaceutically acceptable salt thereof, wherein

[0042] In embodiment no. 32, the present invention provides a compound of Formula I as set forth in embodiment no. 31, or a pharmaceutically acceptable salt thereof, wherein

[0043] In embodiment no. 33, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-24, or a pharmaceutically acceptable salt thereof, wherein R1is 6-10 membered heterocycloalkyl or Cg-Cs cycloalkyl, wherein R1is substituted with 0 to 5 substituents independently selected from a halogen, C1-C6alkyl, C1-C6alkyl substituted with one or more halogen atoms, and C1-C6alkoxy.

[0044] In embodiment no. 34, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-24, or a pharmaceutically acceptable salt thereof, wherein R1is 6-10 membered heterocycloalkyl wherein R1is substituted with 0 to 2 substituents independently selected from Ci-Cs alkyl.

[0045] In embodiment no. 35, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-24, or a pharmaceutically acceptable salt thereof, wherein R1is 6-10 membered heterocycloalkyl, wherein R1is substituted with two methyl groups.

[0046] In embodiment no. 36, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-24. or a pharmaceutically acceptable salt thereof, wherein R1is 6-10 membered heterocycloalkyl containing one or two oxygen atoms as ring members, wherein R1is substituted with 0 to 3 substituents independently selected from OH, Ci-Cs alkyl, or C1-C6alkyloxy,

[0047] In embodiment no. 37, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-24. or a pharmaceutically acceptable salt thereof, wherein R1is C3-C8cycloalkyl, wherein R1is substituted with 0 to 2 substituents independently selected from OH and C1-C6alkoxy.

[0048] In embodiment no. 38, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-24, or a pharmaceutically acceptable salt thereof, whereinalkyl.

[0049] In embodiment no. 39, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-24, or a pharmaceutically acceptable salt thereof, whereinhalogen, or C1-C6alkyl and Rz2is H, halogen or C1-C6alkyl, and ZZ is N.

[0050] In embodiment no. 40, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-24. or a pharmaceutically acceptable salt thereof, wherein R1is tetrahydropyranyl, wherein R1is substituted with 0 or 2 methyl groups.

[0051] In embodiment no. 41, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-5 and 7-24, or a pharmaceutically acceptable salt thereof,

[0052] In embodiment no. 42, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-5 and 7-24, or a pharmaceutically acceptable salt thereof,halogen, C1-C6alkyl, C1-C6alkyl substituted with one or more halogen atoms, and C1-C6alkoxy.

[0053] In embodiment no. 43, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-5 and 7-18, or a pharmaceutically acceptable salt thereof,

[0054] In embodiment no. 44, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-5 and 7-24, or a pharmaceutically acceptable salt thereof,

[0055] In embodiment no. 45, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-5 and 7-24, or a pharmaceutically acceptable salt thereof,

[0056] In embodiment no. 46, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-2, 4-5, 7, 10, 13, and 16-18, 20, 23 and 25-45, or a pharmaceutically acceptable salt thereof, wherein R2is H and R3is H.

[0057] In embodiment no. 47, the present invention provides a compound of Formula I as set forth in any one of embodiment nos.1-2. 4-5, 7, 10, 13, and 16-18, 20, 23 and 25-45, or a pharmaceutically acceptable salt thereof wherein R2is H and R is methyl.

[0058] In embodiment no. 48, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-47, or a pharmaceutically acceptable salt thereof, wherein R4is hydrogen, methyl, or ethyl:R5is hydrogen or methyl:R and R5, together with the atom which they are attached, or R4and R6, together with the atom which they are attached, form a bridged C7-8 heterocyclic ring fused to the pyrazole; andRcis H, halo, or methyl, and R7is H, halo, or methyl, orR6and R7together with the atom to which they are attached, form a cyclopropyl ring or a cyclobutyl ring provided that if there are two R6and R7then only one set forms a ring and the other R6and R' is each independently H or methyl.

[0059] In embodiment no. 49, the present invention provides a compound of Formula I as set forth in embodiment no. 48, or a pharmaceutically acceptable salt thereof, wherein R4is hydrogen or methyl.

[0060] In embodiment no. 50, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-48, or a pharmaceutically acceptable salt thereof, wherein R4is methyl.

[0061] In embodiment no. 51, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-50, or a pharmaceutically acceptable salt thereof, wherein R5is H.

[0062] In embodiment no. 52, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-48, or a pharmaceutically acceptable salt thereof, wherein R4is methyl and R5is H

[0063] In embodiment no. 53, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-7, 10, 13, and 25-52. or a pharmaceutically acceptable salt thereof, wherein R6is methyl, R7is methyl, and n = I.

[0064] In embodiment no. 54, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-7, 10, 13, and 25-52. or a pharmaceutically acceptable salt thereof, wherein R6is halo, R' is halo, and n = 1

[0065] In embodiment no. 55, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-7, 10, 13, and 25-52, or a pharmaceutically acceptable salt thereof, wherein R6is fluoro, R7is fluoro, and n = 1,

[0066] In embodiment no, 56, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-15, 18-48 and 51, or a pharmaceutically acceptable salt thereof, wherein R4and R6, together with the atom to which they are attached, form a bridged C7-s heterocyclic ring fused to the pyrazole.

[0067] In embodiment no. 57, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-7, 10, 13, 25-48 and 5118-34 and 36, or a pharmaceutically acceptable salt thereof, wherein R4and R6, together with the atom to which they are attached, form a bridged C7-8 heterocyclic ring fused to the pyrazole. and n = I.

[0068] In embodiment no. 58, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-15, and 25-49, or a pharmaceutically acceptable salt thereof, wherein R4and R5, together with the atom to which they are attached, form a bridged C7-s heterocyclic ring fused to the pyrazole.

[0069] In embodiment no. 59, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-7, 10, 13, and 25-49. or a pharmaceutically acceptable salt thereof, wherein R4and R \ together with the atom to which they' are attached, form a bridged C7-8 heterocyclic ring fused to the pyrazole, and n=l.

[0070] In embodiment no. 60, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-7, 10, 13, 25-52, 56 and 58, or a pharmaceutically acceptable salt thereof, wherein n is 1.

[0071] In embodiment no. 61, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-7, 10, 13, 25-52, 56 and 58, or a pharmaceutically acceptable salt thereof, wherein n is 2.

[0072] In embodiment no. 62, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-47, or a pharmaceutically acceptable salt thereof, wherein

[0073] In embodiment no, 63, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-47, or a pharmaceutically acceptable salt thereof, wherein

[0074] In embodiment no. 64, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-47. or a pharmaceutically acceptable salt thereof, wherein

[0075] In embodiment no. 65, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-47, or a pharmaceutically acceptable salt thereof, wherein

[0076] In embodiment no. 66, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-47. or a pharmaceutically acceptable salt thereof, wherein

[0077] In embodiment no. 67, the present invention provides a compound of Formula I as set forth in embodiment no. 66, or a pharmaceutically acceptable salt thereof, whereinand Xcis O or NR9wherein t is 1, 2, 3, 4 or 5 and R9is H, Ci-Cg alkyl, SO2-(Ci-Ce alkyd), ((Ci-C6alkylenyl)O)t(Ci-C6 alkyl), -(Ci-C6alkylenylXCs-Cscycloalkyl), -(C)(O)(Ci-C6alkyl), -(CH2)aryl, C?,-Cs cycloalkyl. -(CH^JfCa-Cgcycloalkyl), or Ci-Cg alkyd wherein one or more of the hydrogen atoms of the Ci-Ce alky l may be substituted with fluoro. In embodiments. Xcis O, NH, N(Ci-Ce alkyl). N(C)(O)(CI-C6 alkyd), N(SO2-(Ci-Ce alkyd), or N((Ci-Cs alkylenyl)O)t(Ci-C6 alkyl), wherein t is 1, 2, 3, 4 or 5.

[0078] In embodiment no, 68, the present invention provides a compound of Formula I as set forth in embodiment no. 67, or a pharmaceutically acceptable salt thereof, wherein X“ is NR9and R9is (Ci-C6alkylenyl)(C3-C8cycloalkyl), Cj-C3cycloalkyl, C(O)Ci-C6alkyl, -((Ci-C6alkyl eny])O)t(Ci-Cf, alkyl), or SfOHCj -Ce alkyl) wherein one or more of the hydrogen atoms of the Ci-Ce alkyl may be substituted with fluoro or hydroxy, and wherein t is 1, 2, 3, 4 or 5.

[0079] in embodiment no. 69, the present invention provides a compound of Formula I as set forth in embodiment no. 67, or a pharmaceutically acceptable salt thereof, wherein Xcis NR andR9is -(CH2)an'L -(CH2)(C.-C8cycloalkyl), or Ci-Ce alkyl wherein one or more of the hydrogen atoms of the Ci-Ce alkyl may be substituted with fluoro.

[0080] In embodiment no. 70, the present invention provides a compound of Formula I as set forth in embodiment no. 67, or a pharmaceutically acceptable salt thereof wherein Xcis NR9and R9is H, CH2CF3, CH2CHF2, CH2C(CH3)2OH, cyclopentyl, phenylmethyl, C(O)CH3,

[0081] In embodiment no. 71, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-47. or a pharmaceutically acceptable salt thereof, w'hereinand X° is O, NH. MCb-Ce alkyl), N(C)(O)(CI-C6alkyl), or N(SO2-(CI-C6 alkyl).

[0082] In embodiment no. 72, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-71, or a pharmaceutically acceptable salt thereof, whereinand Xcis O, NH, N(CI-C6alkyl), N(C)(O)(CI-C6alky 1), or N(SO2-(CI-C6alkyl).

[0083] In embodiment no. 73, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-71, or a pharmaceutically acceptable salt thereof, w'hereinand Xcis O, NH, N(CI-C6alkyl), N(C)(O)(CI-C6alkyl), or N(SO2-(CI-C6alkyl).

[0084] In embodiment no. 74, the present invention provides a compound of Formula 1 as set forth in any one of embodiment nos. 1-47, or a pharmaceutically acceptable salt thereof, w'hereinand Xcis O, NH, N(CI-C6alkyl), NC(O)(CI-C6alkyl), or NSO2(CI-C6alkyl).

[0085] In embodiment no. 75, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-74. or a pharmaceutically acceptable salt thereof, wherein

[0086] In embodiment no. 76, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-5, 7, 10, 13, 16-17, 19, 22 and 25-75, or a pharmaceutically acceptable salt thereof, wherein X is O.

[0087] In embodiment no. 77, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-5, 7, 10, 13, 16-17, 19, 22 and 25-75, or apharmaceutically acceptable salt thereof, wherein X is:::NCI13 or

[0088] In embodiment no. 78, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-77, or a pharmaceutically acceptable salt thereof, wherein R4, R5, R6and R7are each independently substituted with 0 to 2 substituents independently selected from halogen. NH2. aminoalkyl, diaminoalkyl, Ci-Ce alkyl, and Ci-Ce alkyl substituted with one or more halogen atoms, C1-C6 alkoxy, and hydroxy.

[0089] In embodiment no. 79, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable salt thereof, wherein Ry, and Rz, together with the atom which they are attached, form a 5-7 membered heterocycloalkyl ring or a 5-6 membered heteroaryl.

[0090] In embodiment no. 80, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable salt thereof wherein Rzis H,[0091 J In embodiment no. 81, the present invention provides a compound of Formula 1 as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable salt R IyR IzRyRI izthereof, wherein Y isZ is CRX, and Rxis H, halo, or CH3;

[0092] In embodiment no. 82, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable saltthereof, wherein

[0093] In embodiment no. 83, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1 -6, 1 - 18 and 25-78, or a pharmaceutically acceptable salt thereof, whereinalternative embodiment, Rxis H, halo, or Ci-Ce alkyl. In another alternative embodiment, Ry, and Rzare each independently H, halo, or Ci-Ce alkyl.

[0094] In embodiment no. 84, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable saltthereof, whereinor s, andRx, Ry, and Rzare each independently H, halogen, or CH3. In a class of this embodiment, the halogen is fluoro.

[0095] In embodiment no. 85, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable saltthereof, whereintogether with the carbon to which they are attached, form a spiro cyclopropyl ring and Rzis H, fluoro, or methyl.

[0096] In embodiment no. 86, the present invention provides a compound of Formula 1 as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable saltthereof, wherein

[0097] In embodiment no. 87, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable saltthereof, whereinare each independently H, halogen, orCH3. In other embodiments,together with the atomwhich they are attached, form a 5-8 membered heterocycloalkyl ring, for example

[0098] In embodiment no. 88, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable saltRx, Ry, and Rzare each independently H. halogen, or CH3.

[0099] In embodiment no. 89, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable salt thereof, whereinX1is N or C(H);X2is N or C(H);X* is N or C(H);Xb is N or C(H); andXo is N or C(H).

[0100] In embodiment no, 90, the present invention provides a compound of Formula I as set forth in embodiment no. 89, or a pharmaceutically acceptable salt thereof, wherein at least one of X1or X2is N.

[0101] In embodiment no. 91, the present invention provides a compound of Formula I as set forth in embodiment no. 89, or a pharmaceutically acceptable salt thereof, wherein at least one of Xa, Xb, and Xcis N.

[0102] In embodiment no. 92, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable salt thereof, whereinare nitrogen and the remaining are C(H).

[0103] In embodiment no. 93, the present invention provides a compound of Formula I as set forth in embodiment no. 92, or a pharmaceutically acceptable salt thereof, whereinone or two of Xd. Xe. Xf, Xg, and Xh, are nitrogen and the remaining are C(H).

[0104] In embodiment no 94, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable salt thereof, whereinY is

[0105] In embodiment no. 95, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable salt thereof, wherein

[0106] In embodiment no. 96 the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable salt thereof, whereinY is

[0107] In embodiment no. 97, the present invention provides a compound of Formula 1 as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable salt thereof, wherein Y is:

[0108] In embodiment no. 98, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable saltthereof, wherein Y is:

[0109] In embodiment no, 99, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable saltthereof, wherein Y is:

[0110] In embodiment no. 100, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable saltthereof, wherein Y is:

[0111] In embodiment no. 101, the present invention provides a compound of Formula 1 as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable saltthereof, wherein Y is:

[0112] In embodiment no. 102, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable salt thereof, wherein Y is:

[0113] In embodiment no, 103. the present invention provides a compound of Formula 1 as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable salt thereof, wherein Y is:

[0114] In embodiment no. 104, the present invention provides a compound of Formulal as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable saltthereof, wherein Y is:

[0115] In embodiment no. 105, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-6, 16-18 and 25-78, or a pharmaceutically acceptable saltthereof wherein Y is:

[0116] In embodiment no. 106, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-78, or a pharmaceutically acceptable salt thereof, wherein

[0117] In embodiment no. 107, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-78, or a pharmaceutically acceptable salt thereof, wherein

[0118] In embodiment no. 108, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-78. or a pharmaceutically acceptable salt thereof, wherein

[0119] In embodiment no. 109, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-78, or a pharmaceutically acceptable salt thereof, wherein

[0120] In embodiment no. 110, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-78, or a pharmaceutically acceptable salt thereof, whereinY is and B is other than

[0121] In embodiment no. 111, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 98-110, or a pharmaceutically acceptable salt thereof.R2is H;R3is H or methyl;R4is hydrogen, methyl, or ethyl;R5is hydrogen or methyl;or R4and R5, together with the atom which they are attached, or R4and R6, together with the atom which they are attached, form a bridged C7-8 heterocyclic ring fused to the pyrazole; and R6is H, halo, or methyl, and R7is H, halo, or methyl, orR6and R7together with the atom to which they are attached, form a cyclopropyl ring or a cyclobutyl ring provided that if there are two R6and R7then only one set forms a ring and the other R6and R7is each independently H or methyl.

[0122] In embodiment no, 112, the present invention provides a compound of Formula I as set forth in embodiment no. 111, or a pharmaceutically acceptable salt thereof, wherein B is

[0123] In embodiment no. 113, the present invention provides a compound of Formula I as set forth in embodiment no. 114. or a pharmaceutically acceptable salt thereof, wherein

[0124] In embodiment no. 114, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-105, or a pharmaceutically acceptable salt thereof, wherein B is 5-13 membered heterocy cl oalkyl, aryl or heteroaryl, and B is substituted by 0, I or 2 substituents, each independently selected from C1-C3 alkyl, halo, -C1-C0 alkylenyl-O-(Ci-C3 alkyl), C1-C5 alkylenyl-O- C1-C3 alkylenyl-O- C1-C3 alkyd, -(XC1-C3 alky l), -NHfCi-Cs alkyd). -O(C3-C-6 cycloalkyl). 5-9 membered heterocycloalky 1. -OfCe-Cio and), and phosphorus atom substituted with oxo and / or Cj-Cs alkyd, wherein one or more of the hydrogen atoms of the -Ci-C3 alkyd or -O(Ci-C'3 alkyl) may be substituted with fluoro, and wherein the 5-9 membered heterocycloalkyl may be unsubstituted or substituted with 1, 2, or 3 substituents independently selected from -C1-C3 alkyl. -Cj-C?. haloalkyl, and oxo

[0125] In embodiment no. 115. the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-103 and 106, or a pharmaceutically acceptable salt thereof, wherein B is substituted by 1 or 2 substituents, each independently selected from fluoro,methyl, CHF2, CFs, cyclopropyl,

[0126] In embodiment no, 116, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-105 110 and 114-115, or a pharmaceutically acceptable salt thereof, whereinas provided for in embodiments 1-105, 110 or 114-115.

[0127] In embodiment no. 117. the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-105, 110 or 114-115, or a pharmaceutically acceptable salt thereof, wherein B is substituted by 1 or 2 C1-C3 alkyd.

[0128] In embodiment no. 1 18, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-105, or a pharmaceutically acceptable salt thereof, whereinone of Rbband Rbois C1-C3 alkyl or heteroalkyl, and the other is not present,Rbdis hydrogen or halogen,wherein one or more of the hydrogen atoms of the -C1-C3 alkyl or heteroalkyl may be substituted with fluoro.

[0129] In embodiment no. 119, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-105 and 111. or a pharmaceutically acceptable salt thereof, whereinherein at least tw o of B1, B" and B3are CH or CH2, and the third is CH, CH: N or NH, and Rberepresents one, or two optional ring substituents, which can be the same or different at each occurrence and wherein each occurrence of Rbeis independently-selected from C1-C3 alkyl, halo, -O(Ci-C? alkyl), -(){(;-(.. cycloalkyl), 5-9 membered heterocycloalkyl. -0(Ce-Cio aryl) and phosphorus atom substituted with oxo and / or C1-C3 alkyl, wherein one or more of the hydrogen atoms of the -C1-C3 alky-1 or -O(Ci-Cj alky-1) is optionally-substituted with fluoro, and wherein the 5-9 membered heterocycloalkyl may be unsubstituted or substituted with 1, 2. or 3 substituents independently selected from -C1-C3 alkyl. -Ci-Cs haloalkyl, -C3-C6 cycloalkyl, and oxo.

[0130] In embodiment no. 120, the present invention provides a compound of Formula I as set forth in embodiment no. 118, or a pharmaceutically acceptable salt thereof, whereinthe heteroalkyl is -O(Ci-C3 alkyl).[01311 In embodiment no. 121. the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-105, 111 and 119-120, or a pharmaceutically acceptable salt thereof, whereinB is substituted with C1-C3 fluoroalkyl.

[0132] In embodiment no. 122, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-105, 111 and 119-120, or a pharmaceutically acceptable salt thereof, whereinB is substituted by 1 or 2 substituents, each independently selected from fluoro, methyl, -CHF2, CF3, -CH2CF3. -OCF2CF3. -CH2CH2-O-CH2CH2-O-CH3, -CH2CH2-O-CH3, -OCH3, NH(CH3),morpholinyl, 3-methyl-2-oxoimidazolidinyl,

[0013] In embodiment no. 123, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 105, 111 and 119-122, or a pharmaceutically acceptable salt thereof, whereinB is substituted by 1 or 2 substituents, each independently selected from fluoro, methyl, -CHF2, CF3, -CH2CF3, -OCF2CF3, -CH2CH2-O-CH2CH2-O-CH3, -CH2CH2-O-CH3, -OCH3, NH(CH3). 3-methyl-2-oxoimidazolidinyl,

[0134] in embodiment no. 124, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-105 and 111, or a pharmaceutically acceptable salt thereof, wherein B is

[0135] In embodiment no. 125, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-105 and 111, or a pharmaceutically acceptable salt thereof, wherein B is

[0136] In embodiment no. 126, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-105 and 111. or a pharmaceutically acceptable salt thereof, wherein B is

[0137] In embodiment no. 127, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-105 and 111. or a pharmaceutically acceptable salt thereof, wherein B is

[0138] In embodiment no, 128, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-111 and 119-120, or a pharmaceutically acceptable salt thereof, wherein R8is substituted by 1 or 2 substituents, each independently selected from fluoro, methyl, CF3, CHF2, cyclopropyl, cyclopropyloxy, and oxo. In embodiment no, 129, R8is substituted by 1 or 2 substituents, each independently selected from fluoro, methyl, CF3, cy clopropyl, and oxo.

[0139] In embodiment no. 130, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-111 and 119-120, or a pharmaceutically acceptable salt thereof, wherein R8is:

[0140] In a sub-embodiment of embodiment no. 130, wherein R8is:

[0141] In embodiment no. 1 1, the present invention provides a compound of Formula! as set forth in any one of embodiment nos. 1-111 and 119-120, or a pharmaceutically acceptable salt thereof, wherein R8is:

[0142] In embodiment no. 132, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-111 and 119-120, or a pharmaceutically acceptable salt thereof, wherein R8is:

[0143] In embodiment no, 132, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-133, or a pharmaceutically acceptable salt thereof, wherein P is 1.

[0144] In embodiment no. 133, the present invention provides a compound selected from:3-(( 1 S,2S)-1 -(2-((S)-3-(3-(4-fluoro-l-methyI-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyI-4,5,6,7-tetrahydro-2H-pyrazolo 4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methy]cyclopropyl)-1.2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3'-(3-(4-fluoro-I-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-1.2.4-oxadiazol-5(4H)-one:3-((l S,2S)-l-(2-((S)-3-(3-(4-fhioro-l-methy!-lH-indazol-5-yl)-2-oxo-2.3-dihydro-lH-imidazol-l-yl)-2-(4-lluoro-3,5-dimethylphenyl)-4-methyl-2,4,5,6,7,8-hexahydropyrazolo|4,3-c]azepine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2 -methylcyclopropyl)- 1,2, 4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3.5-dimethylphenyl)- 4-methyl-2,4,5,6.7,8-hexahydropyrazolo|4,3-c]a epme-5-carbonyl)-lH-indol-l-yl)-2-methy Icy cl opropy 1 )- 1,2,4-oxadi az.ol-5 (4H)-one,ethyl 2-((S)-3-(3-(4-fluoro-l -methyl- lH-indazoI-5-yl)-2-oxo-2.3-dihydro-lH-imidazol-l-yl)-4-methyl-5-(l-((lS,2S)-2-methyl- 1 -(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)acetate;(S)-3-(l-(5-bromo-2-(3-(3-(4-fluoro-l-nietliyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-irmdazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)cy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-benzyl-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-telrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)- 5-(tetrahydro-2H-pyran-4-yl)- IH-indol- 1 -yl)-2-methy 1 cyclopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-((l S,2S)-l-(2-((S)-2-((S)-l-cyclopropylethyl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazoI-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c] pyridine-5-carbony l)-5-(tetrahydro-2H-py ran-4-y 1)- IH-indol- 1 -yl)-2-methylcy clopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-(( 1 S,2S)-1 -(2-((S)-2-((R)-l -cyclopropylethyl)-3-(3-(4-fluoro- 1 -methyl- 1 H-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imid zol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c|pyiidine-5-c rbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyraii-4-yl)-2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-2-(2-methyl-2-(methylsulfonyl)propyl)-4,5,6,7-tetTahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcy clopropyl)-!,2,4-oxadiazol-5(4H)-one;3-(( 1 S,2S)- 1 -(5-(2.2-dimethyltetraliydro-2H-pyran-4-yl)-2-((S)-2-( 1, 1 -dioxidotetraliydro-2H-thiopyran-4-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methy1-4,5,6,7-tetrahydro-2H-pyrazo1o[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yr)-2-methylcyclopropyl)- 1,2,4-oxadiazol-5 (4H)-one;3-((lS,2S)-l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-iridazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yI)-4-melhyl-2-((3-melhyl-l,l-dioxidothietan-3-yl)methyI)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)- IH-indol- l-yl)-2-methy Icy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(5-((S)-2.2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3'-(3-(4-fluoro- 1-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-iiTiidazol-l-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4'.5',6'-tetraliydrospiro|cyclopropane-l,7'-pyrazolo[4,3-c|pyridine]-5'-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazoI-5(4H)-one;3-((lS,2S)-l-(5-((S)-2.2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-irnidazol-l-yl)-2-(4-fluoro-3,5-dimethylplienyl)-4,7,7-trimethyl-4;5,6,7-tetrahydro-2H-pyrazolo[4;3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)- 1,2,4-oxadiazol-5(4H)-one;(4'S)-5'-(5-(2,2-dimetliyltetraliydro-2H-pyran-4-yl)-l-((lS,2S)-2-metliyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyciopropyl)-lH-indole-2-carbonyl)-3'-(3-(4-fluoro-l-methyl-lH-indazo]-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4' -methyl-2',4',5',6'-tetrahydrospiro[cyclobutane-l,7'-pyrazolo[4,3-c]pyridin]-r-ium;3-((lS,2S)-l-(2-((S)-3'-(3-(4-nuoro-l-niethyl-lH-indazol-5-yl)-2-oxo-2,3-diliydro-lH-imidazol-l-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2'.4',5',6'-tetrahydrospiro[cyclobutane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcycIopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3'-(3-(4-fluoro-l-(2-methoxy ethyl)-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazoI-l-yl)-2'-(4-fluoro-3, 5-dimethylphenyl)-4'-methyl-2'54',5'.6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyI)- IH-indol-l -yl)-2-metliylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-(2,2-dimethyltetraliydro-2H-pyran-4-yl)-2-((S)-3'-(3-(4-fluoro-2-(2-methoxy ethyl)-2H-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2'-(4-fluoro-3, 5-dimethylphenyl)-4'-methyl-2',4'.5\6'-tetrahydrospiro[cyclopropane-1.7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS;2S)-l-(5-(2:,2-dimethyltetrahydro-2I-I-pyran-4-yl)-2-((S)-3'-(3-(4-fluoro-l-(2-(2-methoxy ethoxy )ethy])-lH-indaz,ol-5-yl)-2-oxo-2,3-dihydro-lH-imidaz.ol-l -yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4’-methyl-2',4'.5'.6'-tetr hydrospiro[cyclopropane-1.7'-pyrazolo[4,3-c]pyndine]-5'-carbonyl)-lH-mdol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(( 1 S.2S)-1 -(2-((S)-3'-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2,2',3,4'.5,5',6,6'-octahydrospiro[pyran-4,7'-pyrazolo[4,3-c]pyndine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-1.2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((S)-l-cyclopropyl-2,2,2-trifluoroethyl)-3-(3-(4-fluoro-l-methyl-lH-indazoI-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-IH-mdol-l-yJ)-2-methylcyclopropyl)-!, 2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((R)-l-cyclopropyl-2,2,2-trifluoroethyl)-3-(3-(4-fluoro-l -methyl-! H-mdazoi-5-yl)-2-oxo-2,3-dihydro-lII-imidazol-l-yl)-4-methyl-4,5,6,7-tetraliydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyran-4-y1)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((R)-l-cyclopropylethyl)-3-(3-(4-fluoro-l-inethyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazoI-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((S)-2,2-dimetliyltetraliydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2,4-oxadiazol-5(4H)-one or 3-((! S,2S)-l-(2-((S)-2-((S)-l-cyclopropylethyl)-3-(3-(4-fluoro-l -methyl- 1 H-indazol-5-yl)-2-oxo-2,3-dihydro-l H-imidazol-1 -yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((S)-2,2-dirnethylietrahydro-2H-pyran-4-yl)-lH-iiidol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((l S,2S)-l-(2-((S)-2-((R)-l-cyclopropylethyl)-3-(3-(4-fluoro-l -methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methy Icy cl opropy 1 )- 1,2,4-oxadi azol-5 (4H)-one:3-((lS,2S)-l-(2-((S)-2-((S)-l-cyclopropylethyl)-3-(3-(4-fluoro-l -methyl- lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c|pyridine-5-carbonyl)-5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-! H-indol-l-yl)-2-methylcyclopropyl)- 1,2,4-oxadiazol-5(4H)-one:3-(( 1 S.2S)- 1 -(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S )-2-((S)~ 1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-3-(3-(4-fluoro-l-methyl-! H-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-IH-indol - 1 -yl)-2-methylcy clopropy 1)- 1,2,4-oxadiazol-5(4H)-one;3-(( 1 S,2S)- 1 -(5-((S)-2.2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-((R)- 1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-3-(3-(4-fluoro-l-methyl-lH-mdazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazo]-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-IH-indol-l -yl)-2 -methylcy clopropy!)-!, 2, 4-oxadiazol-5(4H)-one;3-(( 1 S,2S)- 1 -(5-((S)-2,2-dimethyltetrahy dro-2H-pyran-4-yl)-2-((S)-2-((S)- 1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-! H-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(( 1S.2S)-1 -(5-((S)-2.2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-((R)-l.1 -dioxidotetrahydro-2H-thiopyran-3-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetraliydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-!,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((S)-l,l-dioxidotetrahydrothiophen-3-yl)-3-(3-(4-fluoro-l -methyl-IH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((R)-l,l-dioxidotetrahydrothiophen-3-yl)-3-(3-(4-fluoro-l -methyl-lH-indazol-5-yi)-2.-oxo-2.3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((S)-l,l-dioxidotetrahydrothiophen-3-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-inudazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-1-yl)-2-methy Icy clopropyl)- 1,2,4-oxadiazol-5 (4H)-one or 3-((l S,2S)- 1 -(2-((S)-2-((R)- 1,1-dioxidotetrahydrothiophen-3-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-IH-iinidazol-l -yl)-4-methy 1-4,5, 6.7-tetraliydro-2H-pyrazolo[4,3-c|pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcy clopropyl)-!, 2, 4-oxadia.zol-5(4H)-one;3-((lS,2S)-l-(2-((4S,7R)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-2,4,5,6,7,8-hexahydro-4,7-epiminocyclohepta[c]pyrazole-9-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((4R,7S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-i idazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-2,4,5,6,7,8-hexahydro-4,7-epiminocyclohepta[c]pyrazole-9-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l -yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((4S,7R)-3-(3-(4-fluoro-l-methyl-lH-mdazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-2,4,5,6,7,8-hexahydro-4,7-epiminocyclohepta[c]pyrazole-9-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methy Icy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((4R,7S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-IH-imidazol-!-yl)-2-(4-fluoro-3,5-dimethy1phenyl)-2,4,5,6,7,8-hexahydro-4,7-epiminocyclohepta[c]pyrazole-9-carbonyl)-5-(tetrahydro-2H-pyran-4-yi)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2,4-oxadiazol-5(4H)-one;3-((! S,2S)-l-(2-((S)-2-((2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-niethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((2R,4s,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((! S,2S)-l-(2-((S)-2-((2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(3-(4-fluoro-1 -methyl - lH-indazol-5-yl)-2-oxo-2,3-dihydro- IH-imidazol- l-yl)-4-methyI-4,5,6,7 -tetrahy dro-2H-pyrazolo[4,3-c]pyndiiie-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-mdol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-2-((2R,4s,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(3-(4-fluoro-l-methyl-lH-mdazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahy dro-2H-pyrazolo [4,3 -c] py ridine-5-carbony l)-5 -(tetrahy dro-2H-pyran-4-yl)- 1 H-indol- 1 -yl)-2-methylcy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-3-(l-(4-fluoro-l-methyl-lH-indazo!-5-yl)-2-oxo-l,2-dihydropyridm-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4, 5,6, 7 -tetrahy dro-2H-pyrazolo[4,3-c]pyn dine-5-carbonyl)-5-(tetrahy dro-2H-pyran-4-y 1)- IH-indoi- 1 -yl)-2-methylcy clopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-((! S.2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyraii-4-yl)-2-((S)-3-(l-(4-fluoro-l-methyl-! H-indazol- -yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c|pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((! S,2S)-l-(5-((S)-2.2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-(l-(l-methyl-! H-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methy ley clopropyl)- 1,2,4-oxadiazol-5 (4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyraii-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-(l-(l-methyl-lH-indazol-5-yl)-6-oxo-l,6-dihydropyrimidin-5-yl)- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l -yl)-2-methy Icy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-(( 1 S.2S)-l -(2-((S)-3-(l -(1 -(difluoromethyl)- lH-indazol-5-y3)-2-oxo-],2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo|4.3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methy Icy cl opropy 1)- 1,2.4-o\a>.h azol-5 (4H)-one;3-((lS,2S)-l-(2-((S)-3-(l-(2-(difluoromethyl)-2H-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4.7,7-trimethyl-4,5,6,7-tetraliydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-y])-2-methylcyclopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-3-(l-(l-methyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c|pyndine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yI)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one,3-(( 1 S,2S)- 1 -(2-((S)-2-(4-fl uoro-3.5 -dimethylpheny l)-4.7.7-tnmethy 1-3 -( 1 -(2-methy 1-2H-indazol-5-yi)-2-oxo-1.2-dihydropyridin-3-yl)-4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadjazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-3-(l-(l,3”dimethyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyI-4,5 6,7-tetrahydro-2H-pyrazoIo[4.3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3.5-dimethylphenyl)-4.7,7-trimethyl-3-(l-(l-methyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-4,5,6,7-tetfahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetr ahydro-2H-pyran -4-yl)- lH-indol-l-yl)-2-methylcyclopropyl)-L2.4-oxadi azol-5(4H)-one;3-((lS;2S)-l-(2-((S)-3'-(l-(l,3-dimethyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin- -yl)-2 4-fluoro-3,5-dimethylphenyl)-4'-melhyl-2 4\5 6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4?3-c]pyridine]-5'-carbonyl)-5-(tetraliydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-(( 1 S,2S)-1 -(2-((S)-2'-(4-fluoro-3,5-dimethylphenyI)-4'-methyl-3'-(l-(2-methyl-2H-indaz,oI-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yr)-lH-indol-l-yl)-2-methy Icy cl opropy 1)-1,2,4-oxadi azol-5 (4H)-one;3-((lS,2S)-l-(2-((S)-3-(l-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(ietrahydro-2H-pyran-4-yI)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(l-(4-fluoro-l-methyl-lH-indazol-5-yI)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fliioro-3,5-dimethylphenyl)-4,7.7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazoIo[4.3-c]pyridine-5-carbonyl)-lH-indoI-l-yl)-2-methylcyclopropyl)-!,2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(l-(2-(difluoromethyl)-2H-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yI)-2-(4-fluoro-3,5-dimethylphenyI)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridme-5-carboiiyl)-5-((S)-2,2-dimethyltetraliydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetraliydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethyIphenyl)-4,7.7-trimethyl-3-(l-(l -methyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-4.5,6,7-telrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-i-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one:3-((l S,2S)-1 -(2-((S)-2'-(4-fliJoro-3,5-dimethylphenyl)-4'-methyl-3'-(l-(l -methyl- 1H-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2’,4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4.3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methy Icy cl opropy 1 )- 1,2,4-oxad i az.ol-5 (4H)-one:3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3.5-dimethylpheny])-4-methyl-3-(2-oxo-l-(2-(trifliioroiwthyl)imidazo[l,2-a]pyridin-6-yl)-l,2-dihydropyridin-3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c|pyridine-5-carbonyl)-5-(tetraliydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)- 1,2,4-oxadiazol-5(4H)-one:3-((lS.2S)-l-(2-((S)-3-(l-(2-cyclopropyl-[1.2?4]triazolo[l,5-a]pyridin-6-yl)-2-oxo-L2-dihydropyndin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-3-(2-oxo-l-(3-(trifluoromethyl)imidazo[l,5-a|pyridin-7-yl)-l,2-dihydropyridin-3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-y])-2-methylcyclopropyl)- 1,2,4-oxadiazol-5 (4H)-one;3-((lS,2S)-l-(2-((S)-3-(l-(l-(difluoromethyl)-lH-mdazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indoI-I-yl)-2-methylcyclopropyl)- 1,2, 4-oxadiazol-5(4H)-one;3-(( 1 S.2S)-l -(2-((S)-3-(l -(1 -(difluoromethyl)- lH-indazol-5-yl)-2-oxo-],2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyI-4,5,6,7-tetrahydro-2H-pyrazolo|4,3-c]pyridine-5-carbonyl)-5-((S)-2,2-dimetliyltetraliydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyI)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2.2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-rnethyl-3-(2'-methyl-2-oxo-2H-[l,4'-bipyridin]-3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-l H-indol-1 -yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethyIphenyl)-3-(l-(imidazo| l,5-a]pyndin-6-yl)-2-oxo-l,2-dihydropyndin-3-yl)-4-methyl-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiaz.ol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3'-(2'-cyclopropoxy-2-oxo-2H-[l,4’-bipyridin]-3-yl)-2'-(4-£luoro-3,5-dimethylphenyl)-4!-methyl-2',4',5'.6'-tetrahydrospiro[cyclopropane-1.7'-pyrazolo[4,3-c]pyridine]-5 '-carbonyl )-5-(tetrahydro-2H-pyran-4-yl)-l H-indol-1 -yf)-2-methylcyclopropyl)-l, 2, 4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-3-(2'-cyclopropoxy-2-oxo-2H-[l,4'-bipyridin]-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c|pyridine-5-carbonyl)-5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcj'clopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(2'-cjclopropoxy-2-oxo-2H-|l,4'-bipyridin]-3-yl)-2-(4-fluoro-3.5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo|4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-oiie;3-((lS,2S)-l-(2-((S)-3'-(2'-cyclopropoxy-2-oxo-2H-[l,4'-bipyridin]-3-yl)-2'-(4-fluoro-3,5-dimethyIphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7’-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-((S)-2, 2-dimethyltetrahydro-2H-pyran-4-y 1)-1 H-indol-1 -yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(2'-cyclopropoxy-2-oxo-2H-| 1.4'-bipyridin]-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-l-y1)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-3-(2'-cyclopropoxy-2-oxo-2H-[l,4'-bipyridin]-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one3-(( 1 S.2S)-1 -(2-((S)-2-(4-fluoro-3.5-dimethylphenyl)-3- l -( soquinolin-€>-yl)-2-oxo- 1.2-dihydropyridin-3-yl)-4-methyl-4.5,6.7-tetrahydro-2H-pyrazolo[4.3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS;2S)-l-(2-((S)-3-(l-(4-(diethyIphosphoryl)-3-(niethylamino)phenyl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-diraethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyI-3-(l-(4-morpholinophenyl)-2-oxo-1.2-dihydropyridin-3-yl)-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcycIopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-7,7-difluoro-2-(4-fluoro-3,5-dimetihylphenyl)-4-methyl-3-(l-(l-niethyl-lH-mdazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c|pyridine-5-carbonyl)-5-((S)-2.2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-],2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethyiphenyl)-4.7,7 -trimethyl-3-( 1 -(1 -methyl- lH-indazol-5-yl)-6-oxo-l,6-dihydropyrimidin-5-yl)-4.5.6.7-tetraliydro-2H-pyrazolo[43-c]pyridine-5-carbony])-lH-indol-l-yl)-2-methy]cyclopropy])-1,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-(l-(l-methyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2,4,5,6.7.8-hexahydropyrazolo[4,3-c]azepine-5-carbonyl)-lH-indol-l-yl)-2-methylcx lopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-3-(l-(3-methoxyphenyl)-2-oxo-l,2-dihydropyridin-3-yl)-4-methyl-4;5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-3-(2-oxo-l-(l-(2.2.2,2,2-trifluoroethyl)-lH-mdazol-5-yl)-L2-dihydropyridin”3-yl)-4.5,6;7-tetraliydro-2H-pyrazolo 4;,3-c]pyridine-5-carbonyl)-5-(tetrabydro-2H-pyran-4-yl)-lH-indol-l-yI)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(l-(l-cyclopropyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5?6,7-tetrahydro-2H-pyraz.olo[4,3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyran4-yl)-lH-indol-l-yl)-2-methylcyclopropy1)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-3-(2-(4-fluoro-l-methyl-lH-indazol-5-yl)-3-oxo-2,3-dihydropyridazin-4-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo|4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methy Ic cl opropy 1 )- 1,2,4-oxad i az.ol-5 (4H)-one,3-(( 1 S,2S)-1 -(2-(( S)-2-(4-fluoro-3.5-dimethylphenyl )-4-methyl-3-(2-(l -methyl- 1H-indazol-5-yl)-3-oxo-2,3-dihydropyridazm-4-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2:,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3.5-dimethylphenyl)-4.7.7-trimetliyl-3-(2-(l-methyl-lH-indazol-5-yl)-3-oxo-2,3-dihydropyridazm-4-yl)-4.5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yI)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one,3-((lS,2S)-l-(2-((S)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-3'-(2-(l-methyl-lH-indazol-5-yl)-3-oxo-2,3-dihydropyridazin-4-yl)-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7!-pyrazolo[4,3-c]pyri dine] -5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)- 1 H-indoI- 1 -yl )-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-2-(4-fluoro-3.5-dimethylphenyl)-4-metliyl-3-(l-(l-niethyl-lH-indazol-5-yl)-6-oxo-l,6-dihydropyrimidin-5-yl)-4,5,6?7-tetraliydro-2H-pyrazolo|4?3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-meihylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3'-(l-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l?7'-pyrazoIo[4;3-c]pyndine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS;2S)-l-(5-((S)-2,2-dimetliyltetraliydro-2H-pyran-4-yl)-2-((S)-3-(l-(4-fluoro-l-methyl-lH-indazol-5-yl)-6-oxo-l,6-dihydropyrimidin-5-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6J-tetrahydro-2H-pyrazolo[43-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(( 1 S.2S)-1 -(2-((S)-3-(4-(4-fluoro-l-methyl-lH-indazol-5-yl)-5-oxo-4,5-dihydro-lH- 1.2.4-triazo1-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyrati-4-yl)-lH-indol-l-yl)-2-methy Icy cl opropy 1)-1,2,4-oxad i azol-5 (4H)-one;3-((lS,2S)-l-(2-((S)-3-(4-(4-fluoro-l-methyl-lH-indazol-5-yl)-5-oxo-4,5-dihydro-lH- 1.2.4-triazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4 -c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-IH-mdol-l-yJ)-2-methylcyclopropyl)-!, 2,4-oxadiazol-5(4H)-one;(S)-3-(l-(2-(3-(4-(4-fluoro-l-metliyl-lH-indazol-5-yl)-5-oxo-4,5-dihydro-lH-l,2,4-triaz.ol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methvl-4,5,6,7-tetrahydro-2H-pyrazolo|4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)cyclopropyl)-I,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3'-(4-(4-fluoro-l-methyl-lH-mdazol-5-yl)-5-oxo-4,5-dihydro-lH-l,2,4-triazol-l-yl)-2'-(4-fluoro-3,5-dimethyIphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4.3-c]pyndine]-5'-carbonyl)-5-(tetrahydro-2H-pyran- 4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2.4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimetliyltetraliydro-2H-pyran-4-yl)-2-((S)-3-(4-(4-fluoro-l-methyl-lH-indazol-5-yl)-5-oxo-4,5-dihydro-lH-l,2,4-triazol-l-yl)-2-(4-fluoro-3,5-dimelliylphenyl)-4-melliyl-4,5,6,7-letraliydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-1.2,4-oxadiazol-5(4H)-one;3-(( 1 S,2S)- 1 -(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3'-(4-(4-fluoro-l -methyl-lH-indazol-5-yl)-5-oxo-4,5-dihydro-lH-l,2,4-triazol-l-yl)-2'-(4-fluoro-3,5-dimethyiphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]- 5 -carbonyl )- 1 H-indol- 1 -y 1 )-2-methy Icy cl opropy 1)- 1,2,4-oxadi zol-5 (4H)-one;N-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyJ-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetraliydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acelamide;2-((4'S)-5'-(5-(2,2-dimetiiyltetrahydro-2H-pyran-4-yl)-I-((lS.2S)-2-methyl-l-(5-oxo-4,5-dihydro-1, 2, 4-oxadiazol-3-yl)cyclopropyl)-lH-indole-2-carbonyl)-2'-(4-fluoro-3.5-dimethyIphenyl)-4'-methyl-2',4',5',6'-tetraliydrospiro[cyclobutane-l,7'-pyrazolo[4,3-c]pyridin]-3'-y 1) -N- (4 -fl uoro- 1 -methyl - lH-indazol-5 -y I)acetami de;N-(4-fluoro-I-nietliyl-lH-indazol-5-yl)-2-((S)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-5'-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-1.2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-2',4',5',6'-tetrahydrospiro[cyrclobutane-l,7'-pyrazolo[4,3-c]pyridin]-3'-y])acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cycIopropyl)-5-(tetrahydro-2H-pyran-4-yI)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(isochroman-7-yl)acetami de;2-((S)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H -pyran -4-yl)-lH-indole-2-carbonyl)- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(4-(3-methyl-2-oxoimidazolidin-l-yl)phenyl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS.2S)-2-methyl-l-(5-oxo-4,5-dihy dro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H -pyran -4-yl)-lH-indole-2-carbonyl)- 4.5.6.7-tetrahydro-2H-pyrazolo|4,3-c]pyridin-3-yl)-N-(l -methyl-lH-benzo[d|imidazol-6-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyi)-4-methyl-5-(l-((lS.2S)-2-metliyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyciopropyl)-5-(tetrahydro-2H -pyran -4-yl)-lH-indole-2-carbonyl)- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(l-methyl-lH-benzo[d]| 1, 2,3 ] tri azol -5-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dinielhylphenyl)-4-melliyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-1, 2, 4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H -pyran -4-yl)- lH-indole-2-carbonyl)- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(l-isopropyl-lH-indazol-5-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(4-morpholinophenyl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(2-methyl-2H-indazol-5-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H -pyran -4-yl)- lH-indole-2-carbonyl)-4,5,6;7-tetrahydro-2H-pyrazolo[4,3-c]pyridm-3-yl)-N-(2-methylpyridin-4-yl)acetamide:2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-1, 2, 4-oxadiazol-3-yl)cy cIopropyl)-5-(tetrahydro-2H -pyran -4-yl)-lH-indole-2-carbonyl)- 4.5.6.7-tetr ally dro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-((lr,4S)-4-hydroxycyclohexyl)acetamide:N-((lr,4S)-4-cyclopropoxycyclohexyl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methy]-l-(5-oxo-4,5-dihydro-1.2,4-oxadiazol-3-yl)cyclopropy])-5-(tetrahydro-2T7l-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-teirahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetamide;N-(4,4-difluorocyclohexyl)-2-((S)-2-(4-lluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((! S,2S)-2-methyl-l -(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetamide2-((S)-2-(4-fluoro-3.5-dimethylphenyI)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyc!opropyl)-5-(tetrahydro-2H -pyran -4-yl)-lH-indole-2-carbonyl)- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(4-(2-methoxy ethoxy )cy cl ohexy 1 )acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS.2S)-2-methyl-l-(5-oxo-4,5-dihy dro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H -pyran -4-yl)-lH-indole-2-carbonyl)- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(trans-4-methoxycyclohexyl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethyIphenyI)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)c.yclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6:7-tetrahydro-2H-pyrazoio[43-c]pyridin-3-yl)-N-(l -methyl- lH-indazol-5-yl)acetamide;2-((4S)-5-(5-(2,2-diniethyltetrahydro-2H-pyran-4-yl)-l-((lS,2S)-2-metliyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-lH-indoIe-2-carbonyl)-2-(4-fluoro-3,5-dimelhylphenyl)-4-methyl-4,5,6,7-letraliydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(4-fluoro-l-methyl- lH-indazol-5-yl)acetamide;N-cyclohexyl-2-((S)-2-(4-fluoro-3,5-dimethy]pheny])-4-methyl-5-(l-((lS,2S)-2 -methyl-l-(5-oxo-4.5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetamide;N-(dibenzo|b?d, ]furan-2-yl)-2-((S)-2-(4-fluoro-3?5-dimethylphenyl)-4-methyl-5-(l-((lS52S)-2-methyI-l-(5-oxo-4,5-djhydro-l,2,4-oxadiazol-3-yl)cyclopropyI)-5-(ietrahydro-2H-pyran-4-yl)-rH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetaniide N-(4-(diethylphosphoryl)-3-(methylamino)phenyl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-niethyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l?2:4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carboiiyl)-4,5,6,7-tetrahydro-2H-pyrazolo|4.3-c]pyridin-3-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropy1)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,67-tetraliydro-2H-pyrazolo[4,3-c]pyridiii-3-yl)-N-((R)-4.5.6 -tetraliydropyrazolo[h5-a|pyndin-5-yl)acetamide or 2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-metliyl-5-(l-((lS,2S)-2-methyl-1 -(5-oxo-4.5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-((S)-4,5,6,7-tetrahydropyrazolo[L5-a]pyridm-5-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dnnethylphenyI)-4-methyl-5-(l -((1 S52S)-2-methyl-l -(5-oxo-4,5-dihydro-1, 2, 4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4.5.6.7-teirahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-((R)-4,5,6,7-tetrahydropyrazoIo[l,5-a]pyridin-5-yl)acetamide;2-((S)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-1, 2, 4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-((S)-4,5,6,7-tetrahydropyrazo1o[L5-a]pyndin-5-yl)acetannde;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)- 4.5.6.7-tetrahydro-2H-pyrazoio[4,3-c]pyridin-3-yl)-N-(4-(4-methyl-lH-imidazoi-l-yl)phenyl)acetamide;3-((lS,2S)-l-(2-((S)-3-(5-(4-fluoro-l-methyl-lH-indazol-5-yl)-lH-l,2,4-triazol-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazoIo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-metliylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(5-(4-fluoro-l-methyl-lH-indazol-5-yl)-lH-l,2,4-triazol-3-yl)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methy Icy cl opropy 1 )- 1,2,4-oxadi azol-5 (4H)-one:(S)-3-(l-(2-(3-(5-(4-fluoro-l -methyl- lH-indaz.ol-5-yl)-lH-l,2,4-triazol-3-yl)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)cyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(( 1 S,2S)-1 -(2-((S)-3'-(3-(4-fluoro- 1 -rnethyl-1 H-indazol-5-yl)-lH-pyrazol-l-yl)-2'-(4-fluoro-35-dimetiiylphenyl)-4'-methyl-2',4',5'.6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine|-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3'-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-IH-pyrazol-l-yl)-2'-(4-fluoro-3.5-dimethylphenyl)-4'-methyl-2',4',5'.6'-tetr ally drospiro[cyclopropane-l,7'-pyrazolo[4,3-c|pyridine]-5'-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-!,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l -(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-lH-pyrazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-nietliyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;(S)-3-(I-(2-(3-(3-(4-fliJoro-]-meihyI-lH-indazoJ-5-yl)-lH-pyrazol-l-yI)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5.6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)cyclopropyl)-l,2,4-oxadiazol-5(4H)-one;2.2-difluoro-2-(4-fluoro-l-methyl-lH-indazoi-5-yl)-N-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-meihyl-5-(l-((! S,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2.4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5.6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetamide:2.2-difluoro-2-(4-fluoro-l-methyl-lH-indazol-3-yI)-N-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-( 1 -(( 1 S,2S)-2 -methyl- 1 -(5-oxo-4,5-dihydro- 1.2.4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetraliydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetamide;N-((S)-5-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-l-((l S,2S)-2-methyl-]-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-lH-indole-2-carbonyr)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetraliydro-2H-pyrazolo 4.3-c]pyridin-3-yl)-2.2-difluoro-2-(4-fluoro- 1 -methyl- lH-indazol-5-yl)acetamide;(S)-2-(4-fluoro-l-methyl-lH-indazol-5-yl)-N-(2-(4-fliioro-3,5-dimethylphenyl)-4-methyl-5-(l-(l-(5-oxo-4?5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetraliydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5.6,7-tetrahydro-2H-pyrazolo[4.3-c|pyridin-3-yl)acetamide;2-(4-fluoro-l-meihyl-lH-indazol-5-yl)-N-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2.4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyraii-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-methy lacetami de;3-((lS.2S)-l-(2-((S)-3-((lS,5R)-4-(4-fluoro-l-methyi-IH-mdazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyI)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-((lR,5S)-4-(4-fluoro-l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0|hexan-2-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetTahydro-2H-pyran-4-yl)-lH-indol-l-y])-2-methy Icy clopropyl)- 1,2,4-oxadiazol-5 (4H)-one;3-((lS,2S)-l-(2-((S)-3-((lS,5R)-4-(4-fluoro-l-methyl-IH-indazol-5-yl)-3-o o-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7 -trimethyl-4,5!6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2 -methylcyclopropyl)-!, 2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-3-((lR.5S)-4-(4-fluoro-l-methyl-lH-indazol-5-y -3-oxo-2,4-diazabicyclo[3 1.0]hexan-2-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetraliydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((l S,2S)-1 -(2-((S)-3'-((lS,5R)-4-(4-fluoro-l -methyl- lH-indazol-5-yl)-3-oxo-2.4-diazabicyclo[3. I.0]hexan-2-yl)-2’-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6’-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3'-((lR.5S)-4-(4-fluoro-l-methyl-lH-indazol-5-yl)-3-oxo-2.4-diazabicyclo[3.1.0]hexan-2-yl)-2'-(4-fluoro-3,5-dimethylphenyi)-4'-methyl-2'.4',5 6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo|4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yI)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2~((S)-2-(4-fluoro-3.5-dmiethylphenyl)-4-methyl-3-((lS,5R)-4-(l-methyl-lH-indazol-5-yl)-3-oxo-2.4-di azabi cyclo[3.1.0]hexan-2-yl)-4, 5,6, 7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-5-(tetrabydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-((lR,5S)-4-(l-methyl-lH-mda ol-5-yl)-3-oxo-2, 4-di azabi cyclop J J3]hexan-2-yI)-4, 5, 6,7-tetrahydro-2H-pyrazolo| 4.3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-melhylcy7clopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-niethyl-3-((lS,5R)-4-(l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-IH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS;2S)-l-(5-((S)-2,2-dimetliyltetraliydro-2H-py an-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-((lR.5S)-4-(l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-((lS,5R)-4-(4-fluoro-l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2-(4-fluoro-3.5-dimethylphenyl)-4.7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-((lR,5S)-4-(4-fluoro- l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2-(4-fluoro-3, 5-dimethylphenyl)-4.7,7-trimetbyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridme-5-carbonyl)-lH-indol-1 -yl)-2-methylcy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3'-((lS,5R)-4-(4-fluoro-l-meth I-! H-indazoI-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexati-2-yl)-2'-(4-fluoro-3,5-dimeihyiphenyl)-4'-methy]-2',4 5'.6'-tetrahydrospiro[cx,clopropane-1.7'-pyraz.olo[4,3-c]pyridine]-5'-carbonyl)- IH-indol- 1 -yl)-2-methylcy clopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3'-((lR,5S)-4-(4-fluoro- l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yi)-2'-(4-fluoro-3, 5-dimethyiphenyl)-4'-methyl-2',4'.5'?6'-tetrahydrospiro[cyclopropane-1.7'-pyrazolo[4,3-c]pyridine]-5-carbonyl)- IH-indol- 1 -yl)-2-methylcy clopropyl)-!,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3,-((lS,5R)-4-(4-(diethylphosphoiyl)-3-(methylamino)phenyl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetraliydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcycIopropyl)-1.2,4-oxadiazol-5(4H)-one:3-((JS,2S)-l-(2-((S)-3'-((lR,5S)-4-(4-(diethylphosphoryl)-3-(methylamino)phenyl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5!,6'-tetrahydrospiro[cyclopropaiie-l,7'-pyrazolo|4.3-c]pyndine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-3'-((lR,5S)-4-(4-fluoro-l-metbyl-lH-mdazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2’-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6’-tetr ally drospiro[cyclobutane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyrari-4-yl)-lH-indol-l-yl)-2-methylcydopropyl)-l,2,4-oxadiazoI-5(4H)-one:3-((lS.2S)-l-(2-((S)-3'-((lS?5R)-4-(4-fluoro-l-methyl-lH-mdazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5 6'-tetrahydrospiro[cyclobutane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yI)-2-methylcyciopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2.2-dimethyltetrahydio-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethyIphenyl)-4-methyl-3-((lS,5R)-4-(l-methyl-lH-indazol-5-yl)-3-oxo-2.4-diaz.abicyc]o[3.1.0]hexan-2-yl)-4,5,6,7-tetrahydro-2H-pyrazo]o[4,3-c]pyridine-5-carbonyl)-lH-indol-1 -yI)-2-methylcy clopropyl)-!, 2, 4-oxadiaz.ol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyraii-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-((lR.5S)-4-(l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1 0]bexan-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;

[0272] 3-((! S,2S)-l-(2-((S)-3-(I-(4-fluoro-l-methyJ-lH-mdazol-5-yl)-2-oxo-l, 2.5.6-tetrahydropyndin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methy Icy cl opropy 1 )- 1,2,4-oxad i azol-5 (4H)-one;

[0281] 3 -(( I S,2S)- 1 -(2-((S)-3-(3-(4-fluoro- 1 -methyl- 1 H-indazol -5-yl)-2-oxo-2.3-dihydro-lH-imidazol-l-yl)-2-(2-(6-fluoro-3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl)-4-methyl-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2II-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yI)-4-methyl-2-(2-oxo-2-(4-azaspiro[2.6]nonan-4-yl)ethyl)-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indoI-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(2-(4-azadispiro[2.1.25.33]decan-4-yl)-2-oxoethyl)-3-(3-(4-Iluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2.3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(2-((lR,5S)-8-azabic 'clo[3.2.1]octan-8-yl)-2-oxoethyl)-3-(3-(4-fluoro- l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-i idazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-mdol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(2-((lR,4R)-7-azabicyclo[2.2.1]heptan-7-yl)-2-oxoethyl)-3-(3-(4-fluoro-l-inethyl-! H-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-metliyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(2-((2S,5R)-2,5-dimethylpyrrolidin-l-yl)-2-oxoethyl)-3-(3-(4-fluoro- 1 -methyl- 1 H-indazol-5-y l)-2-oxo-2,3-dihy dro- 1 H-imidazol - 1 -yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyndine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(( 1 S,2S)-1 -(2-((S)-2-(2-(3,4-dihydroquino!in-l(2H)-yl)-2-oxoethyl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-! H-i idazol-l-yi)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methy Icy cl opropy 1)-1,2,4-oxad i azol-5 (4H)-one;N-benzyl-N-(cyclopropylmethyl)-2-((S)-3-(3-(4-fluoro- l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4- - M -oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-jndole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)acetamide;3-((lS,2S)-l-(2-((S)-2-(2-(4,4-difluoropiperidin-l-yl)-2-oxoethyl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidaz.ol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-iniidazol-l-yl)-4-niethyl-2-(2-oxo-2-(4-azaspiro[2.5]octan-4-yl)ethyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyrati-4-yl)-lH-indol-l-yl)-2-niethylcycIopropyl)-l,2,4-oxadiazol-5(4H)-one;2-((S)-3-(3-(4-fluoro-l-methyl-n-I-indazoS-5-yl)-2-oxo-23-dihydro-lH-imidazol-l-yl)-4-methyl-5-(l-((J S,2S)-2-methyl-J -(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyI)-5-(letrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-telrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)-N-(3-(trifluoromethyl)oxetan-3-yl)acetamide;N-(bicyclo[2.2.2]octan-l-yI)-2-((S)-3-( -(4-fluoro-i-methyl-lH-indazoI-5-yI)-2-oxo-2, -dihydro-lH-imidazol-l-yl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pvrazolo[4,3-c]pyridin-2-yl)acetaniide;

[0285] 3-(( 1 S,2S)-1 -(2-((S)-3'-(3-(4-fluoro-l -methyl-lH-indazol-5-yl)-2-oxoimidazolidin-l-yl)-2'-(5-fluoro-4,6-dimethylpyrimidin-2-yl)-4’-methyl-2'.4',5',6'-tetr ally drospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5’-carbonyl)-5-(tetraliydro-2H-pyran-4-yl)-lH-mdol-l-yl)-2-methylcydopropyl)-l,2,4-oxadiazoI-5(4H)-one:3-((lS.2S)-l-(2-((S)-3'-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxoimidazolidin-l-yl)-r-(5-fluoro-4,6-dimethylpyrimidin-2-yl)-4'-methyl-r?4', 5', 6'-tetr ally drospiro| cyclopropane-1, 7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiaz.ol-5(4H)-one;(S)-3-(l-(5-(3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2.3-dihydro-lH-imidazol-l-yl)-2-(4-fliioro-3,5-dimethylphenyl)-4-methyl-4.5,6,7-tetraliydro-2H-pyrazolo[4,3-c]pyndine-5-carbonyl)-3-(isochroman-6-yl)-lH-pyrazol-l-yl)cyclopropyI)-],2,4-oxadiazol-5(4H)-one;3-(l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-diliydro-lH-imidazol-l-yl)-2-(4-fli!oro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)phenyl)cyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(l-(5-((R)-2.2-dimetbyltetTahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-l -methyl-] H-mdazol-5-yl)-2-oxo-2,3-diliydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)phenyl)cyclopropyl)-L2,4-oxadiazol-5(4H)-one;(S)-3-(l-(5-(3-(3-(4-fluoro-l-methyI-lH-indazol-5-yl)-2-oxo-2.3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4.5A7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-3-((tetrahydro-2H-pyran-4-yI)ethynyl)-lH-pyrazoI-l-yl)cyclopropyl)-l,2,4-oxadiazoi-5(4H)-one;(S)-3-(I-(5-(3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2.3-dihydro-lH-imidazol-l-yl)-2-(4-tluoro-3,5-dimethylphenyl)-4-methyI-4,5,6,7-tetrahydro-2H-pyrazoio[4,3-c]pyridine-5-carbonyl)-3-(4-(l-methoxycyclobutyl)phenyl)-lH-pyrazol-l-yl)cyclopropyl)-l,2,4-oxadiazol-5(4H)-one,3-(l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-metl'iyI-4?5,6J-tetrahydro-2H-pyrazoIo|4.3-c]pyridine-5-carbonyl)-5-((3aR, aR)-hexahydro-lH-cyclopenta[c]furan-5-yl)phenyl)cyclopropyl)-l,2.4-oxadiazol-5(4H)-one;3-(l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-iniidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5.6,7-tetrahydro-2H-pyrazoIo[4.3-c]pyridine-5-carbonyl)-5-((3aS56aS)-hexahy dro-lH-cy clopenta[c]furan-5-yl)phenyI)cy cl opropyl)- 1.2.4-oxadiazol-5(4H)-one;(S)-3-(l-(2-(3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-iinidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-45,6 -tetrahydro-2H-pyrazoIo[43-c]pyndine-5-carbonyl)-5-(2-oxaspiro[3.5]nonan-7-yl)phenyi)cyclopropyl)-L2.4-oxadiazol-5(4H)-one:3-(l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5?6,7-tetrahydro-2H-pyrazoIo[4,3-c]pyridine-5-carbony l)-5 -((3 aR,6aR)-hexahy dro- 1 H-cy clopenta[c] furan -5 -y 1)- 1 H-in dol- 1 -yl)cyclopropyl)- l,2,4-oxadiazol-5(4H)-one;3-(l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyI-4,5,6,7-tetrahydro-2H-pyrazoIo[4,3-c]pyridine-5-carbonyI)-5-((3aS,6aS)-hexahydro-lH-cyclopenta[c]furan-5-yl)-lH-indol-l-yl)cyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(l -(2-((S)-3-(3-(4-fluoro-l -methyl- lH-indaz.ol-5-yl)-2-oxo-2,3-dihy dro- IH-imidazol-l-yl)-2-(4-fluoro-3,5-dimetbyIphenyl)-4-metbyl-4,5.6,7-tetrahydro-2H-pyrazolo[4,3-c]pyndine-5-carbonyl)-5-((R)-2,5-dioxaspiro[3.5]nonan-7-yl)-lH-indol-l-yJ)cyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(l-(2-((S)-3-(3-(4-fluoro-l-metliyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-inndazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyraz.oIo[4,3-c]pyridine-5-carbonyl)-5-((S)-2,5-dioxaspiro[3.5]nonan-7-yl)-lH-mdol-l-yl)cyclopropyl)-L2,4-oxadiazol-5(4H)-one;3-(l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-metliyl-4,5,6,7-tetraliydro-2H-pyrazoIo[4,3-c]pyridine-5-carbony l)-5 -(2-hy droxybicy clo [3.2.1 ] octan-6-yI)- 1 H-indol- 1 -y l)cy clopropy 1)- 1,2,4-oxadiazol-5(4H)-one:(S)-3-( 1 -(2-(3 -(3 -(4-fluoro- 1 -methyl- 1 H-indazol-5 -yl)-2-oxo-2,3 -dihy dro- 1 H-i midazol - 1 -yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(4-methoxycyclohexyl)-lH-indol-l-yl)cy clopropy l)-l,2,4-oxadiazol-5(4H)-one:N-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-((S)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-5'-( 1 -(( I S,2S)-2-methyl-l -(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-2',4'.5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4.3-c]pyridin]-3'-yl)acetamide;2-((S)-5'-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-vl)-l-((lS,2S)-2-methyl-l -(5-oxo- 4.5-dihydro-l,2,4-oxadiazol-3-yl)cyc]opropyl)-lH-jndole-2-carbonyl)-2'-(4-fluoro-3,5-dimethylphenyl)-4!-methyl-2',4',5'.6'-tetraliydrospiro[cyclopropane-L7'-pyrazolo[4,3-c]pyridin]-3'-yl)-N-(4-fluoro- 1 -methyl- lH-indazol-5-yl)acetamide;2-((S)-5'-(5-((S)-2,2-dimethyltetrahydro-2H-pyrari-4-yl)-l-((lS.2S)-2-methyl-l-(5-oxo- 4.5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-lH-indole-2-carbony])-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2 4 5\6'-tetrahydrospiro[ cyclopropane-1, 7'-pyrazolo[4,3-c]pyri dm]-3'-yI)-N-(l-methyl-lH-indazol-5-yl)acetamide;2-((S)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-5'-(l-((lS,2S)-2 -methyl- l-(5-oxo-4, 5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-2'.4',5',6'-tetrahydrospiro| cyclopropane- l,7'-pyrazoloS4,3-c]pyridin]-3'-yl)-N-(l-methyl-lH- dazol-5-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(l-methyl-lH-indazol-5-yl)acetamide;N-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-((S)-2-(4-fluoro-3,5-dimetbylphenyl)-4,7,7-trimethyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2.4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetamide;2.2-difluoro-N-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-((S)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-5-(l-((lS.2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetamide;3-((lS,2S)-l-(2-((S)-3-(l-(4-fluoro-l-methyl-lH-indazol-5-yl)-5-oxo-l,5-dihydro-4H-l,2,4-triazol-4-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4.5,6 -tetrahydro-2H-pyrazolo[43-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-((S)-l-(4-fluoro-l-melhyl-lH-indazol-5-yl)-2-oxopiperidin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-mdol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadjazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-3-((R)-l-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxopiperidin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-metliyl-4,5,6,7-tetrahydro-2H-pyrazoloS4?3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-((lS.6S)-3-(4-fluoro-l-methyl-lH-indazoi-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yI)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-4,5,6,7-(.etrahydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indoi-l-yl)-2-methylcyclopropyl)- l,2,4-oxadiazol-5(4H)-one;3-((lS;2S)-l-(2-((S)-3-((lR,6R)-3-(4-fluoro-l-metliyl-lH-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methy1-4,5,6,7-tetrahydro-2H-pyrazolo[4?3-c]pyridine-5-carbonyl)-5-(tetraliydro-2H-pyran-4-yl)-lH-mdol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-((lR,6R)-3-(4-fluoro- l-methyl-lH-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l -yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methyIcydopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-((lS,6S)-3-(4-fluoro- l-methyl-lH-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl)-2-(4-fluoro-3, 5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4 -c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one3-((lS.2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-((lR,6R)-3-(4-fluoro-l-niethyl-lH-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-meihyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2;2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-((lS,6S)-3-(4-fluoro-l-methyl-lH-indazoI-5-yl)-2-oxo-3-azabic>’clo[4.1.0]heptan-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-mdol- 1-yl)-2-methylcyclopropyl)-L2,4-oxadiazol-5(4H)-one:3-((lS;2S)-l-(2-((S)-3-((lR56R)-3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-3-a abicyclo[4.1.0]hept n-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahy dro-2H-pyrazolo[4,3-c]pyndine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yr)-lH-indol-l-yl)-2-methylcyciopropyl)-R2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-((lS, S)- -(4-fluoro-l-methyl-lH-indazol-5-y])-2-oxo-3-azabicyclo[4.1.0]heptan-l-yI)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahy dro-2H-pyrazolo [4.3 -c] py ridine-5-carbony l)-5 -(tetrahy dro-2H-pyran-4-yl)- 1 H-indol- 1 -yl)-2-methylcyclopropyl)-l;2,4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-3-((lR,6R)-3-(4-fluoro-I-methy]-lH-indazol-5-yl)-2-oxo-3-azabicyclo[4 1.0]heptaii-l-yl)-2-(4-fluoro-3.5-dimethylphenyl)-4.7,7-trimethyl-4.5,6.7-tetr ally dro-2H-pyrazolo[4,3-c]pyridine-5-carbonyi)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-3-((lS,6S)-3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-3-azabicyclo[41.0iheptan-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4.7,7-trimethyl-4,5,6,7-tetrahy dro-2H-pyrazolo[4;3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(5-(4-fluoro-l-niethyl-lH-indazol-5-yl)-lH-pyrazol-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c|pyridine-5-carbonyl)-5-( tetrahy dro-2H-pyran-4-yl)-l H-indol- l-yI)-2-methylcyclopropyl)- 1, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((Z)-((S)-3-(3-(4-fluoro-l-nietliyl-lH-indazol-5-yl)-2-oxo-2,3-diliydro-lH-imidazol-l-yl)-2-(4-fluoro-3?5-dimethylphenyl)-4-methyl-2,4,6?7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)(methylimino)methyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)- 2-methylcy clopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((Z)-(ethylimino)((S)-3-(3-(4-fluoro-l -methyl- lH-mdazoi-5-yI)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylpheny!)-4-methyl-2,4,6,7-tetrahydro-5H-pyra olo|4,3-c]pyridin-5-yl)methyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methy Ic cl opropy 1 )- 1,2,4-oxadi azol-5 (4H)-one,3-((1S,2S)-1-(2-((Z)-((cyclopropylmethyl)imino)((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)methyl)-5-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;3-((1S,2S)-1-(2-((S)-3-(4-(4-fluoro-1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one,(2S,4S)-2,5,12-trihydroxy-7-metlioxy-4-(((lS,3R,4aS,9S,9aR,10aS)-9-methoxy-l-methyloctahydro-lH-pyrano[4',3':4,5]oxazolo[2,3-c] | 1.4|oxazin-3-yl)oxy)-6.11-dioxo-N-(pyrrolidin-3-yl)-l,2,3,4,6,l l-hexahydrotetracene-2-carboxamide;3-((1S,2S)-1-(2-((S)-3-(1-(4-fluoro-1-methyl-1H-indazol-5-yl)-1H-pyrazol-4-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one; and3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxopyridin-l(2H)-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2.4-oxadiazol-5(4H)-one,or a pharmaceutically acceptable salt thereof.

[0145] In embodiment no. 134, the present invention provides a compound selected from:3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[3-(3-methylbenzimidazol-1-ium-5-yl)-2-oxo-imidazol-1-yl]-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[3-(1-methylbenzotriazol-5-yl)-2-oxo-imidazol-1-yl]-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-1-ium-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[2-[(4S)-3-[3-(2,3-dimethylimidazo[1.2-a]pyridin-l -ium-6-yl)-2-oxo-imidazol-l-yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4.6,7.8-tetrahydropyrazolo[4.3-c]azepine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[2-[(4S)-3-[3-[2-(difiuoromethyl)indazol-5-yl]-2-oxo-imidazol-l -yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-1-ium-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cyclopropyl] -4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[3-(2,3-dimethylpyridin-l-ium-4-yl)-2-oxo-imidazol-l-yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4.6,7,8-tetrahydropyrazolo[4.3-c]azepine-5-carbonyl]-5-[(4S)-2.2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-c clopropy]]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimelhylteirahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[3-(l-methyiisoquinolin-2-ium-6-yl)-2-oxo-imidazoi-l-yl|- 4.6.7.8-tetrahydropyrazo]o[4,3-c]azepine-5-carbonyl]indo]-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-pheoyl)-3-[3-(4-fluoro-l-methyl-mdazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c] azepin- l-ium-7 '-cyclopropane]-5-carbonyl]indol-l-yl]-2-methyl-cyciopropyl]-4H-l,2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-|(4S)-2,2-dimethyItetrahydropyran-4-yl]-2-|(4S)-2-(5-fluoro-4,6-dimethyl-pyridin-l-ium-2-yl)-3-|3-(4-fluoro-l-methy]-indazol-5-yl)-2-oxo-imidazoI-l -yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]indol-l-yl]-2-methyi-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-4-methyI-3-[2-oxo-3-[2-(2,2,2-trifluoroethyl)indazol-5-yl]imidazol-l -yl]- 4.6.7.8-tetrahydropyrazolo[4,3-c]azepin-l-ium-5-carbonyl]indol-I-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[3-(I-methylindazol-5-y])-2-oxo-imidazoI-l -yl]-4,6,7,8-tetrahydropyrazolo[4.3-c]azepin-l-ium-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol -5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethy]tetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-diniethyl-phenyI)-4-methyl-3-[2-oxo-3-[l-(trideuteriomethyl)indazol-5-yl]imidazol-l-yl]-4.6.7.8-tetrahydropyrazoJo[4,3-c]azepin-l-ium-5-carbonyl]indoI-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[3-(l-cyclopropylindazol-5-yl)-2-oxo-iniidazol-l-yl|-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyi-4,6,7,8-tetrahydropyrazolo[4,3-c] azepin-l-ium-5-carbonyI]-5-[(4S)-2,2-dimethylteirahydropyran-4-yl]indol-l-yl]-2-methyl-cyc1opropyJ]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4,7,7-tnmethyl-6,8-dihydro-4H-pyrazolo[4,3-c]azepine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one:3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-4-methyl-3-[2-oxo-3-[l-(2,2,2-trifluoroethyl)indazol-5-yl]imidazol-l -yl]- 4.6.7.8-lelrahydropyrazolo[4.3-c]azepiii-l-iuni-5-carbonyl]indol-l-yl]-2-melhyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one:3-[(l S,2S)-l-[5-(2,2-dimethylmorpholin-4-ium-4-yI)-2-[(4S)-4-ethyl-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-mdazol-5-yI)-2-oxo-imidazol-l-yl]-4.6,7,8-tetraliydropyrazolo[4,3-c]azepine-5-carbonyl]indol-l-yl]-2-methyi-cyclopropyl|-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimelhy]tetrahydropyran-4-yl]-2-[(4S)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-2-[5-(trifliioromethyl)-3-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,4'-tetrahydropyran]-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;calcium 3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetraliydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[l-(2-methyl-6-quinolyl)-2-oxo-3-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-l-oxa-2-aza-4-az.anidacyclopent-2-eii-5-one;3-[( 1 S,2S)-1 -[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyi-3-[ 1 -(2-methyl-6-quinolyl)-2-oxo-3-pyridylj-6,7-dihydro-4H-pyrazo]o[4,3-c]pyridine-5-carbonyl]-5-[(2S)-2-methylmorpholin-4-yl]jndol-i-y]]-2-methyl-cyclopropy]]-4H-l,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-3-[l-(2-methyl-6-quinolyl)-6-oxo-pyrimidin-5-yl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl|indol-l-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyJtetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-diniethyl-phenyr)-3-[l-(4-fluoro-l-methyl-indazol-5-yl)-6-oxo-pyrimidin-5-yl]-4-methyl-4, 6.7, 8-tetrahydropyraz.olo|4,3-c| azepin- l-ium-5-carbonyl]indoI-l-yl]-2-methyl-cyclopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-3-| l-(l-methylisoqumolm-2-ium-6-yl)-2-oxo-3-pyridyl|-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]indol-l-yl|-2-rnethyl-cyclopropyl|-4H-l,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-3-[1-[2-(cyclopropoxy)pyridin-1-ium-4-yl]-2-oxo-3-pyridyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4.6.7.8-tetrahydropyrazolo[4.3-c]azepine-5-carbonyl]-5-[(4S)-2.2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-rnethy]-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyi-phenyl)-3-[l-(4-fluoro-l-methyi-mdazoI-5-yl)-2-oxo-3-pyridyl]-4-methyI-4.6,7,8-tetrahydropyrazolo[4,3-c]azepin-l -ium-5-carbony l]indol-l -yl]-2-methyi -cyclopropyl] -4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[2-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|l-(4-fluoro-l-methyl-indazol-2-ium-5-y!)-2-oxo-3-pyridyl] -4-methyl-spiro[4,6-dihydropyrazolo|4,3-c]pyridine-7,r-cyclobutane]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-l-yl]-2-methyl-cyclopropyl]-4H-1.2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-3-[l-(5-fluoro-2-methyl-6-quinolyI)-2-oxo-3-pyridyl]-4-melhyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridiiie-5-carbonyl]mdol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l-(4-fluoro-l-methyl-indazol-5-yI)-2-oxo-3-pyridyl]-4-methyl-r-(2,2,2-trifluoroethyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-l-ium]-5-carbonyl]indol-l-yl]-2-methyl-cyclopropylj-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethy]tetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l-(5-fluoro-l-niethyl-isoquinoliii-2-ium-6-yl)-2-oxo-3-pyridyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimetliyl-phenyl)-3-[l-(4-fluoro-l-methyl-indazol-2-iuni-5-yl)-2-oxo-3-pyridyl]-4-methyl-spiro[4,6-dihydropyrazolo[4.3-c]pyridine-7 / l'-cyclobutane]-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;N-(l -cyclopropyl-4-fluoro-indazol-5-yl)-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4- l]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihy dro-4H-pyrazolo[4, 3-c] azepin- l-ium-7,l'-cyclopropane]-3-yI] acetamide;2-[(4S)-5-]5-[(4S)-2,2-dimethyitetrahydropyran-4-yl]-l-[(lS,2S)-2-methyI-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c]azepin-l-ium-7,r-cyclopropane]-3-yl]-N-(l-methyIindazol-5-yl)acetamide:2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6.8-dihydro-4H-pyrazolo[4, 3-c] azepin- l-ium-7,r-cyclopropane] -3-yl] -N-(6-fluoro-l-methyl-indazol-5-yl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyI-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c]azepin-l-ium-7,r-cyclopropane]-3-yl] -N-(4-fluoro-l-methyl-indazol-5-yl)acetamide;N-(1-methylindazol-5-yl)-2-[(4S)-4,7,7-trimethyl-5-[1-[(1S,2S)-2-methyl-1-(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-2-[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]-4,6-dihydropyrazolo[4,3-c]pyridin-1-ium-3-yl]acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4,7,7-trimethyl-2-[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]-4,6-dihydropyrazolo[4,3-c]pyridin-1-ium-3-yl]-N-(1-methylindazol-5-yl)acetamide;2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-[(IS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(2-methylquino]in-l-ium-6-yl)acetamide;2-[(4S)-2-(4-fluoro-3,5-diniethyl-phenyD-4,7,7-trimethyl-5-[5-[(2S)-2-methylmorpholin-4-yl]-l-[(l S,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-N-(2-methylquinolin- 1 -iurn-6-y I (acetamide;2-[(4S)-2-(4-fluoro-3.5-dimethyl-phenyl)-4.7.7-trimethyl-5-[5-[(2S)-2-methylmorpholin-4-ium-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-N-(l-methylindazol-5-yl)acetarnide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyi-l-(5-oxo-4H-l,2,4-oxadiazoi-3”yl)cyclopropyl]mdoie-2"Carbonyi]-2-(4”fluoro-3,5"dimethyI-phenyl)- 4.7.7-trimethyI-4,6-dih dropyrazolo|4,3-c]pyridin-l-ium-3-yl]-N-(4-fluoro-l -methyl-indazol-5-yl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimelhyheirahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazoI-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)- 4,7,7-trimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-N-(2-methylquinolin-1-ium-6-yl)acetamide;2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l -ium-3-yl]-N-(4-methoxy-l-bicyclo[2.2.2]octanyl)acetamide:2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4.7.7-trimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(l-methylmdazol-5-yl)acetamide;2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[5-[(2S)-2-methylmorpholin-4-ium-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-1-methyl-indazol-5-yl)acetamide;2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[5-[(2R)-2-methylmorpholin-4-ium-4-yl]-l-[(l S,2S)-2-methy1-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indo1e-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)acetamide;N-[4-(cyclopropoxy)cyclohexyl]-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyI]-2-(4-fluoro-3,5-dimethyl-phenyl)-4,7,7-trimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-l-ium- 3-yl]acetamide;3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[4-(4-fluoro-1-methyl-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-1-ium-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-nnidazoI-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbon T|-5-[(lS,5R)-6-hydroxy-2-bicyclo[3.2.1]octanyl]indol-l-yl]cyclopropyl]-4H-1.2.4-oxadiazol-5-one;3-[1-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-5-[(1S,5R)-6-hydroxy-2-bicyclo[3.2.1]octanyl]indol-1-yl]cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(4-f1uoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]-5-(4-oxa-7-azoniaspiro|2.5]octan-7-yl)indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]-5-[(2S)-2-methylmorpholin-4-ium-4-yl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[5-(2,2-dimethylmorpholin-4-ium-4-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one,3-[l-[3-(4,4-difluoroisochroman-6-yl)-5-[(4S)-2-(4-fluoro-3.5-dimethyI-phenyi)-3-|3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-6.7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]pyrazol-l-yl]cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[3-(l,7-dimethylindazo3-2-ium-6-yl)-5-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yr)-2-oxo-imidazol-l-yl]-4-methyl-6.7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]pyrazol-]-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c|pyridin-3-yr|-2,2-difluoro-N-(4-fluoro-l -methyl-indazol-5-yl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methy 1-4, 6, 7, 8-tetraliydropyrazolo[4,3-c] azepin- l-ium-3-yi]-N-(4-fluoro-l -methyl-indazol-5-yl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-1'-(2,2,2-trifluoroethyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-1-ium]-3-yl]-N-(4-fluoro-1-methyl-indazol-5-yl)acetamide;3-[(lS,2S)-l-[5-[(4S)-2,2-dimelhyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|(lS.6S)-3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-3-azabicyclo[4, 1.0]heptan-l-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,r-cyclopropane]-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[(1R,6R)-3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-1-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,1'-cyclopropane]-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l -yl]-4-methyl-4,6,7.8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyI]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one:3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-1-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-4-methyl-5-[l -[(IS, 2S)-2 -methyl- 1 -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(l-methylindazol-5-yl)cyclopropanecarboxamide;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[l-(l -methylmdazol-5-yl)-2-oxo-pyrrolidin-3-yl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-5-tetrahydropyran-4-yl-indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3.5-dimethyl-phenyI)-4-methyl-3-[(lS,6S)-3-(2-methyl-6-quinolyl)-2-oxo-3-az.abicyclo[4.1.0]heptan-l-y1]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cydopropyl]-4H-l,2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[(lS,6S)-3-(l-methyl-6-isoquinolyl)-2-oxo-3-azabicydo[4.1.0]heptan-l-yl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl|-2”methyl-cyclopropyl]-4H-1.2,4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-3-[(1S,6S)-3-[2-(cyclopropoxy)-4-pyridyl]-2-oxo-3-azabicyclo[4.1.0]heptan-1-yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-I-[2-[(4S)-3-[l-[4-(cyclopropoxy)cyclohexyI]-6-oxo-pyrimidin-5-yl]-2-(4-fiuoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4.3-c]pyridine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyI-cydopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[1-(4-methoxycyclohexyl)-6-oxo-pyrimidin-5-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-1-ium-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-1'-(2,2-dimethylpropanoyl)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-1'-(2,2-difluoroacetyl)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-r-(2.2-difluoropropanoyl)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-ylJ-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyI-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-mdazol-5-yr)-2-oxo-imidazol-l-yl]-4-methyl-r-(2,2,3,3-tetrafluoropropanoyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyI]indol-l-yI]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiaz.oI-5-one,3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyJtetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyr)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-r-(2,2,2-trifluoroacetyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyI]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-1'-acetyl-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-1'-(2,2,2-trifluoroethyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-1-ium]-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-1'-(2,2,2-trifluoroethyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-1'-(2,2-difluoroethyl)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-1-ium]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-y1]-r-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethyl]-4-methyI-spiro[4,6-dihydropyrazolo[4.3-c]pyridine-7,3'-azetidin-I-ium]-5-carbonyl]-5-tetrahydropyran-4-yl-mdol-l-yl]-2-methyl-cyclopropyl]-4H-1.2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-r-benzyl-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyI-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-spiro[4,6-dihydropyrazo1o[4,3-c]pyridine-7,3'-azetidin-l-ium]-5-carbonyl]-5-tetraliydropyran-4-yl-indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethy]tetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-r-(2-hydroxy-2-methyl-propyl)-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-1-ium]-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-r-cyclohexyl-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l -yl]-4-niethyl-spiro|4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-l-ium]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazoI-5-one;3-[(1S,2S)-1-[2-[(4S)-1'-(cyclopropylmethyl)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-1-ium]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-y1]-4-methyl-r-methylsulfonyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-l-yl]-2-methyl-cyclopropyl|-4H-1.2.4-oxadiazol-5-one;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4-methyl-2-[5-(trifluoromethyl)-3-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-1-methyl-indazol-5-yl)acetamide;2-[(4S)-2-(3-cyclopropyl-4-fluoro-phenyl)-5-[7-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-3-[1-(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]indolizine-2-carbonyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-1-methyl-indazol-5-yl)acetamide;3-[l-[2-[(4S)-2-(3-cyclopropyl-4-fluoro-phenyl)-4-methyl-3-[l-(l-methyIindazol-5-yl)-2-oxo-3-pyridyl]-6.7-dihydro-4H-pyrazolo[4.3-c]pyridine-5-carbonyl]-7-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indolizin-3-yl]cyclopropyl]-4H-l;2;4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-4-methyl-3-[5-(3-methylimidazo[l,5-a]pyridin-7-yl)-lH-l,2.4-triazol-4-ium-3-yl]-6,7-dihydro-4H-pyrazolo[4.3-c]pyridme-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[5-(4-fluoro-l-methyl-indazoI-5-yI)-lH-1.2.4-triazol-4-ium-3-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]indol-l-yl]-2-methyl-cyciopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[5-(2,3-dimethylimidazo[l,2-a]pyri din-6-yl)-lH-l,2,4-triazol-4-iiini-3-yI]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyi]-5-[(4S)-2.2-dimethyltetrahydropyran-4-yl]indol-l-yi]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetraliydropyran-4-yl-indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4.3-c]pyridin-3-yl]-N-(4-fluoro-] -methyl-indaz.ol-5-yl)cyclopropanecarboxamide:l-[(4S)-5-[5-|(4S)-2,2-dimethyltetrali dropyr n-4-yl]-l-[(l S,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluofo-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(l-methylindazol-5-yl)cyclopropanecarboxamide;N-[2-(cyclopropoxy)pyridin-l-ium-4-yl]-l-[(4S)-5-[5-|(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-Huoro-3,5-dimethyl-phenyr)-4-methyl-6.7-dihydro-4H-pyrazolo|4,3-c]pyridin-3-yl| cyclopropanecarboxamide;N-[4-(cyclopropoxy)cyclobexyl]-l -[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-niethyl-6,7-dihydro-4H-pyrazolo|4.3-cjpyridin-l-ium-3-yl]cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyr zolo[4,3-c]pyridin-l-ium-3-yl]-N-(2-fluorophenyllcyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(2-fluoroph eny l)cy cl opropanecarboxamide;1-[(4S)-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-5-[5-[(2S)-2-methylmorpholin-4-ium-4-yl|-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-6,7-dihydro-4H-pyraz.olo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyI-indazol-5-yllcyclopropanecarboxamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyi-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(4-fluoro-l -methyl-indazol- 5-yl)propanannde;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyi-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo|4,3-c|pyridin-l-ium-3-yl]-N-(4-fluoro-l-methyl-indazol- 5-yl)propan amide;N-(l-methy1indazol-5-yl)-2-[rac-(4S)-5-[5-(2,2-dimeihy1tetrahydropyran-4-yl)-l-[rac-(lSt2S)-2-metliyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyI-phenyI)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]propanamide;N-(l-methylindazol-5-yl)-2-[rac-(4S)-5-[5-(2.2-dimethyltetrahydropyran-4-yl)-l-[rac-(lS?2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyI|-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazo1o[4,3-c|pyri din-3-yl]propan amide;N-(2-fluorophenyl)-2-[rac-(4S)-5-[5-(2,2-dimethyltelrahydropyran-4-yl)-l-[rac- (15.25)-2-methyl-l-(5-oxo-4H-l,2?4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl|-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazoIo[4,3-c]pyri din-3-yl]propanamide;N-(2-fluorophenyl)-2-|rac-(4S)-5-[5-(2,2-dimethyltetraliydropyran-4-yl)-l-[rac- (15.25)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4:3-c]pyridin-3-yl]propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4.3-c]pyridin-l-ium-3-yl]-N-(4-methoxy-l-bicyclo[2.2.2]octanyl)propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fIuoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(4-methoxy-l-bicyclo|2.2.2|octanyl)propanannde;N-[4-(cyclopropoxy)cyclohexyI]-2-[rac-(4S)-5-[5-(252-dimethyItetrahydropyran-4-y])-l-[rac-(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yI)cy opropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c] py ridin-3 -y I] propanamide;N-[4-(cyclopropoxy)cyclohexyl]-2-[rac-(4S)-5-[5-(2,2-dimethyltetrahydropyran-4-yl)-l-[rac-(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6.7-dihydro-4H-pyrazolo[4.3-c]pyndin-3-yl]propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)propanamide;2-[(4S)-5-[5-|(4S)-2,2-dimethyltetraliydropyran-4-yl]-l-[(l S,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)propanamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methy 1-4, 6, 7, 8-tetrahydropyrazolo[4,3-c] azepin- l-ium-3-yl]-N-(4-fluoro-l -methyl-indazol-5-yl)cyclopropanecarboxamide:N-( 1,3-benzothiazol-3-ium-6-yl)-l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo|4,3-c|azepin-3-yl] cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4, 6,7, 8-tetraliydropyrazolo[4,3-c] azepin- 1 -ium-3-yl]-N-(2-methylindazol-5-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-l-ium-3-yl]-N-(l-methylindazol-5-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazoIo[4,3-c]azepin-l-ium-3-yl]-N-[l-(trideuteriomethy])indazol-5-yl]cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyi-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-l-ium-3-yl]-N-(6-fluoro-l -methyl-indazol-5-yl)cyciopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yS,2S)-2-methyi-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methy 1-4,6, 7, 8-tetrahydropyrazolo[ 4, 3-c] azepin- 1 -ium-3 -yl] -N-(l -ethylindazol-5 -yl)cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl ]-2-(4-fluoro-3, 5-dimethy l-phenyl)-4-methy 1-4,,7,8-tetrahy dropyrazolo[4, 3-c ]azepin- 1 -ium-3 -yl] cyclopropanecarboxamide;N-(l-cyclopropylindazol-5-yl)-l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]- 1-[(lS,2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-l-ium-3-yl]cyclopropan ecarboxamide;l-[(4S)-2-(4-fluoro-3,5-dimethyl-pheiiyl)-4-methyl-5-[l-[(lS,2S)-2-melhyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-4,6,7,8-tetrahydropyrazol o[4, 3-c] azepin- l-ium-3-yl]-N-(4-fluoro-l -methyl-indazo]-5-yl)cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-5-j 1-[(1 S,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiaz.ol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-l -ium-3-yl] cyclopropanecarboxamide;N-[4-(cyclopropoxy)cyclohexyl]-l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]- 2-(4-fluoro-3.5-dimethyl-pheiiyl)-4-methyl-4.6,7,8-tetrahydropyrazolo[4.3-c]azepiii-l-ium- 3-yl]cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indaznl-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-5-[5-[(2S)-2-methylmorpholin-4-ium-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H- 1,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4.6,7,8-tetrahydropyrazolo[4.3-c]azepin-3-yl]cyclopropanecarboxamide;l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[5-[(2S)-2-methylmorpholin-4-ium-4-yl]-l-[(l S,2S)-2-methy1-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indo1e-2-carbonyl]-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4, 6,7, 8-tetrahydropyrazolo[4,3-c]azepin-l-ium-3-yi]-N-[l -(2,2,2-tnfltJoroethy!)indazol-5-yl]cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-mdazol-5-yl)-l-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-5-[5-|(2S)-2-methylmorphoIin-4-ium-4-yl]-l-[(lS,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropy]]mdole-2-carbonyl]spiro[6,8-dihydro-4H-pyrazolo[4,3-c]azepine-7,l'-cyclopropane]-3-yl]cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl ]-l-|(l S,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl]-N-isoquinolin-2-ium-6-yl-cyciopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-niethyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl]-N-(l-methylisoqumolin-2-ium-6-yljcyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl|-N-(5,6,7,8-tetrahydroquinolin-l-ium-6-yl)cyclopropanecarboxamide:l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c] zepin-3-yl]-N-(5,6,7,8-tetrahydroisoquinolin-7-yllcyclopropanecarboxamide;1-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl]-N-(5,6,7,8-tetraJhydroisoquinolin-7-yl)cyclopropanecarboxamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)-2-hydroxy-propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyi-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazo1o[4,3-c]pyridin-3-yl]-2-fluoro-N-(4-fluoro-l -methyl-indazol-5-yl)propanamide;2-cycIopropyl-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-I-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyi)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c|pyridin-3-yr|-N-(4-fluoro-l-methyI-indazol-2-ium-5-yI)-2-hydrox -acetamide;2-cyciopropyl-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethy]-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-2-ium-5-yI)-2 -hydroxy-acetamide;2-cyclopropyl-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-I-[(lS,2S)-2-methyI-l-(5-oxo-4H-L2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyI)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-2-fluoro-N-(4-fluoro-1 -methyl -indazol-5-yI)acetamide;2-cyciopropyl-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyi|-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyri din-3-yl]-2-fluoro-N-(4-fluoro-l-methyl-indazol-5-yl)acetamide:2-cyclopropyl-2-|(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cycIopropyl]indole-2-carbonyl]-2-(4-fluoro-3?5-dimethyl-phenyl)-4-metbyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-2-fluoro-N-(l-methyl-6-isoquinolyl)acetamide;2-cyclopropyl-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl|-l-[(lS,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyI)-4-methyi-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-2-fluoro-N-(l-methyl-6-isoquinolyl)acetamide;[l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-2-[(4-fluoro-l-methyl-indazol-2-ium-5-yl)amino] - 1 -methy l-2-oxo-ethyl]-dimethyl-ammomum;[l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-y]]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridm-3-yl]-2-[(4-fluoro-l-methyI-mdazol-2-ium-5-yl)amino]-l-methyI-2-oxo-ethylj-dimethyl-ammonium;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2.4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)~4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)-2-methoxy-propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,24-oxadiazol-3-yl)cycIopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-y])-2-methoxv-propanamide;3-[(lS,2S)-l-[2-[(4S)-2-(l-cyclopropylpyrazol-4-yl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l -yl|-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,l'-cyclopropane]-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indoi-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-3-[3-(4-fluoro-l -methyI-indaz.ol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-2-[l-methyl-5-(lrifluoromethyl)pyrazol-3-yI]-6,7-dihydro-4H-pyrazolo[4.3-c]pyridme-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl|-4H-1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-3-[3-(4-fluoro-l-methy l-indazol-5 -yl)-2-oxo-imidazol- 1 -yl] -4-methy l-2-[ 1 -methyl-5 -(trifluoromethyl)pyrazol-3-yl]spiro[4,6-dihydropyrazolo|4,3-c|pyridine-7,r-cyclopropane|- 5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one:3-[(lS,2S)-l-[5-[(4S)-2,2-dimelhy]tetrahydropyran-4-yl]-2-[(4S)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-2-[5-(trifluoromethyl)-3-pyridyl]spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7.r-cyclopropane]-5-carbonyl]indol-l-yl]-2-methyl-cycIopropyl|-4H-1.2.4-oxadiazol-5-one;3-[(lS?2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[5-(2-methyl-4-pyridyl)-lH-I.2,4-tnazol-4-ium-3-yl]-6,7-dihydro-4H-pyrazolo[4,3-c|pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazo1-5-one;3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yi]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|3-(4-fluoro- 1 -methyl-indazol-5-yl)-2-oxo-3-azabicy clo| 3.1. OJhexan- 1 -y]]-4-methyl-6;7-dihydro-4H-pyrazolo[4,3-c]pyrjdirie-5-carbonyl]indol-l -yl]-2-methyi-cy clopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethy!-phenyl)-3-[3-(4-fluoro-l-methy!-indazol-5-yl)-2-oxo-3-azabicyclo[3.1,0]hexan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyI-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[5-(4-fluoro-l-methyl-indazol-2-ium-5-yl)-6-oxo-pyridazin-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl|-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;1-[(4S)-5-[7-(2,2-dimethyltetrahydropyran-4-yl)-3-[l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indolizine-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methy 1-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyI-indazol-5-yl)cyclopropanecarboxamide;3-[l-[7-(2,2-dimethyltetraliydropyran-4-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-pyrrolidin-3-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indolizin-3-yl] cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[l-[7-(2,2-dimethyltetrahydropyran-4-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-| l-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-pyrrolidin-3-yl|-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indo1izin-3-yl]cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[5-(4-fluoro-l-methyl-mdazoI-5-yl)-6-oxo-pyrimidin-l-yr|-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-5-carbonyl]indol-l -yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethy 1-pheny l)-3-[5-(4-fl uoro-l-methyl-indazol-5-yl)-6-oxo-pyri midin- l-yl]-4-methyl-4,6,7,8-tetraliydropyrazolo[4,3-c]azepme-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fIuoro-3,5-di ethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-I-ium-3-yl]-4-(4-fluoro-l-methyl-indazol- 5-yl)-2-methyl-morpholin-3-one;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl]-4-(4-fiuoro-l-methyl-indazol- 5-yl)-2-methyl-rnorpholin-3-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-diniethyl-phenyI)-4-methyl-3-[4-(l-methylindazol-2-ium-5-yl)-5-oxo-l,2,4-triazol-l-yl]-4,6,7,8-tetrahydropyrazoJo[4,3-c]azepine-5-carbonyl]indoJ-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(3-cyclopropyl-4-fluoro-phenyl)-3-[4-(4-fluoro-l-methyl-indazol-2-iiim-5-yl)-5-oxo-l,2,4-triazol-l-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c] azepine-5-carbonyl]-5-[(4S)-2.2-dimethyitetrahydropyran-4-yl]indo3-l-y]]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazoI-5-one;2-[(4S)-5-[5-|(4S)-2,2-dimethyltetraliydropyran-4-yl]-l-[(l S,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-2-ium- 5-yl)-2-methyl-propanamide;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-y1]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-l-yl]-2-methyl-cyclopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-y3]-2-[(4S)-4-ethyl-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4,6,7,8-tetraliydropyrazolo[4,3-c]azepin-l-ium-5-carbonyl]indol-l-yl]-2-methyi-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-(2,2-dimethyltetrahydropyran-4-yl)-2-[(4S)-2-(4-fluoro-3,5-diniethyl-pheny!)-3-[l-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-pyrrolidin-3-yl]-4-methyl- 6.7-dihydro-4H-pyrazolo|4,3-c]pyridin-l-ium-5-carbonyl]mdol-l-yl]-2-methyl-cy clopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS,2S)-I-[5-(2,2-dimethyltetrahydropyran-4-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l-(4-fluoro-l-methyl-indazol-5-yi)-2-oxo-pyrrolidin-3-yl]-4-methyl- 6.7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-5-carbonyl]indol-l-yl|-2-methyl-cyc1opropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[2-[2-(cyclopropoxy)-4-pyridyl]-3-oxo-pyridazin-4-yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-6,7-dihydro-4H-pyrazolo 4,3-c]pyridine-5-carbonyl]-5-[(4S)-2,2-dimethyItetrahydropyran-4-yl]indol-i-y]]-2-methyl-cyclopropyl]-4H-l,2,4-oxadi azol-5 -one;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyi-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4-methyI-2-[5-(trif!uoroinethy])-3-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-f!uoro-l -methyl-indazol-5-yl)propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyi-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4-methyl-2-[5-(trifluoromethyl)-3-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)propan amide:N-(4-fluoro-l-methyl-indazol-5-yl)-2-[(4S)-4.7,7-trimethyl-5-[5-[(2S)-2-methy lmorpholin-4-yl] - 1 - [(I S,2S)-2-methyl- 1 -(5 -oxo-4H- 1,2,4-oxadiazol-3 -yl)cy clopropyl]indole-2-carbonyI]-2-[5-(trifluoromethyl)pyridin-l-ium-3-yl ]-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]propanamide;N-(4-fluoro-l-methyl-indazol-5-yl)-2-[(4S)-4.7.7-trimethyl-5-[5-[(2S)-2-methyImorpholin-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-L2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-[5-(trifluoromethyl)pyridin-l-ium-3-yl]-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]propanamide;1-[(4S)-5-[5-[(4S)-2,2-dimelhylteirahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indoIe-2-carbonyi]-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-l '-(2?2,2-trifluoroethyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-l -ium] -3-y 1] -N -(4-fluoro- 1 -methyl-mdazol-5 -y l)cy clopropanecarboxamide;3-[(lS,2S)-l-[2-[(4S)-2-(5-cyclopropylpyri din- l-ium-3-yl)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-6.7-dihydro-4H-pyrazolo[4.3-c]pyridine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[2-|(4S)-3-[l-|4-(cyclopropoxy)cyclohexyl]-6-oxo-pyrimidin-5-yl]-2-(4-fluoro-3,5-dimelhyl-phenyl)-4-meth l-4,6,7 8-tetraliydropyrazolo[4,3-c]azepin-l -ium-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fIuoro-3,5-dimethyl-phenyl)-4.7,7-trimethyl-6,8-dihydro-4H-pyrazolo[4.3-c]azepin-l-ium-3-yl]-N-(4-fiuoro-l-methyl-indazol-5-yl)acetamide;l-[(4S)-r-(2,2-difluoroethyl)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(1 S,2S)-2-methy1-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indo1e-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)-4-metliyl-spiro[4,6-diliydropyrazolo[4.3-c]pyndme-7,3'-azeti din- l-ium]-3-yl]-N-(4-tluoro-l-methyl-indazol-5-yl)cy clopropanecarboxamide;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[2-(l -methylindazol-5-yl)-3-oxo-pyridazin-4-yl]spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,r-cyclopropane]-5-carbonyJ]-5-[(2S)-2-methylmorpholin-4-ium-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[l-[2-(difluoromethyl)indazol-5-yl]-2-oxo-3-pyridyl]-2-(5-fluoro-4,6-dimethyl-py ri din- l-iom-2-yl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyri dine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-metbyl-cyc]opropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|2-(4-fliioro-l-methyl-indazol-5-yl)-3-oxo-pyridazin-4-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-5-[(2S)-2-methylmorpholin-4-ium-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazoi-5-one;3-[(lS,2S)-l-[5-(2,2-difluoromorpholin-4-ium-4-yl)-2-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-3-[l-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-3-pyridyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]mdoi-l-yl]-2-melhyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dirnethyl-phenyl)-3-[l-(4-fluoro-l-rnethyl-indazol-5-yl)-2-oxo-3-pyridyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridme-5-carbony 1] -5 -morpholin-4-ium-4-yl-indol- 1 -yl | -2-methy 1-cy clopropyl] -4H- 1,2,4-oxadiazol-5-one;3-[( IS, 2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l-(4-fluoro-l -methyl-indazol-5-yl)-6-oxo-pyrimidin-5-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyndine-5-carbonyl |-5-[(2S)-2-methylmorpholin-4-ium-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l-(4-fluoro-l-methyl-indazol-5-yl)-6-oxo-pyrimidin-5-yl|-4-niethyl-6,7-dihydro-4H-pyrazolo|4.3-c]pyridine-5-carbony l]-5-morpholin-4-ium-4-yl -indol-l-yl|-2-methy 1-cy clopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyr)-3-[l-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-3-pyridyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-5-[(2S)-2-methylmorpholin-4-ium-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4,7,7-tnmethyl-3-[l-(l-methylindazol-5-yl)-2-oxo-3-pyridyl]-4,6-dihydropyrazolo[4,3-c]pyridine-5-carbonyl]-5-[(2S)-2-methylmorpholin-4-ium-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[2-[(4S)-3-[l-[2-(cyclopropoxy)-4-pyridyl]-2-oxo-3-pyridyJ]-2-(5-fluoro-4,6-dimethyl-pyridm-l-ium-2-yl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyndine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)- -[(lS,6S)-3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl|-5-[(2S)-2-methylmorpholin-4-ium-4- l]indol-l-yl]-2-methyl-cyclopropyl|-4H-l,2,4-oxadiazol-5-one,2-[(4S)-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-5-[l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazoi-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indoIe-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-] -methyl-indazo1-2-ium-5-yl)-2-methy I -prop an ami de;2-[(4S)-5-[5-[(4S)-2,2-dimelhylteirahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indoIe-2-carbonyi]-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c] azepin-3-yl]-2-fluoro-N-(l-methyl-6-isoquinolyl)propanamide;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-fluoro-l-(4-fluoro-l-methyl-indazol-2-ium-5-yl)-2-oxo-pyrrolidin-3-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyI-phenyI)-3-[3-fluoro-l-(4-fluoro-l-methyl-indazol-2-ium-5-yl)-2-oxo-pyrroHdin-3-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyi]indol-l-yl]-2-niethyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one:3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-3-[3-(4-fluoro-l-methyl-indazoI-2-ium-5-yl)-2-oxo-3-azabicyclo[3.1.0]hexan-l-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl|indol-l-yl]-2-methyl-cyclopropyl]-4H-l?2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[3-(2-methy1quinolin-l-ium-6-yl)-2-oxo-3-azabicyclo[3.1.0]hexan-l-yl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]mdol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;2-[(4S)-2-(4-fluoro-3.5-dimethyi-phenyI)-4,7,7-trimethyi-5-[l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-4,6-dihydropyrazolo[4.3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)-2-methyl-propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,24-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4.7.7-trimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)- 2-methyl-propanamide;3-[(lR,2S)-l-[5-(2,2-dimethyltetrahydropyran-4-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-5-carbonyl]phenyl]-2-methyl-cyclopropyi]-4H- 1,2,4-oxadiazoi-5-one;2-[(4S)-2-(4-fluoro-3,5-dimethyl-pheny])-4-methyl-5-[2-|(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-(l,3,7-trimethylindazol-6-yl)pyrazole-3-carbonyl]- 6.7-dihydro-4H-pyrazolo[4,3-c]pyridiii-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)acetaniide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-5-[5-(3.3-dimethyi-2-oxo-indolin-5-yl)-2-[(l S?2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadia o3-3-yl)cyclopropyl]pyrazoJe-3-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c|pyridin-3-yl]cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[2-[(l S,2S)-2-methyJ-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-[l-methyl- 3-(trifluoromethyl)pyrazol-5-yl]pyrazole-3-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]cyclopropanecarboxamide;l-[(4S)-5-[5-(l,7-dimethylindazol-6-y])-2-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2;4-oxadiazol-3-yl)cyclopropyl]pyrazole-3-carbonyl]-2-(4-fluoro-3?5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c|pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazo1-5-y1)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[5-[4-(3-methyloxetan-3-yl)phenyl]-2-[(lS.2S)-2-methyl-l-(5-oxo-4H-L2.4-oxadiazol-3-yl)cyclopropyl|pyrazole-3-carbonyl|-6.7-dihydro-4H-pyrazolo[4.3-c|pyndin-3-y 1 ] cyclopropanecarboxamide;l-[(4S)-5-[5-(l,7-dimethylindazol-6-yl)-2-[(l S,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]pyrazole-3-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,r-cyclobutane]-3-yI]-N-(4-fluoro-l-methyl-indazol-5-yl)cyclopropanecarboxamide;N-(l-cy opropyl-4-fluoro-indazol-5-yl)-l-[(4S)-5-[5-(1.7-dimethyHndazol-6-yl)-2-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]pyrazole-3-carbonyl]-2-(4-fluoro-3, 5-dimethyl-phenyl)-4-methyl-6, 7-dihydro-4H-pyrazolo[4,3-c]pyri din-3- 1] cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazo1-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-5-[5-[4-(l -methoxy cyclobutyl)phenyl]-2-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]pyrazole-3-carbonyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4;3-c]pyridin-3-yl]cyclopropanecarboxamide;3-[(lS,2S)-l-[5-[(4S)-2-(4-fluoro-3,5-dimethyl- henyl -3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-3-(5-methyI-6-isoquinolyl)pyrazol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;5-[4-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-2-iiini-5-yl)-2-oxo-imidazol-l-yI]-4-methyl-6,7-dihydro-4H-pyrazoio[4,3-c]pyridm-l-ium-5-carbonyl]-3-[(lR,2S)-l -(5-hydroxy-l,2,4-oxadiazole-2,4-diium-3-yl)-2-methyl-cyclopropyl]phenyl]-3,3-dimethyl-indolin-2-one;N-(2,3-dimethyl-4-pyridyl)-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyraii-4-yl|-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2.,4-oxadiazol-3-yl)cycIopropyl|indole-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-4.6,7,8-tetrahydropyrazolo[4.3-c]azepin-3-yl] acetamide;N-(l-cyclopropylindazol-5-yl)-2-|(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-1 -[(1 S.2S )-2-methy 1- 1 -(5-oxo-4H-l,2,4-oxadiazoi-3-yI )cy clopropyl]indole-2-carbonyl| -2-(4-fiuoro-3,5-dimethyl-phenyi)-4-methyl-spiro[6f8-dihydro-4H-pyrazolo[4,3-c]azepm-l-ium-7,r-cyclopropane]-3-yI]acetamide;N-(l-cycIopropylindazol-2-ium-5-yl)-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4,7,7-trimethyl-6,8-dihydro-4H-pyrazolo[4,3-c]azepm-3-yl]acetamide;N-(l-cyclopropylindazol-5-yl)-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-1-[(1 S,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-y1)cyclopropyl]indole-2-carbonyl]-2-(4-fiuoro-3,5-dimetliyi-phenyl)-4-methyl-spiro[4.6-dihydropyrazolo[4,3-c]pyridme-7,r-cy cl obutane] -3-yi ] acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2.4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6.8-dihydro-4H-pyrazolo[4.3-c]azepin-l-ium-7,r-cyciopropane]-3-yl]-N-(4-fluoro- l-methyl-indazol-5-yl)acetamide:2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-diniethyl-phenyl)-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4.,3-c]azepine-7,l'-cyclopropane]-3-yl]-N-(l-methylisoquinolin-2-ium-6-yl)acetamide;N-(l -cyclopropyl -4-fluoro-indazol-5-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7.1'-cyclo butane] -3-yl] acetamide;N-(4,6-difluoro-l-methyl-indaz.ol-5-yl)-2-[(4S)-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-5-[l-[(l S,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-mdole-2-carbonyl]spiro[4,6-dihydropyrazolo[4,3-c]pyndine-7.1'-cyclobutane] -3-yl jacetamide;N-( 1 -cyclopropyl-4-fluoro-indazol-5-yl)-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahy dropyraii-4-y 1] - 1 - [( 1 S,2S)-2-methy 1- 1 -(5-OXO-4H-1,2.4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro|4,6-dihydropyrazolo[4,3-c]pyridine-7,r-cyclobutane]-3-yl] acetamide;N-(4T6-difluoro-l-methyl-indazol-5-y])-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS.2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihy dro-4H-pyrazolo[4, 3-c] azepin- l-ium-7.r-cyclopropane]-3-yI] acetamide:2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c]azepine-7,r-cyclopropane]-3-yl]-N-(3-metbylisoquinolin-2-ium-6-yl)acelamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2T4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c]azepir!e-7,r-cydopropane]-3-yi]-N-(2-methylquinolin-l-ium-6-yl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4,7,7-trimethyl-6,8-dihydro-4H-pyrazolo[4,3-c]azepin-l-ium-3-yl]-N-(4-fluoro-l -methyl-indazol-5-yl)acetamide;3-[(lS.2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[3-(l-methylisoquinolm-2-ium-6-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl]-6,7-dihydro-4H-pyrazolo|4,3-c|pyridine-5-carbonyl]-5-[(2S)-2-methylmorphoiin-4-yl]indol-l-yl]-2-methyl-cyciopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyJtetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-diniethyl-phenyr)-3-[3-(7-fluoro-l-methyl-isoquinolin-2-ium-6-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo|4,3-c|pyridine-5-carbonyl|indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(5-fluoro-l-methyl-isoquinolin-2-ium-6-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-y1]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyI]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimelhylteirahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|3-(7-fluoro-2-methyl-quinolin-l-ium-6-yl)-2-oxo-3-azabicyclo[4, 1.0]heptan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[3-(l-cyclopropyl-4-fluoro-indazoi-2-ium-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-y]]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazoJo[4,3-c]pyridine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyI-phenyI)-3-[(l S,6S)-3-(4-h droxycycIohexyl)-2-oxo-3-azabicycIo[4,1.0]heptan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-niethyl-cyclopropyl]-4H-l,254-oxadiazol-5-one:3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-3-[3-(6-fluoro-l-methyl-indazoI-2-ium-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl|indol-l-yl]-2-methyl-cyclopropyl]-4H-l?2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[(lS,6S)-3-[4-(cyclopropoxy)cyclohexyl]-2-oxo-3-azabicyclo[4, 1.0]heptan-l-yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methy1-6,7-dihydro-4H-py azolo[4,3-c]pyridine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cycIopropyI]-4H-l,2,4-oxadiazoI-5-oneN-(4-chloro-l -methyl -indazoI-5-yI)- 1 -[(4S)-5-[5-[(4S)-2,2-dimethy]tetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2.4-oxadiazol-3-yl)cyclopropyI]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6.7-dihydro-4H-pyrazolo[4.3-c]pyndin-l-ium-3-yl]cyclopropanecarboxamide;l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-|(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetraliydropyran-4-yl-indole-2-carbonyl]spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7, 1 '-cyclobutane]-3-yl]-N-( 1 -methylisoquinolin-2-ium-6-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-|(4S)-2,2-dimethyltetrali dropyr n-4-yl]-l-[(l S,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(6-fluoro-l-metliyl-mdazol- 5-yl)cyclopropanecarboxamide;l-[(4S)-2-(4-fluoro-3,5-dimethyl-pheny])-4-methyl-5-[l-|(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(6-fluoro-l-methyl-indazol-5-yljcyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl“6,7-dihydro-4H-pyrazolo[4,3"C]pyridiii-3-yl]-N-(5,6,7,8-tetrahydroisoquinoiin-2-ium-7-yl)cyclopropanecarboxamide:N-(4.6-difluoro-l -methyl-indazoJ-5-y])-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonylj-6,7-dihydro-4H-pyrazolo|4,3-c|pyridin-l-ium-3-yl]cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(5.6,7,8-tetrahydroisoquinolin-2-ium-7-yl)cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-y])cycIopropyl]indole-2-carbonyi]-2-(4-fluoro-3,5-djmethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyri din- l-ium-3-yl] cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyi-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(2-methylqinnolin-l-ium-6-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-y 1]-1-[(1 S.2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)- 4.7.7-trimethyl-4,6-dihydropyrazolo|4,3-c]pyridin-l-ium-3-yl| -N-(l-methylindazol-5-yl)cyclopropan ecarboxamide;l-[(4S)-2-(4-fluoro-3.5-dimethyl-pheny])-4-methyl-5-[l-[(lS,2S)-2-meihyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]spiro[4.6-dihydropyrazolo[4,3-c]pyridin-l-ium-7,r-cyclobutane]-3-yl]-N-(l-methylindazol-5-yl)cyclopropanecarboxamide;N-(4.6-difluoro-l-methyl-indazol-5-yl)-l-[(4S)-5-[5-[(4S)-2.2-dimethyitetrahydropyran-4-yl]-l-[(lS?2S)-2-methyl-l-(5-oxo-4H-l,2,4”Oxadiazoi-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7.8-tetrahydropyrazolo[4,3-c]azepin-l-ium-3-y]] cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimelhylteirahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3?5-dimethyl-phenyl)- 4.7.7-trimethy]-4,6-dihydropyrazolo[4?3-c]pyridin-l -ium-3-yl]-N-(4-fluoro-l-methyI-indazol-5-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4.6,7,8-tetrahydropyrazolo[4,3-c]azepir!-l-ium-3-yl]-N-(7-fluoro-2-methyl-indazol-5-yl)cyclopropanecarboxamide;N-(4.6-difluoro-l-methyl-indazol-5-yl)-l"[(4S)-5-[5-[(4S)-2,2-dimethylte(.rahydropyran-4-yl]-l-[(lST2S)-2-methyl-l-(5-oxo-4H-l,2.4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3?5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl] cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS;2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fIuoro-3,5-dimethyl-phenyl)-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridin-l-ium-7,r-cyclobutane]-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)cyclopropanecarboxamide;N-(l -cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[2-[(lS,2S)-2-methyi-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cycIopropyl]-5-(4-morpholinophenyl)pyrazole-3-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yljcyclopropanecarboxamide;N-(4-chloro-l-methyl-indazol-5-yl)-l-[(4S)-5-[5-[(4S)-2,2-dimethy]tetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2.4-oxadiazol-3-yl)cyclopropyI]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4.6.7.8-ietrahydropyrazolo[4,3-c] azepin- l-ium-3-yl] cyclopropanecarboxamide:1-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[5-|(2S)-2-methylmorpholin-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-L2,4-oxadiazol-3-yl)cyclopropyi]indole-2-carbonyI]spiro[4,6-dihydropyrazoio[4?3-c]pyridine-7,r-cyclobutane]-3-yl]-N-(l-methylisoquinolin-2-ium-6-yl)cy clopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazol-2-ium-5-yl)-2-[(4S)-5-[5-[(4S)-2,2-dimethyitetrahydropyran-4- ll-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxad azol-3-yl)cyclopropyl]iiidole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4,7,7-trimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-2-hydroxy-propanamide;2-cyclopropyl-2-[(4S)-5-[5-|(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-diniethyl-phenyI)-4-niethyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-2-fluoro-N-(l-methylindazol-5-yl)acetamide:1-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-r-[(l-methylcyclopropyl)methyl]spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-l-ium]-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)cyclopropanecarboxamide:2-[(4S)-5-[5-[(4S)-2,2-dimethyitetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[4,6-dihydropyrazolo 4,3-c]pyridine-7,r-cyclobutane]-3-yl|-N-(5-fluoro-l-methyl-6-isoquinolyl)acetamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yi)-I-[(4S)-5-[4-(3?3-dimethyI-2-oxo-indolin-5-yl)-2-[(lR.2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]benzoyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyri din-3-yl]cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-5-|4-isochroman-6-yl-2-|(lR,2S)-2-methyl-l-(5-oxo-4H-l,2T4-oxadiazol-3-y])cycIopropyl]benzoyl]-4-methyl-6,7-dihydro-4H-pyrazoio[4,3-c]pyri din-3-y 1 ] cy clopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-mdazol-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-5-[4-(6-isoquinolyl)-2-|(lR,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropy]]benzoyi]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]cy clopropanecarboxamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-raethyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[4,6-dihydropyrazofo[4,3-c]pyridine-7,r-cyclobutane]-3-yl]-N-(7-fluoro-l-methyI-6-isoquinolyl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4.7.7-trimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-N-(5-fiuoro-2-methyl-6-quinolyl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazoi-3”yl)cyclopropyl]mdoie-2"Carbonyi]-2-(4”fluoro-3,5"dimethyI-phenyl)- 4.7.7-trimethyI-4,6-dih dropyrazolo|4,3-c]pyridin-3-yl]-N-(5-fluoro-l-methyl-6-isoquinolyl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimelhyheirahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indoIe-2-carbonyi]-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7 '-cyclobutane]-3-yl]-N-(5-fluoro-2-methy I -6 - quin oly 1) acetami de;l-[(4S)-5-[5-[(4S)-2,2-dimethyitetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4II-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazoio[4,3-c]pyridin-3-yl]-N-(5-fluoro-2-methyl-quinolin-l-iiim-6-y!)cyclopropanecarboxamide; and3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|3-(5-fluoro-2-niethyl-quinolin-l-ium-6-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one,or a pharmaceuticall acceptable salt thereof

[0146] In embodiment no, 136, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-132, or a pharmaceutically acceptable salt thereof, wherein Y is other thanbound to B.

[0147] In embodiment no. 1 7, the present invention provides a compound of Formula 1 as set forth in any one of embodiment nos. 1-132 and 136, or a pharmaceutically acceptable salt thereof, wherein Y is other thano o£, A 1 or £ Ax wherein the lefton Y is bound to the pvrazole moietv and tyV N -" * N - %Z_\ HHAthe right X on Y is bound to B.

[0148] In embodiment no. 138, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-132 and 136-129, or a pharmaceutically acceptable salt thereof, wherein Y is other thanowherein the left x on Y is bound to the pyrazole moiety and the right x on Y isbound to B

[0149] In embodiment no. 139, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-132 and 136-138, or a pharmaceutically acceptable salt thereof, wherein Y isleft X is bound to the pyrazole moiety and the right X is bound to B;

[0150] In embodiment no. 140, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-132 and 136-139, or a pharmaceutically acceptable salt thereof, wherein Y is other thano o£ A 1 and £ £"N AN— \ y. wherein the left x on Y is bound to the pyrazole moiety and the V Hright X on Y is bound to B.

[0151] In embodiment no. 141, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-132 and 136-140, or a pharmaceutically acceptable salt thereof, wherein Y is other thanwherein is selected from C1-C3 alkyl or C1-C3 cycloalkyl, wherein the left Y on Y is bound to the pyrazole moiety and the right X on Y is bound to B.

[0152] In embodiment no. 142, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-132 and 136-141, or a pharmaceutically acceptable salt thereof, wherein Y is other thanpyrazole moiety and the right Y on Y is bound to B.

[0153] In embodiment no. 143, the present invention provides a compound of Formula I as set forth in any one of embodiment nos. 1-132 and 136-142, or a pharmaceutically acceptable saltthe leftxon Y is bound to the pyrazole moiety and the right Y on Y is bound to B.

[0154] In instances, the pyrazole moiety is referred to as the pyrazolopyridine structure or the pyrazole.

[0155] The present disclosure is also directed to a pharmaceutical composition which comprises a compound according to any one of embodiments 1-135, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0156] The present disclosure is also directed to a method for treating obesity or non-insulin-dependent diabetes mellitus (Type 2 diabetes) which comprises administering to a subject in need of such treatment (i) a therapeutically effective amount of a compound according to any one of embodiments 1-135. or a pharmaceutically acceptable salt thereof, or (ii) a pharmaceutical composition which comprises a compound according to any one of embodiments 1-135, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0157] The present disclosure is also directed to use of a compound according to any one of embodiments 1-135. or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating obesity or non-insulin-dependent diabetes mellitus (Type 2 diabetes).Definitions

[0158] Listed below are definitions of various terms used herein. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.

[0159] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, and peptide chemistry7are those well-known and commonly employed in the art.

[0160] As used herein, the articles “a” and “an” refer to one or to more than one (i.e.. to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element. Furthermore, use of the term “including” as well as other forms, such as “include,” “includes,” and “included,” is not limiting,

[0161] As used herein, the term “about” in quantitative terms refers to plus or minus 10% of the value it modifies (rounded up to the nearest whole number if the value is not sub-dividable, such as a number of molecules or nucleotides).

[0162] All ranges disclosed herein are inclusive of the recited endpoint and independently combinable (for example, the range of “from 50 mg to 500 mg” is inclusive of the endpoints, 50 mg and 500 mg, and all the intermediate values ). The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value; they are sufficiently imprecise to include values approximating these ranges and / or values.

[0163] As used herein, the term “comprising” may include the embodiments “consisting of’ and “consisting essentially of.” Hie terms “comprise(s),” “include(s),” “’having,” “has,” “may,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that require the presence of the named ingredients / steps and permit the presence of other ingredients / steps. However, such description should be construed as also describing compositions or processes as “consisting of' and “consisting essentially of' the enumerated components, which allows the presence of only the named components or compounds, along with any acceptable carriers or fluids, and excludes other components or compounds.

[0164] With respect to a compound of the invention which has one or more asymmetric centers and can occur as mixtures of stereoisomers, a substantially pure compound can be either a substantially pure mixture of the stereoisomers or a substantially pure individual diastereomer or enantiomer unless expressly depicted otherwise The present invention encompasses all stereoisomeric forms of the compounds of Formula I. Unless a specific stereochemistry7isindicated, the present invention is meant to comprehend all such isomeric forms of these compounds. Centers of asymmetry that are present in the compounds of Formula I can all independently of one another have (R) configuration or (S) configuration. When bonds to the chiral carbon are depicted as straight lines in the structural Formulas of the invention, it is understood that both the (R) and (S) configurations of the chiral carbon, and hence both enantiomers and mixtures thereof, are embraced within the Formula. Similarly, when a compound name is recited without a chiral designation for a chiral carbon, it is understood that both the (R) and (S) configurations of the chiral carbon, and hence individual enantiomers, diastereomers and mixtures thereof, are embraced by the name. The production of specific stereoisomers or mixtures thereof may be identified m the Examples where such stereoisomers or mixtures were obtained, but this in no way limits the inclusion of all stereoisomers and mixtures thereof from being within the scope of this invention,

[0165] The invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and / or diastereomers, m all ratios. Thus, enantiomers are a subject of the invention in enantiomerically pure form, both as levorotatory and as dextrorotatory7antipodes, in the form of racemates and m the form of mixtures of the tw o enantiomers in all ratios. In the case of a cis / trans isomerism the invention includes both the cis form and the trans form as w ell as mixtures of these forms in all ratios. The preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture by customary methods, for example by chromatography or cry stallization, by’ the use of stereochemically uniform starting materials for the synthesis or by stereoselective synthesis. Optionally a derivatization can be carried out before a separation of stereoisomers. The separation of a mixture of stereoisomers can be carried out at an intermediate step during the synthesis of a compound of Formula I or it can be done on a final racemic product. Absolute stereochemistry may be determined by X-ray crystallography of cry stalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing a stereogenic center of known configuration. Unless a particular isomer, salt, solvate (including hydrates) or solvated salt of such racemate, enantiomer, or diastereomer is indicated, the present invention includes all such isomers, as well as salts, solvates (including hydrates) and solvated salts of such racemates, enantiomers, diastereomers and mixtures thereof

[0166] The term '‘alkyl”, as well as other groups having the prefix “alk”, such as alkoxy, dialky lamino, and trialkylammonium, and the like, refers to an aliphatic hydrocarbon group having one of its hydrogen atoms replaced with a bond. An alkyd group may be straight or branched and contain from about 1 to about 10 carbon atoms. In one embodiment, an alkyd groupcontains from about 1 to about 10 carbon atoms In different embodiments, an alkyl group contains from 1 to 6 carbon atoms (C1-6 alkyl) or from about 1 to about 4 carbon atoms (C1-C4 alkyl). Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, w-butyl, sec-butyl, isobuty 1. z -but 1, w-pentyl, neopentyl, isopentyl, w-hexyl, isohexyl and neohexyl. In one embodiment, an alkyl group is linear. In another embodiment, an alkyl group is branched. Unless otherwise indicated, an alkyl group (and any other group recited herein) is unsubstituted.

[0167] "Alk lene” or “alkyleny 1” refers to an alkyl group, as defined above, wherein one of the alkyl group's hydrogen atoms has been replaced with a bond. The alkylene diradicals are also known as alkylenyl radicals. Non-limiting examples of alkylene groups include -CH?-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, -CH(CH3)CH2CH2-, -CH(CH?)- and -CH2CH(CH3)CH2-. In one embodiment, an alkylene group has from I to about 10 carbon atoms. In another embodiment, an alkylene group has from 1 to about 6 carbon atoms. In another embodiment, an alkylene group is branched. In another embodiment, an alkylene group is linear. In one embodiment, an alkydene group is -CH2-. The term “Ci-Ce alkylene” refers to an alkylene group having from 1 to 6 carbon atoms.

[0168] "Alkynylene,” and “alkynylenyl” as used herein, refers to an alkynyl group, as defined above, wherein one of the alkynyl group's hydrogen atoms has been replaced with a bond. Nonlimiting examples of alkylene groups include -C=C-, -C=CCH?-, and -C≡CCH(CH3)2- In one embodiment, an alky nylene group has from 2 to about 6 carbon atoms. In another embodiment, an alkynylene group has from 2 to about 10 carbon atoms. In another embodiment, an alky nylene group is branched. In another embodiment, an alkynylene group is linear. The term “C2-C6 alkynylene” refers to an alkynylene group having from 2 to 6 carbon atoms. The term “C2-C10 alkynylene” refers to an alkynylene group having from 2 to 10 carbon atoms.

[0169] “Alkoxy”, “alkyloxy” and “alkyl O ” are used interchangeably and refer to an alky l (carbon and hydrogen chain) group linked to oxygen (R-O). Non-limiting examples of alkoxy-are methoxy (CH3O-). ethoxy (CH3CH2O-) and propoxy (CH3CH2CH2O-).

[0170] "Ammoalky 1" means saturated carbon chains which may be linear or branched or combinations thereof which are substituted with one amino group which may be terminal (-NH2) or internal (-NTI-).

[0171] "Hydroxyalkyl” means saturated carbon chains which may be linear or branched or combinations thereof which are substituted with one hydroxy (-OH) group.

[0172] "Diaminoalkyl” means saturated carbon chains which may be linear or branched or combinations thereof which are substituted with two amino (-NH2) groups.

[0173] "Dihydroxyalkyl” means saturated carbon chains which may be linear or branched or combinations thereof which are substituted with two hydroxy (-OH) groups.

[0174] "Hydroxyaminoalkyl” means saturated carbon chains which may be linear or branched or combinations thereof which are substituted with one hydroxy (-OH) group and one amino (-NH2) group.

[0175] "And" refers to an aromatic monocyclic or multicyclic ring moiety comprising 5 to 14 ring carbon atoms, or more specifically, 6 to 10 ring carbon atoms. Monocyclic aryl rings include, but are not limited to, phenyl and naphthyl. Bonding can be through any of the carbon atoms of any ring.

[0176] “Cycloalkyd” (or "C3-12 cycloalky l”) means any univalent non-aromatic radical derived from a monocyclic, bicyclic, tricyclic or tetracyclic ring system having 3 to 12 ring carbons atoms. These non-aromatic radicals, which have 3, 4, 5, 6, 7, 8, or up to 12 carbon ring atoms may be fully saturated, or partially unsaturated. Unless slated specifically in the specification, the cycloalkyd radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems Here, the point of attachment for a “cycloalkyl” to the rest of the molecule is on the saturated ring. Bicyclic cycloalkyl ring systems include fused ring systems, where two rings share two atoms (e.g., decalin), spiro ring systems where two rings share one atom (e.g.. spiro

[0045] decanyl) and bridged groups (e.g.. norbornyl).

[0177] Additional examples within the above meaning include, but are not limited to univalent radicals of cyclopropyl, cy clobutyl, cyclopentyd, cyclohexyl, cycloheptyd, bicyclo[2.2.2]octany 1, bicyclo[l.l.l]pentanyd, bicyclo[2.2.1]heptanyl, [1.1.1] -bicyclo pentane, bicyclo[3.1.0]hexanyl, cyclohexenyl, cyclopentenyl, 1 -decalinyl, spiro[2.4]heptyl, spiro[2.3]hexyl, spiro[2.2]pentyl, and norbomyl.

[0178] The term “C3-8 cycloalkyl” (or “Cs-Cs cycloalkyl” or “C3-8 cycloalkyd”) means a cyclic ring of an alkane having three to eight total carbon atoms ( i. e., cyclopropy l, cyclobutyl, cyclopentyl, cyclohexyd. cycloheptyl, or cyclooctyd). The terms “C3-7 cycloalkyl”, “C3-6 cycloalkyd”. “C5-7 cycloalkyd” and the like have analogous meanings.

[0179] "Cycloheteroalkyd" or “heterocycloalk l” means a stable and non-aromatic (including not fully aromatic, e.g., one double bond) monocyclic, bicyclic (including spirocyclic) or bridged carbocyclic ring or ring system comprising 3 to about 12 ring atoms, containing at least one ring heteroatom selected from N. S and O and the remainder of the ring atoms are carbon atoms. The nitrogen or sulfur atom of the heterocycloalkyl can be optionally oxidized to the corresponding N-oxide, S-oxide (S=O) or S-dioxide (SO2). Where the ring or ring system contains one or more N atoms, the N can be in the form of quaternary amine. A heterocycloalkyl group can be joinedvia a ring carbon, or ring nitrogen atom, unless specified otherwise. The cycloheteroalkyl ring may be substituted on the ring carbons and / or the ring nitrogen(s). Whenever it appears herein, a numerical range such as “3 to 12” or ‘3-12” refers to each integer in the given range, in one embodiment, a heterocycloalkyl group is monocyclic and has from about 3 to about 7 ring atoms (a ‘‘3 to 7-membered monocyclic heterocycloalkyl” group). In another embodiment, a heterocycloalkyl group is monocyclic has from about 4 to about 7 ring atoms (a ‘"4 to 7-membered monocyclic heterocycloalkyl” group). In other embodiments, the heterocycloalkyl group is bicyclic and has 7-10 ring atoms, 8-10 ring atoms, or 9 or 10 ring atoms (a “9 or 10-membered bicyclic heterocycloalkyl” group). In still another embodiment, a heterocycloalky 1 group is monocyclic and has 5 or 6 ring atoms. In one embodiment, a heterocycloalkyd group is monocyclic. There are no adjacent oxygen and / or sulfur atoms present in the ring system. In some embodiments, the cycloheteroalkyl or the heterocycloalkyl is a tricyclic or tetracyclic ring system which are optionally spirocyclic containing at least one spiro atom.

[0180] Non-limiting examples of heterocycloalkyl rings include decahydroisoquinoline, dioxaspiro[4.5]decane, 2,5-diazabicyclo[2.2 1]heptyl, quinuclidinyl, oxetanyl, piperidyl, pyrrolidmyl, piperazinyl. morpholinyl. tliiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, teto-lactam, gamma-lactam, e / ta-lactam, 6eto-lactone, gamma-lactone, delta-lactone. pipendinyl, 3-azabixyclo[3.1.0]hexyl, 2-azabicyclo[2.1.1]hexyl, 6-azaspiro[2.5]octanyl, azetidinyl, 2,3-dihydro-lH-indenyl, dihydro-l / f-indenyl, 3 / 7-spiro[benzofuran-2’,4‘-pipendinyl, 2,3-dihydro- 17 / -pyrrolo[3,2, 1 - / / '][!,6]naphthyridinyl, 3.4, 6,7-tetrahydro-5 / / -imidazo[4,5-c]pyridyl, 3a,5,6,6a-tetrahydro-4 / f-pyiTolo[3,4-r / ]isoxazole, diazabicyclo[3.3.2]decanyl, 2,3,4,5,6,7-hexahydroisothiazolo|5,4-u]pyridyI, hexahydro-2 / 7-pyrrolo[3,4-<7]isothiazolyl, 3,9-diazabicyclo[3.3.2]decanyl, bicyclo[2.2,l]heptenyl, 2',3'-dihydro-177-spiro[piperidine-4,4'-qumazolin], octahydropyrrolo| 3.4-6] [l,4|oxazinyl, (diazabicyclo[2.2.1 ]heptanyl), 2,5-diazabicyclo[2.2.1 Jheptanyl, tetrahy drobenzo|<7]thiazolyl, 4,5,6,7-tetrahydrobenzo[d]thiazo1yl, 2,3-dihydrobenzofuranyl, oxabi cyclo[2, 1. l]hexyl, dihydro-5 / 7-pyrrolo[3,4-tf]thiazolyl, 4,6-dihydro-5H-pyrrolo[3,4-< / ]thiazolyl, dihydro-5 / 7-pyrrolo[3,4-r / joxazolyl, 4.6-dihydrO"5 / / -pyrrolo[3,4- ]oxazolyl, dihydrothiazolo[5,4-c]pyndin-5(4 / 7)-yl, 6.7-dihydrothiazolo[5,4-c]pyridin-5(4 / 7)-yl, benzo [<7] imidazolyl, l / 7-enzo[cZ]imidazolyl, diazaspiro[4.4]nonanyl, and 2,7-diazaspiro[4.4]nonanyl, and pyrrolidinone, and oxides thereof and all isomers thereof.

[0181] “Fluoroalkyl” includes mono-substituted as well as multiple fluoro-substituted linear and branched alkyl groups, up to perfluoro substituted alkyl. “Ci-6 fluoroalkyl” refers to afluoronated alkyl group containing from 1 to 6 carbon atoms. For example, fluoromethyl, 1,1-difluoroethyl, difluoromethyl, trifluoromethyl or 3,3,4,4,4-pentafluorobutyl are included.

[0182] “Heteroalky -1” means a non-cyclic stable straight or branched chain, or combination thereof, including at least one carbon atom and at least one heteroatom selected from O, N, P, Si, and S, (including S(O). S(O)2, NH, and N(alkyl)). wherein the heteroatoms may be placed at any interior position of the heteroalkyl group or at the position at which the heteroalkyl group is attached to the remainder of the molecule. Non-limiting examples include ethers, thioethers, amines, and the like. Other non-limiting examples include alkoxy, and aminoalkyl. Further nonlimiting examples include -OCi-Cg alkyl, -(Ci-Cg alkyl)-OCi-C6 alky l, -(Ci-Cg alkyl)-O-(Ci-C6 alkyl)-OCi-Cg alkyl, -NCi-Cg alkyl, -(Ci-Cg alkyl)-NCi-Cg alkyl, and -(Ci-Cg alkyl)-N-(Ci-Cg alkyl)-NC]-Cg alk l. Additional non-limiting examples include -OCF2CF3, -CH2CH2-O-CH2CH2-O-CH3, -CH2CH2-O-CH3, and -OCH3.

[0183] “Heteroaryl” refers to an aromatic monocyclic or multicyclic ring moiety comprising ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from S, N, or O Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings. Examples of heteroaryl rings include pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl. tetrazolyl, furanyl, triazinyl. thienyl, pyrimidyl. pyridazinyl, and pyrazinyl. Other examples of heteroaryl rings include indolyl, indazolyl, and isoquinolinyl.

[0184] "Halogen" or “halo” includes fluorine, chlorine, bromine and iodine

[0185] “Oxo” means an oxygen atom connected to another atom by a double bond and is represented by “::O” herein.

[0186] Where any amine is present in the compound, the N atom may be optionally m the form of a quaternary- amine having one or more appropriate additional substitutions, as further described herein.

[0187] When any ring atom is specified as being optionally substituted with, or in a specified form, for example. S substituted with oxo groups, or N in the form of a N-oxide, this does not preclude the substitution of any ring atom with the other listed optional substituents when not substituted with oxo groups or in the form of a N-oxide.

[0188] When any variable (e.g., n, Ra. Rb. etc ) occurs more than one time in any constituent or m Formula 1 (or any other Formula), its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.

[0189] A wavy line -^vw^asused herein, indicates a point of attachment to the rest of the (RD)Xcompound. Lines drawn into a ring system, for example:N' ', indicate that the bond may be attached to any of the substitutable ring atoms.

[0190] Under standard nomenclature used throughout this disclosure, the terminal portion of the designated side chain is described last, preceded by the adjacent functionality' toward the point of attachment.

[0191] In choosing compounds of the present invention, one of ordinary skill in the art will recognize that the various substituents, R1, RA, etc., are to be chosen in conformity with well-known principles of chemical structure connectivity' and stability.

[0192] The term "substituted" shall be deemed to include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different.

[0193] In the compounds of Formula I, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly' found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of Formula I. For example, different isotopic forms of hydrogen (H) include protium (’H) and deuterium (2H or D). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-ennched compounds within Formula I, can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically -enriched reagents and / or intermediates.

[0194] Unless expressly stated to the contrary in a particular context, any of the various cyclic ring and ring system variables or substituents described herein may be attached to the rest of the compound at any ring atom (i.e.,any carbon atom or any heteroatom) provided that a stable compound results.

[0195] Unless expressly stated to the contrary', all ranges cited herein are inclusive. For example, a heteroaryl ring described as containing from " 1 to 4 heteroatoms" means the ring can contain 1, 2, 3 or 4 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range. Thus, for example, a heterocycloalkyl ring described as containing from "1 to 4 heteroatoms" is intended to include as aspects thereof, heterocycloalkyd rings containing 2 to 4 heteroatoms, 3 or 4 heteroatoms, 1 to 3 heteroatoms, 2 or 3 heteroatoms, 1 or 2 heteroatoms, 1 heteroatom, 2 heteroatoms, 3 heteroatoms, and 4 heteroatoms. Similarly, Ci-C'e when used with a chain, for example an alkyl chain, means that the chain can contain I, 2, 3, 4, 5 or 6 carbon atoms. It also includes all ranges contained therein including C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C3-C6, C2-C6, C3-C6, and all other possible combinations.

[0196] A "stable" compound is a compound which can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic administration to a subject). The compounds of the present invention are limited to stable compounds embraced by Formulas I.

[0197] The term "compound" refers to the compound and, in certain embodiments, to the extent they are stable, any hydrate or solvate thereof. A hydrate is the compound complexed with water, and a solvate is the compound complexed with an organic solvent.

[0198] As indicated above, the compounds of the present invention can be employed in the form of pharmaceutically' acceptable salts. Those skilled in the art will recognize those instances in which the compounds of the invention may form salts. The term "pharmaceutically acceptable salt" refers to a salt (including an inner salt such as a zwitterion) which possesses effectiveness similar to the parent compound and which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof). Thus, an embodiment of the invention provides pharmaceutically acceptable salts of the compounds of the invention. The term “salt(s)’', as employed herein, denotes any of the following: acidic salts formed with inorganic and / or organic acids, as well as basic salts formed with inorganic and / or organic bases. Salts of compounds of the invention may be formed by methods known to those of ordinary- skill in the art, for example, by reacting a compound of the invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in aqueous medium followed by lyophilization.

[0199] Exemplary' acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates,fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates ("mesylates"), naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al., et al., Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCII; S. Berge et al., et al.. Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al., et al., The Practice of Medicinal Chemistry (1996). Academic Press. Mew York; and in The Orange Book (Food & Ding Administration, Washington, D C. on their website). These disclosures are incorporated herein by reference thereto.

[0200] Exemplar}' basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamine, t-butyl amine. choline, and salts with amino acids such as arginine, lysine and the like. Basic nitrogencontaining groups may be quartemized with agents such as lower alkyl halides (e.g., methyl, ethyl, and buty l chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g., decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.

[0201] All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.

[0202] In addition, when a compound of the invention contains both a basic moiety, such as, but not limited to an aliphatic primary', secondary', tertiary' or cyclic amine, an aromatic or heteroaryl amine, pyridine or imidazole, and an acidic moiety, such as, but not limited to tetrazole or carboxylic acid, zwitterions (“inner salts’') may be formed and are included within the terms “salt(s)” as used herein. It is understood that certain compounds of the invention may exist m zwitterionic form, having both anionic and cationic centers within the same compound and a net neutral charge. Such zwitterions are included within the invention,

[0203] The compounds of Formula I may exist as rapidly interconverting tautomers with different points of attachment of hydrogen accompanied by one or more double bond shifts. The individual tautomers as well as mixtures thereof are encompassed by the present invention. The ratio between the tautomeric forms will vary' depending on the conditions. As is well known to one of ordinary' skill in the art, such compounds may be drawn and named in different ways. Forexample. the following structures depicted below show different ways that an illustrative compound of the invention may be drawn:

[0204] Furthermore, a subject of the present disclosure are pharmaceutical preparations (or pharmaceutical compositions) which comprise as active component a therapeutically effective dose of at least one compound of Formula I and / or a pharmaceutically acceptable salt thereof and a customary pharmaceutically acceptable carrier, i.e., one or more pharmaceutically acceptable carrier substances and / or additives.

[0205] Thus, a subject of the invention is, for example, said compound and its pharmaceutically acceptable salts for use as a pharmaceutical, pharmaceutical preparations which comprise as active component a therapeutically effective dose of said compound and / or a pharmaceutically acceptable salt thereof and a customary pharmaceutically acceptable carrier, and the uses of said compound anchor a pharmaceutically acceptable salt thereof in the therapy or prophylaxis of the above mentioned syndromes as v> eH as their use for preparing medicaments for these purposes.

[0206] The pharmaceuticals according to the invention can be administered orally, for example in the form of pills, tablets, lacquered tablets, sugar-coated tablets, granules, hard and soft gelatin capsules, aqueous, alcoholic or oily solutions, syrups, emulsions or suspensions, or rectally, for example in the form of suppositories. Administration can also be carried out parenterally, for example subcutaneously, intramuscularly or intravenously in the form of solutions for injection or infusion. Other suitable administration forms are, for example, percutaneous or topical administration, for example in the form of ointments, tinctures, sprays or transdernial therapeutic systems, or the inhalative administration in the form of nasal spray s or aerosol mixtures, or, for example, microcapsules, implants or rods. The preferred administration form depends, for example, on the disease to be treated and on its severity.

[0207] For the production of pills, tablets, sugar-coated tablets and hard gelatin capsules it is possible to use. for example, lactose, starch, for example maize starch, or starch derivatives, talc, stearic acid or its salts, etc. Carriers for soft gelatin capsules and suppositories are, for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc. Suitable carriers for the preparation of solutions, for example of solutions for injection, or of emulsions or syrups are, for example, water, physiologically sodium chloride solution, alcohols such as ethanol, glycerol, polyols, sucrose, invert sugar, glucose, mannitol, vegetable oils, etc. It is also possible tolyophihze the compounds of Formula I and their pharmaceutically acceptable salts and to use the resulting lyophilizates, for example, for preparing preparations for injection or infusion. Suitable carriers for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid.

[0208] Suitable solid or galenical preparation forms are. for example, granules, powders, coated tablets, tablets, capsules, microcapsules, suppositories, syrups, juices, suspensions, emulsions, drops or injectable solutions and preparations having prolonged release of active substance, in whose preparation customary excipients such as vehicles, disintegrants, binders, coating agents, swelling agents, glidants or lubricants, flavorings, sweeteners and solubilizers are used.Frequently used auxiliaries which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, lactose, gelatin, starch, cellulose and its derivatives, animal and plant oils such as cod liver oil, sunflower, peanut or sesame oil, polyethylene glycol and solvents such as. for example, sterile water and mono- or polyhydric alcohols such as glycerol.

[0209] Besides the active compounds and carriers, the pharmaceutical preparations can also contain customary additives, for example fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coaling agents or antioxidants,

[0210] The compounds of the present disclosure can be administered alone or in combination with one or more additional therapeutic agents disclosed herein or other suitable agents, depending on the condition being treated. Hence, in some embodiments the one or more compounds of the invention will be co-administered with other agents as described herein. When used in combination therapy, the compounds described herein are administered with the second agent simultaneously or separately. This administration in combination can include simultaneous administration of the two agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. That is. a compound of Formula I and any of the agents described herein can be formulated together in the same dosage form and administered simultaneously. Alternatively, a compound of Formula I and any of the agents described herein can be simultaneously administered, wherein both the agents are present in separate formulations. In another alternative, a compound of Formula 1 can be administered just followed by any of the agents described herein, or vice versa. In some embodiments of the separate administration protocol, a compound of Formula I and any of the agents described herein are administered a few minutes apart, or a few hours apart, or a few days apart.

[0211] As one aspect of the present disclosure contemplates the treatment of the disease / conditions with a combination of pharmaceutically active compounds that may be administered separately, the invention further relates to combining separate pharmaceutical compositions in kit form. The kit comprises two separate pharmaceutical compositions: a compound of Formula I, and a second pharmaceutical compound The kit comprises a container for containing the separate compositions such as a divided bottle or a divided foil packet.Additional examples of containers include syringes, boxes, and bags. In some embodiments, the kit comprises directions for the use of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral, parenteral; IV, transdemial and subcutaneous), are administered at different dosage intervals, or when titration of the indiv idual components of the combination is desired by the prescribing health care professional.

[0212] One or more additional pharmacologically active agents may be administered in combination with a compound of Formula 1. An additional active agent (or agents) is intended to mean a pharmaceutically active agent (or agents) that is active in the body, including pro-drugs that convert to pharmaceutically active form after administration, which are different from the compound of Formula I and also includes free-acid, free-base and pharmaceutically acceptable salts of said additional active agents. Generally, any suitable additional active agent or agents, including but not limited to anti -hypertensive agents, anti-obetic. anti-inflammatory, anti-fibrotic, and anti-atherosclerotic agents such as a lipid modifying compound, anti-diabetic agents and / or anti-obesity agents may be used in any combination with the compound of Formula I in a single dosage formulation (a fixed dose drug combination), or may be administered to the patient in one or more separate dosage formulations which allows for concurrent or sequential administration of the active agents (co-administration of the separate active agents).

[0213] Examples of additional active agents which may be employed include but are not limited to anti -myostatin or anti-promyostatin antibodies (e. g. trevogrumab, apitegromab), anti-ACVR2 / ACVR2B antibodies (e. g. bimagrumab). angiotensin converting enzyme inhibitors (e.g., alacepnl, benazepril, captopril, ceronapril, cilazapril, delapnl, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltipril, perindopril, quinapril, ramipril, spirapril, temocapril, or trandolapril), angiotensin II receptor antagonists (e.g., losartan, valsartan, candesartan, olmesartan, telmesartan and any of these drugs used in combination with hydrochlorothiazide such as HYZAAR®); inhibm / active [3C or pE antibody or siRNA (e.g., WVE-007), apelin receptor antagonist (e, g. ANPA-0073), DGAT2 inhibitor (e.g., those disclosed in US2024-0327391 and WO2022 / 076496, each of which is hereby incorporated by reference), neutralendopeptidase inhibitors (e.g.. thiorphan and phosphoramidon). aldosterone antagonists, aldosterone synthase inhibitors, renin inhibitors (e.g., urea derivatives of di- and tri-peptides, ammo acids and derivatives, amino acid chains linked by non-peptidic bonds, di- and tri-peptide derivatives, peptidyl amino diols and peptidyl beta- minoac l aminodiol carbamates; also, and small molecule renin inhibitors including diol sulfonamides and, N-morpholino derivatives, N-heterocychc alcohols and pyrolimidazolones; also, pepstatin derivatives and fluoro- and chloro-derivatives of statone-containing peptides, enalkrein, remikiren, A 65317, terlakiren, ES 1005, ES 8891, SQ 34017, SPP600, SPP630 and SPP635), endothelin receptor antagonists, phosphodiesterase-5 inhibitors (e.g.. sildenafil, tadalfil and vardenafil), vasodilators, calcium channel blockers (e.g., amlodipine, nifedipine, veraparmil, diltiazem, gallopamil, niludipme, nimodipins, nicardipine), potassium channel activators (e.g., nicorandil, pinacidil, cromakalim, minoxidil, aprilkalim, loprazolam), diuretics (e.g,, hydrochlorothiazide), sympatholitics, beta-adrenergic blocking drugs (e.g., propranolol, atenolol, bisoprolol, carvedilol, metoprolol, or metoprolol tartate), alpha adrenergic blocking drugs (e.g.. doxazosin, prazosin or alpha methyldopa) central alpha adrenergic agonists, peripheral vasodilators (e.g., hydralazine); lipid lowering agents e.g., HMG-CoA reductase inhibitors such as simvastatin and lovastatin, and pharmaceutically acceptable salts of dihydroxy open ring acid HMG-CoA reductase inhibitors such as atorvastatin (particularly the calcium salt thereof), rosuvastatin (particularly the calcium salt thereof), pravastatin (particularly the sodium salt therof), fluvastatin (particularly the sodium salt thereof), cerivastatin, and pitavastatin; a cholesterol absorption inhibitor such as ezetimibe (ZETIA®) and ezetimibe in combination with any other lipid lowering agents such as the HMG-CoA reductase inhibitors noted above and particularly with simvastatin (VYTORIN®) or with atorvastatin calcium: niacin in immediate-release or controlled release forms, and / or with an HMG-CoA reductase inhibitor; niacin receptor agonists such as acipimox and acifran, as well as niacin receptor partial agonists; anti-cholesterol agents such as PCSK9 inhibitors (alirocumab, evolocumab), NexletolTM (bempedoic acid, ACL inhibitor), and Vascepa® (Icosapent ethyl); insulin or insulin analogs (e.g., insulin detemir, insulin glulisine, insulin degludec, insulin glargine, insulin lispro and inhalable formulations of each); leptin and leptin derivatives and agonists; amylin and amylin analogs (e.g., pramlintide); sulfonylurea and non-sulfonylurea insulin secretagogues (e.g., tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, meglitinides, nateglinide and repaglinide): metabolic altering agents including insulin and insulin mimetics mentioned above, dipeptidyl peptidase-IV (DPP-4) inhibitors (e.g., sitagliptm, alogliptin, omarigliptin, linagliptin, vildagliptin); insulin sensitizers, including (i) 0-klotho / 'FGFRl activating monoclonal antibody (e.g., those disclosed in US 10,093,735, thecontents of which are hereby incorporated by reference), pan FGFR1-4 / KLB modulators, FGF19 analogue (e.g., Aldafermin) (ii) PPARy agonists, such as the glitazones (e.g., pioglitazone, AMG 131, initoglitazone, lobeglitazone, rosiglitazone, and balaglitazone), and other PPAR ligands, including (1) PPARa / y dual agonists (e.g.. ZYH2, ZYH1, GFT505, chiglitazar, muraglitazar, aleglitazar. sodelglitazar, and naveglitazar); (2) PPARa agonists such as fenofibric acid derivatives (e.g., gemfibrozil, clofibrate, ciprofibrate, fenofibrate, bezafibrate), (3) selective PPARy modulators (SPPARyM’s), (e.g., such as those disclosed in WO 02 / 060388, WO 02 / 08188, WX) 2004 / 019869, WO 2004 / 020409, WO 2004 / 020408, and WO 2004 / 066963); (4) PPARy partial agonists, (5) PPAR a / 5 dual agonists (e.g., elafibranor); (iii) biguanides, such as metformin and its pharmaceutically acceptable salts, in particular, metformin hydrochloride, and extended-release formulations thereof, such as Glumetza™, Fortamet™, and GlucophageXR™; and (iv) protein tyrosine phosphatase- IB (PTP-1B) inhibitors (e.g., ISIS-113715 and TTP814); a-glucosidase inhibitors (e.g., acarbose, voglibose and miglitol); PPAR modulators such as PPAR pan agonists (e.g., lanifibranor), PPARa agonists (e.g., pemafibrate), PPARy agonist (e.g., CHS 1 1), MPC inhibitor (e g., PXL065), PPAR o / y agonist (e.g., T3D 959)); glucagon receptor antagonists (e.g., 3-(4-((lR,2S)-l-(4-chlorophenyl)-l-(7-fluoro-5-methyl-lH-indol-3-yl)pentan-2-yl)benzamido)propanoic acid, N-[(4-{(lS)-l-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-lH-pyrazol-l-yl]ethyl}phenyl)carbonyl |-p-alanine, adomeglivant and KT6-971); incretin mimetics, bile acid sequestering agents (e g., colestilan, colestiraide, colesevalam hydrochloride, colestipol, cholestyramine, and dialkylaminoalkyl derivatives of a cross-linked dextran), acyl CoA: cholesterol acyltransferase inhibitors, (e.g., avasimibe); antiobesity compounds; agents intended for use in inflammatory conditions, such as aspirin, nonsteroidal anti-inflammatory drugs or NSAIDs, glucocorticoids, and selective cyclooxygenase-2 or COX-2 inhibitors; glucokinase activators (GKAs) (e.g. AZD6370); inhibitors of llp-hydroxy steroid dehydrogenase type 1, (e.g., such as those disclosed in U. S. Patent No. 6,730,690, and LY-2523199); CETP inhibitors; inhibitors of fructose 1,6-bisphosphatase, (e.g., such as those disclosed in U. S. Patent Nos. 6,054,587; 6,110,903; 6.284,748; 6.399.782; and 6.489,476); inhibitors of acetyl CoA carboxylase- 1 or 2 (ACC1 or ACC2); AMP-activated Protein Kinase (AMPK) activators; other agonists of the G-protein-coupled receptors: (i) GPR-109, (ii) GPR-119 (e.g., MBX2982 and PSN821), and (iii) GPR-40 (e.g., TAK875); SSTR3 antagonists (e.g,, such as those disclosed in WO 2009 / 001836); neuromedin U receptor agonists (e.g., such as those disclosed in WO 2009 / 042053, including, but not limited to, neuromedin S (NMS)); SCD modulators (e.g., Aramchol); GPR-105 antagonists (e.g., such as those disclosed in WO 2009 / 000087); glucose pathway modulators such as SGLT inhibitors (e.g., ASP1941, SGLT-3,SGLT-2 such as empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin, BI-10773, remogloflozin, TS-071, tofogliflozin, ipragliflozin, and LX-4211); dual SGLT-1 / 2 inhibitor (e.g, licogliflozin), Glucose-6-P dehydrogenase inhibitor (e.g., fluasterone) LAPS glucagon combo (e.g., HM14320), SGLT-1 inhibitor (e.g., SGL521 )); inhibitors of acyl coenzyme A carboxylase (ACC, 5-( 1 -11 -cyclopropyl-4-methoxy-3-methyl-lH-indole-6-carbonyl)-4-oxospiro[chrornane-2.4'-pipendin]-6-yl)nicotinic acid); inhibitors of diacylglycerol acyltransferase 1 and 2 (DGAT-1 and DGAT-2); inhibitors of fatty acid sy nthase; inhibitors of acyl coenzyme A: monoacylglycerol acyltransferase 1 and 2 (MGAT-1 and MGAT-2); agonists of the TGR5 receptor (also known as GPBAR1, BG37, GPCR19, GPR131, and M-BAR); ileal bile acid transporter inhibitors; bile acid modulators; PACAP, PACAP mimetics, and PACAP receptor 3 agonists; IL-lb antibodies, (e.g., XOMA052 and canakinumab); anti-fibrotic and / or antiinflammatory agents (CCR2 / CCR5 dual receptor antagonist (e.g., cenicriviroc); gal ectin 3 inhibitor (e.g., belapectin, GB-1107. GB-1211), siRNA against HSP 47 (e.g., BMS-986263); NSA1D derived from pirfenidone (e.g., hydronidone). A3 AR agonist (e.g., namodenoson, FM101 ); TGFTX4 (e.g, nitazoxani e); 5 -lipoxygen se inhibitor (e.g, tipelukast), bifunctional urate inhibitor (e.g., ACQT1127), adiponectin receptor agonist (e g., ALY688), TNF receptor antagonist (e.g., atrosimab), autotaxin inhibitor (e.g., BLD-0409, TJC 0265, TJC 0316), CCL24 blocking monoclonal antibody (e.g.. CM101). IL-11 inhibitor (e.g.. ENx 108A), LPA1 receptor antagonist (e g.. EPGN 696), Dual JAK1 / 2 inhibitor (e.g,, EX 76545), GPR antagonist (e.g.. GPR91 antagonist), integrin avbl, avb3 and avb6 inhibitor (e.g., 1DL 2965), NLRP3 antagonist (e.g., IFM-514), inflammasome inhibitors (e.g., JT194, JT349), Cell membrane permeability inhibitor (e.g., larazotide), CCR5 antagonist (e.g., leronlimab), TNF inhibitor (e.g., LIVNate), integrin avp6 inhibitor (e.g., MORE beta6), NLRP inflammasome antagonists, siRNA (e.g., OLX 701), dual TFGp / Hedgehog inhibitor (e.g., Oxy 200), GPR40 agonist / GPR84 antagonist (e.g., PBI-4547), neutrophil elastase inhibitor (e.g., PHP-303), integrin inhibitor (e.g., PLN-1474), TGFpl modulator (e.g., PRM-151), CCK receptor antagonist (e.g., proglumide), LOXL2 inhibitor (e.g., PXS-5338K, PXS-5382A). MPYS protein inhibitor (e.g., cGAS / STING antagonists), kinase inhibiting RNase, membrane protein mAbs, tumor necrosis factor inhibitor, NRF2 activator (e.g., SCO 116), SSAO inhibitor (e.g., TERN 201), TRAIL2 agonist (e.g., TLY012), IL-6 receptor antagonist (e.g,, TZLS 501), AOC3 inhibitor (e.g., UD-014), SSAO / VAP-1 inhibitor, TREM2); anti-oxidant (e.g., vitamin E); anti-inflammatory agents (e.g., norfloxacin, ciprofloxacin, ceftriaxone); coagulation modifiers (e.g., anti-coagulants, anti-platelet agents, pentoxify lline, vitamin K, DDAVP); GRP120 stimulant / inflammasome modulator / PPARg dual agonist (e.g., KDT501); selective thyroid hormone receptor-P agonist(e.g.. resmetirom); apoptosis modulators (JNK-1 inhibitor (e.g., CC-90001), peroxidase inhibitor (e g., AZM198), ASK-1 inhibitor (e g., CS-17919, SRT 015); erythropoietin-stimulating agents (erythropoietin receptor agonist (e.g., cibinetide)); immune modulators (TLR4 inhibitor (e.g., GBK-233). immunomodulatory polyclonal antibody (e.g., IMM-124E), TLR4 antagonist (e.g., JKB-122), CD3 monoclonal antibody (e.g., foralumab). TLR4 antagonist (e g.. JKB 133), TLR4 inliibitor (e.g., mosedipimod), macrophage inhibitor via CD206 targeting (e.g., MT2002), TLR2 / 4 antagonist (e.g., VB-201, VB-703), immunomodulatory polyclonal antibody (e.g., IMM-124E)); prandial insulin (e.g., ORMD 0801)); lipid modulators (AMPK activator / glutathione transferase (e.g., oltipraz), THR-beta agonist (e.g., resmetirom, VK2809, MGL-3745, ALG-009, ASC41, CNPT-101101, TERN 501), IBAT inliibitor (e.g., elobixibat, CJ 14199), omega-6- fatty’ acid (e.g.. epeleuton), FASN inhibitor (e.g., TVB2640, FT 4101, FT 8225), ANGPTL3 inhibitor (e.g,, vupanorsen), PNPLA3 inhibitor (e.g., AZD2693), RAS domain kinase inhibitor (e.g., BioEl 115), NTCP inhibitor (e.g., bulevirtide), P2Y13 receptor agonist (e.g., CER-209), omega-3 fatty’ acid, HSD17 [313 inhibitor; metabolism modulators (FXR agonist (e.g., obeticholic acid, IOT022), recombinant variant of FGF19 (e.g., aldafermin), bi-specific FGFR1 / KLB antibody (e.g., BFKB8488A), mTOT modulator (e.g., MSDC-0602K), pegylated analog of FGF21 (e.g., pegbelfermin, BMS-986171), non-bile FXR agonist (e.g., cilofexor, EDP-305, EYP 001. tropifexor, MET409. AGN-242256, AGN-242266, EDP 297, HPG 1860. MET642, RDX023, TERN 101), ACC inhibitor (e.g.. firsocostat, PF-05221304), ketohex okinase inhibitor (e g, PF-06835919), AMPK activator (e.g., PXL770, MSTM 101, 0304), bile acid modulator (e.g., Albiero), FGF21 analog (e.g., BI089-100), MOTSc analog (e.g., CB4211), cyclophilin inhibitor (e.g., CRV 431, NV556), FGF19 (e.g., DEL 30), mitochondrial uncoupler (e.g., GEN 3026). FXR / GPCR dual agonist (e.g., 1NT-767), cysteamine derivative (e.g., KB-GE-001), dual amylin and calcitonin receptor agonist (e.g., KBP-089), transient FXR agonist (e.g., M 1217), anti-beta-klotho (KLB)-FGFRlc receptor complex mAb (e.g., those disclosed in US 10,093,735), GDF15 analog (e.g., NGM395), LXR modulator (e.g.. PX 329, PX 655, PX 788), LXR inverse agonist (e.g., PX016), deuterated obeticholic acid (e.g., ZG5216)); RAAS mIMModulators (mineralocorticoid receptor antagonist (e.g., apararenone, eplerenone, or spironolactone), angiotensin receptor blocker (e.g., losartan potassium)); neurotransmitter modulators (cannabinoid receptor modulator, CB1 receptor antagonist (e.g,, CRB-4001, IM-102, nimacimab), TPH1 inliibitor (e.g., CU 02), GPR120 agonist (e.g.. KBR2001), combination of cannabinoid and botanical anti-inflammatory compound (e.g., SCN 002)); PDE modulator (PDE4 inhibitor (e.g., ART 648)); CYP2E1 inhibitor (e g., SNP-610); cell therapies (e g., liver-derived mesenchymal stem cells such as HepaStem®)and bromocriptine mesylate and rapid-release formulations thereof; or with other drugs beneficial for the prevention or the treatment of the above-mentioned diseases including nitroprusside and diazoxide the free-acid, free-base, and pharmaceutically acceptable salt forms of the above active agents where chemically possible.

[0214] Preferred examples of additional active agents include GIP modulators, AMYR agonists, APLNR agonists and PDE10 inhibitors.Dosages of the Compounds of the Present Disclosure

[0215] The dosage regimen utilizing a compound of the present disclosure is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the potency of the compound chosen to be administered; the route of administration; and the renal and hepatic function of the patient. A consideration of these factors is well within the purview of the ordinarily skilled clinician for the purpose of determining the therapeutically effective or prophylactically effective dosage amount needed to prevent, counter, or arrest the progress of the condition. It is understood that a specific daily dosage amount can simultaneously be both a therapeutically effective amount, e.g., for treatment of an immunological condition, and a prophylactically effective amount, e.g., for prevention of an immunological condition.

[0216] While individual needs vary, determination of optimal ranges of effective amounts of the compound of the present disclosure is within the skill of one of ordinary skill in the art. For administration to a human in the curative or prophylactic treatment of the conditions and disorders identified herein, for example, typical dosages of the compounds of the present disclosure can be about 0.05 mg / kg / day to about 1000 mg / kg / day. Such doses may be administered in a single dose or may be divided into multiple doses.

[0217] For administration to a human in the curative or prophylactic treatment of the conditions and disorders identified herein, for example, typical dosages of the compounds of the present disclosure can be preferably 0.025-7.5 mg / kg / day, more preferably 0.1-2.5 mg / kg / day, and most preferably 0.1-0.5 mg / kg / day (unless specified otherwise, amounts of active ingredients are on free base basis). For example, an 80 kg patient would receive between about 0.8 mg / day and 2.4 g / day. preferably 2-600 mg / day, more preferably 8-200 mg / day, and most preferably 8-40 mg / kg / day. A suitably prepared medicament for once a day administration would thus contain between 0.8 mg and 2,4 g, preferably between 2 mg and 600 mg, more preferably between 8 mg and 200 mg, and most preferably between 8 mg and 100 mg, e.g.. 8 mg, 10 mg. 20 mg, 30 mg. 40 mg, 50 mg. 60 mg, 70 mg, 80 mg, 90 mg and 100 mg. Advantageously, the compounds may be administered in divided doses of two, three, or four times daily For administration twice a day, a suitably prepared medicament would contain between 0.4 mg and 4 g, preferably between 1 mgand 300 mg, more preferably between 4 mg and 100 mg, and most preferably between 4 mg and 50 mg, e.g., 4 mg, 5 mg, 10 mg 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 45 mg, and 50 mg.Pharmaceutical Compositions

[0218] The compounds of the disclosure and their pharmaceutically acceptable salts can be administered to animals, preferably to mammals, and particularly to humans, as pharmaceuticals by themselves, in mixtures with one another or in the form of pharmaceutical compositions. The term “subject” or “patient” includes animals, preferably mammals and especially humans, who use the instant active agents for the prevention or treatment of a medical condition.

[0219] Administering of the drug to the subject includes both self-administration and administration to the patient by another person. The subject may be in need of or desire treatment for an existing disease or medical condition or may be in need of or desire prophylactic treatment to prevent or reduce the risk of occurrence of the disease or medical condition. As used herein, a subject “in need” of treatment of an existing condition or of prophylactic treatment encompasses both a determination of need by a medical professional as well as the desire of a patient for such treatment.

[0220] It is understood that all possible tautomeric forms of the compounds of Formula I are contemplated as being within the scope of the instant invention, as well as mixtures thereof. It is further understood that while only one said tautomeric form of each example compound and embodiment of the invention may be depicted in the specification and appended claims, such depiction includes reference to all tautomeric forms of said compounds, which are included within the scope of the invention.EXAMPLES

[0221] The following examples are meant to be illustrative and should not be construed as further limiting. The contents of the figures and all references, patents, and published patent applications cited throughout this application are expressly incorporated herein by reference. AbbreviationsAbbreviations and acronyms employed herein include the following:IntermediatesScheme Areductiveintermediate A

[0222] Xeis CHO, halide, OTs, or OMs; Reais alkyl group substituted with 1 or 2 substituents to include H, alky l, cycloalkyls, OR, F, NRR, or can be combined m a cycloalkyl or saturated heterocycle: n is 1 or 2; Re?is aryl, heteroaryl. linear alkyl, cycloalkyl or saturated heterocycle.

[0223] Intermediate A is prepared according to Scheme A via reductive amination or alkylation of intermediate A-2 with amine A-1 to yield intermediate A-3, Protection of A-3 provides intermediate A-4, which is subsequently transformed by a condensation reaction to ketone A-5. Treatment of A-5 with known or synthesized hydrazines (A-6) provides intermediate A.Intermediate Altert-butyl (S)-3-amino-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-2,4.6.7-tetraliydro-5H- Pyrazolo[4,3-c|pyridine-5-carboxylate (Scheme A)Step 1: methyl (S)-3-((1-cyanopropan-2-yl)amino)-2,2-dimethylpropanoate

[0224] To a solution of (S)-3-aminobutanenitrile hydrochloride (71.0 g, 589 mmol) and methyl 2,2-dimethyl-3-oxopropanoate (76.6 g, 589 mmol) in 1,2-dichloroethane (2.10 L) stirred at 25°C was added NaO Ac (48.3 g. 589 mmol) and NaBH(OAc)3 (187 g, 883 mmol). The reaction mixture was stirred for 12 h at 25°C. Upon reaction completion, the mixture was quenched with NaHCO3(saturated aq., 3 L) and extracted with CH2Cl2(3 * 1 L). The combined organic layers were dried over anhydrous Na2SO4, filtered, and then concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (petroleum ether / EtOAc: 1 / 0 to 0 / 1) to provide the title compound. ’H NMR: (400MHz, DMSO-d6) 63.58 (s, 3H), 2.78 - 2.84 (m, 1H).2.54 - 2.63 (m, 2H), 2.50 - 2.52 (m, 2H), 1.68 - 1.69 (m, 1H), 1.09 (d, J = 0.8 Hz, 6H), 1.06 (t, J = 3.2 Hz, 4H). TLC Rf 0.3 (petroleum ether / EtOAc: 3 / 1, KMnO4).Step 2: methyl (S)-3-((tert-butoxycarbonyl)(1-cyanopropan-2-yl)amino)-2,2-dimethylpropanoate

[0225] To a solution of methyl (S)-3-((l-cyanopropan-2-yl)amino)-2,2-dimethylpropanoate (109 g, 548 mmol) in dioxane / H2O (1 / 2, 750 mL) at 25°C was added K2CO3 (4 M, 270 mL, 1.97 eq) and Boc2O (198 g, 908 mol). The reaction mixture was stirred for 12 h at 25°C. The reaction mixture was poured into water (1 L) and extracted with EtOAc (2 x 300 mL). The combined organic layers were washed with brine (500 mL), dried over anhydrous Na2SO4. concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (petroleum ether / EtOAc: 1 / 0 to 0 / 1) to provide the title compound. TLC Rf 0.5 (petroleum ether / EtOAc: 3 / 1, I2).Step 3: tert-butyl (2S)-3-cvano-2.5.5-trimethyl-4-oxop peridine-l-carboxylate

[0226] To a solution of methyl (S)-3-((tert-butoxycarbonyl)(1-cyanopropan-2-yl)amino)-2,2-dimethylpropanoate (72.0 g, 241 mmol) in THF (2.10 L) at 25°C was added t-BuOK (27.1 g, 241 mmol). The reaction mixture was stirred for 12 h at 25°C. Upon reaction completion, the mixture was quenched with HC1 (0.5M aq., 483 mL), diluted with water (2 L), and then extracted with EtOAc (2 x 1 L). The combined organic layers were washed with brine ( 1 L), dried overanhydrous NazSCL, filtered and then concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (petroleum ether / EtOAc: 1 / 0 to 0 / 1) to provide the title compound. TLC Rf 0.4 (petroleum ether / EtOAc: 3 / 1, Iz).Step 4: tert-butyl (S)-3-amino-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate

[0227] To a solution of tert-butyl (2S)-3-cyano-2,5,5-trimethyl-4-oxopiperidine-1-carboxylate (53.7 g, 202 mmol) in EtOH (430 mL) at 25°C was added pyridine (39.9 g, 504 mmol) and (4-fluoro-3,5-dimethylphenyl)hydrazine (46.0 g, 242 mmol). The reaction mixture was stirred for 12 h at 90 °C. Upon reaction completion, the mixture was concentrated under reduced pressure and then redissolved in a mixture of MTBE (450 mL) and NaOH (10% aq. 450 mL). The layers were separated, and the aqueous layer was extracted with MTBE (2 x 150 mL). The combined organic layers were washed with CuSO4(aq. 350 mL) and brine (350 mL), dried over anhydrous Na2SO4, filtered, and then concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (petroleum ether / EtOAc: 1 / 0 to 0 / 1) and then by reverse phase chromatography (neutral conditions) to provide the title compound.1H NMR: (400MHz, DMSO-d6) δ7.20 (d, J = 6.4 Hz, 2H), 5.01 - 5.16 (m, 3H), 3.67 - 3.82 (m, 1H), 2.79 - 2.94 (m, 1H), 2.25 (d, J = 1.6 Hz, 6H), 1.42 - 1.44 (m, 9H), 1.20 - 1.21 (m, 6H), 1.06 - 1.09 (m, 3H). MS: 403.3.Intermediate A2tert-butyl (S)-3-amino-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-2,6,7.8-tetrahydropyrazolo[4,3- c|azepine-5(4H)-carboxylate (Scheme A)Step 1: ethyl (S)-4-((l-cyanopropan-2-yl)amino)butanoate

[0228] To a solution of 3-aminobutanenitrile (3.9 g. 47 mmol) in DMF (50 mL) was added ethyl 4-bromobutyrate (10 g. 52 mmol), sodium iodide (35 g, 230 mmol) and potassium carbonate (19 g, 140 mmol). The reaction mixture was stirred at 20 °C for 16 h, then filtered and concentrated under reduced pressure to provide the title compound. 'H NMR (400 MHz, chloroform-d) 54.21-4.01 (m, 2H), 2.67-2.60 (m, 1H), 2.48-2.29 (m. 4H), 2.17 (s, 1H), 1.82-1.70 (m, 2H), 1.29-1.17 (m, 6H). MS (ESI) m / z: 199.2 [M+H] +.Step 2-4: tert-butyl (S)-3-amino-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-2,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5(4H)-carboxylate

[0229] The procedures described for preparation of Intermediate Al were followed for ethyl (S)-4-((l-cyanopropan-2-yl)amino)butanoate to provide the title compound.1H NMR (CH3OH-d4, 400 MHz): δ 7.15 (2H, d, J = 6.3 Hz), 5.28-5.30 (1H, m), 4.09 (1H, d, J = 15.0 Hz), 3.36 (1H,d, J = 13.0 Hz), 2.71-2.77 (2H, m), 2.28 (6H, d, J = 2.2 Hz), 1.62-1.93 (2H, m), 1.40-1.45 (12H, m). MS (ESI) m / z: 389.2 [M+H]+Table AINTERMEDIATE A21tert-butyl (S)-3-amino-7,7-difluoro-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylateStep 1: (S)-3-(benzylamino)butanenitrile

[0230] To a solution of (S)-3-aminobutanenitrile hydrochloride (4.0 g, 33 mmol) in DCE (100 ml.) was added sodium acetate (5.4 g, 66 mmol) and benzaldehyde (3.5 g, 33 mmol), and stirred at 0°C for 30 min under an atmosphere of N2. Then, sodium triacetoxyhydroborate (15 g, 66 mmol) was added and the resulting mixture was stirred at 0 °C for 3 h. The mixture was quenched with sat aq. NH4CI (20 mL) and H2O (50 mL) at 0° C, and extracted with DCM (3 x 80 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by SiO2chromatography (1:1 Pet. ether / EtOAc) to afford the title compound. LCMS m / z[M+H]: 175.2Step 2: (S)-3-(((1H-benzo[d][1,2,3]triazol-1-yl)methyl)(benzyl)amino)butanenitrile

[0231] To a solution of (S)-3-(benzylamino)butanenitrile (4.0 g, 23 mmol) in ethanol (30 mL) was added (1H-benzo[d][1,2,3]triazol-1-yl)methanol (3.4 g. 23 mmol). The reaction mixture was stirred at 25 °C for 1 h under a N2 atmosphere. Then, the mixture was concentrated to afford the title compound, which was used in the next step.1H NMR (400 MHz, DMSO-d6) δ ppm 8.05 (d, J = 8.46 Hz, 1H) 7.75 (d, J = 8.46 Hz, 1H) 7.50 - 7.56 (m, 1 H) 7.37 - 7.43 (m. 3 H) 7.35 (t, J = 7.33 Hz, 2H) 7.25 - 7.30 (m, 1H) 5.61 - 5.71 (m, 1H) 5.50 (d, J = 14.31 Hz, 1H) 3.94 (d, J = 14.31 Hz,1 H) 3.74 - 3.83 (m, 1 H) 3.41 - 3.49 (m, 1 H) 2.77 - 2.89 (m. 1 H) 2.62 - 2.72 (m, 1 H) 0.83 -0.89 (m, 3 H).Step 3: ethyl (S)-3-(benzyl(1-cyanopropan-2-yl)amino)-2,2-difluoropropanoate

[0232] To a solution of (S)-3-(((1H-benzo[d][1,2,3]triazol-1-yl)methyl)(benzyl)amino)butanenitrile (2.0 g, 5.9 mmol) in THF (10 mL) was added (2-ethoxy-1,1-difluoro-2-oxoethyl)zinc(II) bromide (98 mL, 18 mmol) at 25 °C. Then, the reaction mixture was stirred for 16 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure The crude residue was purified by SiO2chromatography (0 to 10% EtOAc / Pet. ether) to afford the title compound. LCMS m / z[M+H]: 311.0Step 4: (2S)-1-benzyl-5,5-difluoro-2-methyl-4-oxopiperidine-3-carbonitrile

[0233] To a solution of ethyl (S)-3-(benzyl(1-cyanopropan-2-yl)amino)-2,2-difluoropropanoate (200 mg, 0.644 mmol) in THF (2.00 mL) was added lithium diisopropylamide (0.644 mL, 1.29 mmol) at -78 °C under a N2atmosphere. The mixture was stirred at -78 °C for 0.5 h, then stirred at 25°C for 2 h. The mixture was quenched with NH4Cl (3 mL), extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over Na2SO4. filtered and concentrated under reduced pressure to afford the title compound without further purification. MS (ESI) m / z: 265.0 [M+H]+.Step 5: (S)-5-benzyl-7,7-difluoro-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3

[0234] To a solution of (4-fluoro-3,5-dimethylphenyl)hydrazine (23 mg, 0.15 mmol) in toluene (1.0 mL) was added (2S)-l-benzyl-5,5-difluoro-2-methyl-4-oxopiperidine-3-carbonitrile (40 mg, 0.151 mmol) and pyridine (17 mg, 0.15 mmol). The mixture was stirred at 90 °C for 40 rnin under an atmosphere of N2. The reaction was concentrated under reduced pressure and then purified by Prep-TLC (2: 1 Pet.ether / EtOAc) and reverse-phase HPLC (36 to 56% MeCN / H2O + 0.1%TFA) to afford the title compound. LCMS m / z[M+H], 401.1Step 6: tert-butyl (S)-3-amino-7,7-difluoro-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate

[0235] A solution of (S)-5-benzyl-7,7-difluoro-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-amine (30 mg, 0.075 mmol), BOC2O (0.035 mL, 0.15 mmol) and Pd / C (8.0 mg, 7.5 pmol) in EtOAc (6.0 mL) was stirred at 25 °C under a H2atmosphere (via balloon / 15 psi) for 16 h. Then, the atmosphere was replaced with an inert atmosphere and the reaction mixture was filtered. The filtrate was concentrated under reduced pressure. The crude residue was purified by Prep-TLC (SiO2, 1 / 3= EtOAc / petroleum ether) to afford the title compound. LCMS m / z[M+H]: 411.1.Intermediate BW-1Step 1: methyl (S)-2-(1-(((1-cyanopropan-2-yl)amino)methyl)cyclopropyl)acetate

[0236] To a 200 mL round- bottomed flask was added (S)-3-aminobutanenitrile hydrochloride (5.300 g, 43.95 mmol, 1 molar, 1 equiv, 43.95 mmol), potassium carbonate (18.2 g, 3 equiv, 132 mmol), sodium iodide (33 g. 5 equiv, 220 mmol), and DMF (44 mL) under nitrogen atmosphere, methyl 2-(l-(bromomethyl)cyclopropyl)acetate (9.1 g, 1 equiv, 44 mmol) was then added dropwise, and the resulting heterogeneous mixture stirred rapidly for 18 h. Then, the mixture was diluted with EtOAc (50 mL), filtered over Celite® (a product made from diatomaceous earth) and concentrated. The crude material was used directly in the next step. MS (ESI) m / z: 211.0 [M+H]+Step 2: methyl (S)-2-(1-(((1-cyanopropan-2-yl)amino)methyl)cyclopropyl)acetate

[0237] To a mixture of methyl (S)-2-(1-(((1-cyanopropan-2-yl)amino)methyl)cyclopropyl)acetate (9.25 g, 1 equiv, 44.0 mmol) and potassium carbonate (12.2 g, 2 equiv, 88.0 mmol) was added 1,4-dioxane (40 mL), water (80 mL), and then BOC2O (10.1 mL. 1 equiv, 44.0 mmol). The mixture was stirred for 18 h before sat. aq. NaHCO3(100 mL) was added, and the resulting biphasic mixture as extracted with EtOAc (3 x 100 mL), washed with IM HC1 (100 mL), then NaHCO3(100 mL). The organic layer was dried over Na2SO4and concentrated. Purified by silica gel flash column chromatography (220 g column. 0 to 80% EtOAc / hexanes, 150 mL / min). Isolated methyl (S)-2-(1-(((tert-butoxycarbonyl)(1-cyanopropan-2-yl)amino)methyl)cyclopropyl)acetate as an oil. MS (ESI) m / z: 233.2 [M+Na]+Step 3: tert-butyl (S)-3'-amino-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',8'-dihydro-4'H-spiro[cyclopropane-1,7'-pyrazolo[4,3-c]azepine]-5'(6'H)-carboxylate

[0238] To a 250 mL round-bottomed flask was added methyl (S)-2-(1-(((tert-butoxycarbonyl)(1-cyanopropan-2-yl)amino)methyl)cyclopropyl)acetate (1.20 g, 77.3 mL, 1 equiv, 3.866 mmol) and THF (65 mL, 0.05 M) under N2. Then cooled to -78 °C and KHMDS (1.620 g, 8.119 mL, 1 molar, 2.1 equiv, 8.119 mmol) added dropwise to form a solution. After stirring for 30 min at this temperature. AcOH (1.161 g, 1.107 mL. 5 equiv, 19.33 mmol) added to quench. Then aq. NH4CI (50 mL) and EtOAc (50 mL) were added, and the mixture warmed toambient temperature The biphasic mixture was extracted with EtOAc (3 x 40 mL), dried over Naj-SOr, and concentrated to a colorless oil.

[0239] Then to the crude mixture was added (4-fluoro-3,5-dimethylphenyl)hydrazine (655.7 mg, 14.18 L, 0.3 molar, 1.1 equiv, 4.253 mmol) along with AcOH (1.161 g, 1.107 mL, 5 equiv, 19.33 mmol) and EtOH (12 mL). The vial was capped and heated to 90 °C for 2 h. Then the mixture was concentrated under reduced pressure and directly' purified by flash column chromatography' (40 g ISCO, 0 to 40% EtOAc / hexanes, 30 mL / min) to give tert-butyl (S)-3'-amino-2'-(4-fluoro-3,5-dimethylpheny-l)-4'-methyl-2',8'-dihydro-4'H-spiro[cy;clopropane-l,7'-pyrazolo[4.3-c]azepine]-5'(6H)-carboxylate. MS (ESI) m / 'z: 417.6Step 4: tert-buty l (S)-3-amino-2-(4-fluoro-3.5-dimethylphenyl)-4.7.7-trimethyl-2,6,7,8-c]azepine-5(4H)-carboxylate

[0240] To a solution of tert-butyl (S)-3'-amino-2'-(4-fluoro-3,5-dimethylphenyJ)-4'-methyl-2l,8'-dihydro-4'H-spiro[cyclopropane-l,7'-pyrazolo[4.3-c]azepine]-5'(6'H)-carboxylate in AcOH (1.5 mL) was added platinum(IV) oxide hydrate (30 mg, 0.1 mmol. 0.5 equiv). The mixture was then sparged with H2 for 10 min and stirred for 7 days under a balloon of H2. The mixture was then purged with Nz, filtered over Celite®, and concentrated under reduced pressure. The crude residue was purified by' flash column chromatography (0 to 70% EtOAc / hexanes) to give tertbutyl (S)-3-amino-2-(4-lluoro-3.5-dimethylphenyl)-4.7.7-trimethyl-2, 6,7,8-tetrahydropyrazolo[4,3-c]azepine-5(4H)-carboxylate Tl NMR (500 MHz. CDCly 57,16 (d, J = 6.0 Hz, 2H), 6.40 (s, 4H), 5.45 (d, J = 6.9 Hz, 1H), 3.83 (d, J = 15.0 Hz, 1H), 3.23 (d. J = 15.1 Hz, 1H), 2.78 - 2.66 (m, 2H), 2.28 (d, J = 1.6 Hz, 6H), 1.44 (d, J = 6.5 Hz, 12H), 1.07 (s, 3H), 0.88 (s, 3H). MS (ESI) m / z: 419.6 [M-HTfIntermediate MU-13tert-butyl (S)-3-amino-4-methyl-2-(5-(trifluoromethy'l)pyridm-3-yl)-2,4,6,7-tetrahvdro- 5H-pyrazolo[4.3-c1pyridine-5-carboxy lateStep 1: 3-hvdrazineyl-5-(trifluoromethyl)Dyridine

[0241] To a solution of 5-Trifluoromethyl-pyridin-3-yl amine (900 mg, 5.55 mmol) in 6N HC1 (aq) (9 mL) was added a solution of sodium nitrite (383 mg, 5.55 mmol) in water (5 mL) dropwise over 3 minutes at 0 °C After stirring for 1 hour at 0 °C. a solution of di chlorostannane(2.63 g. 682 pL, 2.5 Eq, 13.9 mmol) in 6N HC1 (aq) (9 ml..) was added dropwise over 5 minutes. After 30 minutes at 0 °C, this mixture was stirred at room temperature for 18 hours. The mixture was cooled to 0 °C and 6M aqueous sodium hydroxide (25 ml) was added dropwise. The mixture was extracted with EtOAc (3 x 25 ml) and the combined organic phase was washed with brine, dried over Na2SC>4, filtered and concentrated under reduced pressure, MS (ESI) m / z: 178.1 [M+H]+.Step 2: tert-butyl (S)-3-amino-4-methyl-2-(5-(trifluoromethyl)pyridin-3-yl)-2.4.6.7-tetraliydro-5H-pyrazolo[4,3-c|pyridine-5-caiboxylate

[0242] (2S)-tert-Butyl 3-cyano-2-methyl-4-oxopiperidine-l -carboxylate (899 mg, 3.77 mmol), 3-hydrazmeyl-5-(trifluoromethyl)pyndine (668 mg, 1 Eq, 3.77 mmol), pyridine hydrochloride (43.6 mg, 377 pmol) and dry toluene (10 mL) was heated at 90 °C for 1 h. After cooling to room temperature, the mixture was poured into water (10 mL) and the pH adjusted to 9 with IM NaOH (aq). Ihe organic phase was extracted with ethyl acetate (10 mL 3), and the combined organic layers were dried over sodium sulfate and concentrated. The crude product was purified over silica by flash column chromatography (40 g silica, 0 to 30% ethyl acetate in heptane). MS (ESI) m / z: 398.1 [M+H]+.Intermediate Z A- 15-fluoro-2-methylquinolin-6-amine

[0243] To a solution of 2-methylquinolm-6-amine (1.0 g, 6.3 mmol) in MeCN (40 mL) was added l-chloromethyl-4-fluoro-l,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)(2.24 g, 6.32 mmol), and the resulting mixture was stirred at 20 °C for 2 hours. The reaction mixture was poured into water (50 mL), and extracted with EtOAc (3 x 50 mL), washed with brine (2 x 200 mL), dried over Na2SO4. filtered, and concentrated under reduced pressure to afford crude product. The crude material was purified by Prep-HPLC (YMC-Actus Triart Cl 8 MeCN / LbO (0.1%TFA) 3-100%) to provide the title compound. MS (ESI) m / z: 177.1 |M+H]+.Intermediate ZA-2tert-butyl (7 -fluoro- 1 -methyl isoquinolin-6-y 1 Icarbamate

[0244] Tris((lE,4E)-l,5-diphenylpenta-l,4-dien-3-one) dipalladium (0.12 g, 0.14 mmol) and dicyclohexyl( {3,6-dimethoxy-2-|2,4,6-tris(propan-2-yl)phenyl]phenyl})phosphane (0.15 g, 0.27 mmol) were added to an argon flushed mixture of 6-bromo-7-fluoro-l -methylisoquinoline (0.65 g, 2.7 mmol) To these solids were added tert-butyl carbamate (0.48 g, 4, 1 mmol) and cesium carbonate (1.8 g, 5.4 mmol, m 0.43 mL H2O) followed by dioxane (14 mL). The suspension was stirred for 16 hours at 90 °C, filtered, and concentrated under reduced pressure. The crude mixture was purified by silica gel column chromatography (0-100% EtOAc in heptane) to afford the title compound._MS (ESI) m / z: 277.1 [M+H]+.Intermediate ZA-37 -fluoro- 1 -methy lisoquinolin-6-amine

[0245] Hydrogen chloride (4.0 M in 1,4-dioxane) (18 mL, 72 mmol) was added to a solution of tert-butyl (7-f1uoro-l-methylisoquinolin-6-yl)carbamate (610 mg, 2.21 mmol) in DCM (18 mL). The mixture w as stirred for 16 hours at room temperature. The mixture was then concentrated under reduced pressure to afford the title compound. MS (ESI) m / z: 177.2 |M+H]+.Intermediate ZA-45 -fluoro- 1 -methylisoquinolin-6-amineThis procedure was performed in a similar fashion as described for Intermediate ZA-1 to provide the title compound. MS (ESI) m / z: 177.1 [M+H]+.Scheme BB-1 B-2 Intermediate B

[0246] Rebis CH2or O; en IS 1, 2 or 3; Reo(independently) = CH2, CHRecl, or CReo’Rec2, wherein Rocland Rec2can form a carbocycle or heterocycle: R2 = aryl, heteroaryl, alkyl, cycloalkyl, or heterocycle

[0247] Intermediate B is prepared according to Scheme B via cyanation of intermediate B-l with cyanide reagents such as p-toluenesulfonyl cyanide to yield intermediate B-2. Subsequently, treatment of B-2 with known or synthesized hydrazines (A-6) provides intermediate B.Intermediate B 1tert-butyl 3-amino-2-(4-fluoro-3,5-dimethylphenyl)-2,4,5,6,7.8-hexahydro-4.7- epiminocycloheptalclpyrazole-9-carboxylate (Scheme B) Step 1: tert-butyl 2-cvano-3-oxo-8-azabicvclo[3.2. Hoctane-8-carboxylate

[0248] To a solution of LDA (5.33 mL, 10.7 mmol) at -78 °C under an atmosphere of nitrogen was added tert-butyl 3-oxo-8-azabicyclo[3.2.1 ]octane-8-carboxylate (2.00 g, 8 88 mmol) in THF (10 mL), After 25 minutes, the solution containing the above enolate was cannulated into a solution of 4-methylbenzenesulfonyl cyanide (3.22 g, 17.8 mmol) in THF (5.00 mL) at -78 °C. The resultant mixture was stirred at -78 °C for 30 min. Then, the reaction mixture was quenched by addition of concentrated ammonium hydroxide (5 mL) and was warmed to rt. The resultant mixture was neutralized with 3 N HC aq. solution (adjusting the pH of the mixture to approx 6 to 7). The mixture was then extracted with EtOAc, washed with brine, dried over Na2SC>4, filtered, and concentrated under reduced pressure. The etude residue was purified by SiO2chromatography (0 to 50% EtOAc / hexanes) to provide the title compound. MS (ESI) m / z: 250.9 [M+H]+.Step 2: tert-butyl 3-amino-2-(4-fluoro-3,5-dimethylphenyl)-2.4,5,6,7,8-hexahydro-4,7-epiminocyclohepta[clpyrazole-9-carboxylate

[0249] To a solution of tert-butyl 2-cyano-3-oxo-8-azabicyclo[3.2. l]octane-8-carboxylate (100 mg. 0.40 mmol) in EtOH (10 mL) was added (4-fluoro-3,5-dimethylphenyl)hydrazme (80 mg, 0.52 mmol), the resulting mixture was stirred at 90°C for 3 h. Then, the reaction mixture was poured into water (20 mL), the pH of the mixture was adjusted to 9 by the addition of aqueous NaOH. and extracted with EtOAc (3 x 20 mL), The combined organic layers were dried over NaiSOi, filtered, and concentrated under reduced pressure to provide the title compound. MS (ESI) in / z: 387.0 [M-t-H]+. The following intermediates in table B were prepared according to scheme B using the procedures outlined in the synthesis of intermediates Bl.Scheme CIntermediate A Intermediate C

[0250] Intermediate C is prepared according to Scheme C via nucleophilic aromatic substitution of intermediate A by treatment with sodium nitrite or isoamyl nitrite (or other diazotization reagents) and bromide salts such as Cu(I)Br and to yield intermediate C.Intermediate C 1tert-butyl (S)-3-bromo-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-2.4.6.7-tetrahvdro-5H- Pyrazolo|4,3-c]pyridme-5-carboxylate (Scheme C)Step 1: tert-butyl (S)-3-bromo-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-2.4,6.7-tetrahydro-5H-pyrazolo[4.3-clpyridine-5-carboxylate

[0251] To a solution of tert-butyl (S)-3-amino-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-2,4,6.7-tetrahydro-5H-pyrazolo|4,3-c]pyridine-5-carboxylate in MeCN (1.40 L) at room temperature under an inert (nitrogen) atmosphere was added copper(I) bromide (188 g, 1310 mmol) then isoamyl nitrite (153 g, 1310 mmol) drop-wise. The resulting mixture was stirred for 1 h at room temperature. The solid precipitate was filtered and washed with MeCN (2 x 100 mL). The resulting mixture was concentrated under reduced pressure, then purified by silica gelchromatography (petroleum ether / EtOAc: 5 / 1) to provide the title compound. 1H NMR:(400MHz, DMSO-d6) 57.27 (d, J = 6.3 Hz, 2H), 5.02 (d, J = 33.2 Hz, 1H), 4.21 (d, J = 27.9 Hz, 1H), 3.14 (s, 1H), 2.76-2.52 (m, 2H), 2.28 (d, J = 2.2 Hz, 6H), 1.44 (s, 9H), 1.36 (d, J = 6.6 Hz, 3H). MS: 438.1, 440.1. The following intermediates in table C were prepared according to scheme C using the procedures outlined in the synthesis of intermediate C 1,Table CScheme DH O R11condensation R11,., R R” M12intermediate D

[0252] Intermediate D is prepared according to Scheme C via condensation of hydrazine D-1 with ketone or aldehyde D-2 to yield intermediate D-3. Subsequently, treatment of D-3 with organometallic reagents (e.g., RLi or RMgBr) or hydride reagents (e.g., NaCNBHs orNaBH4) synthesized D-4. Removal of the protecting group (e.g,. acidic conditions or Pd-catalyzed hydrogenolysis) provides intermediate D.Intermediate DI(1 -cyclopropy 1-2,2, 2-trifluoroethyl)hydrazine (scheme D)Step 1: N '-(2.2.2-trifluoroethylidene)benzohydrazide

[0253] A solution of benzohydrazide (10 g, 73 mmol) and 2,2,2-trifluoroethane-I,l-diol (8.5 g, 73 mmol) in MeOH (37 mL) was placed in a sealed tube. After addition of freshly dried 4 molecular sieves (10 g), the tube was sealed and heated in an oil bath to 75 °C for 24 h. Upon reaction completion, the mixture was cooled to rt, filtered, and w ashed with a portion of MeOH (3 x 50 mL), The combined filtrate was concentrated under reduced pressure. The crude mixture was then purified by silica gel chromatography (0 to 45% EtOAc / Pet. ether) to provide the title compound. LCMS (ESI) m / z: 217.1 [M+H]+.Step 2: N'-(l-cyclopropyl-2,2.2-trifluoroethyl)benzohydrazide

[0254] To a solution of N'-(2,2,2-trifluoroethylidene)benzohydrazide (2 g, 9.3 mmol) in THF (60 mL) at 0 °C was added a cyclopropylmagnesium bromide (0.5 M in THF) (40 mL, 20 mmol). The reaction mixture was stirred at 10°C for 16 h. Upon reaction completion, the mixture was quenched with a saturated aqueous solution of NH4CI (50 mL) and extracted with EtOAc (3 x 50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (9% EtOAc / Pet. ether) to provide the title compound. LCMS (ESI) m / z: 259.2 [M+H]+.Step 3: (l-cvcloproDyl-2.2.2-trifluoroethyl)hvdrazine

[0255] To a solution of hydrochloric acid (12 M in water) (50 mL) was added N'-(l-cyclopropyl-2,2,2-trilluoroelhyl)benzohydrazide (5.6 g. 22 mmol). The reaction mixture was stirred at 80 °C for 16 h, then concentrated under reduced pressure. The crude residue was suspended in EtOAc, and the solid precipitate was filtered and washed with EtOAc to provide the title compound. ’H NMR (400 MHz, MeOD) 5 = 2.85 (qd, J = 6.6, 9.8 Hz, 1H), 1.05 - 0.91 (m, 1H), 0.82 - 0.74 (in, 2H), 0.60 - 0.50 (m, 2H).Intermediate D2((2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)hydrazine hydrochloride and ((2R,4s,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)hydrazine hydrochloride (scheme D)Step 1: tert-butyl 2-(2,6-dimethyltetrahydro-4H-pyran-4-ylidene)hydrazine-l -carboxylate

[0256] To a stirred solution of 2,6-dimethyltetrahydro-4II-pyran-4-one (500 mg, 3.9 mmol) in methanol (3.9 mL) was added tert-butyl hydrazinecarboxylate (516 mg, 3.9 mmol) at rt. Thereaction mixture was stirred at rt for 19 hours. The reaction was concentrated to afford the title compound that was used directly in the next step LCMS (ESI) m / z: 187.1 [M-tBu]Step 2; tert-butyl 2-((2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)hydrazine-l-carboxylate and tert-butyl 2-((2R.4s.6S)-2.6-dimethyltetrahydro-2H-pyran-4-yl)hydrazine-l -carboxylate

[0257] To a stirred solution of tert-butyl 2-(2,6-dimethyltetrahydro-4H-pyran-4-ylidene)hydrazine-l -carboxylate (945 mg, 3.9 mmol) in water (3.9 inL) and acetic acid (3.9 m ) was added sodium cyanoborohydnde (270 mg, 4.29 mmol) at rt. The reaction mixture was stirred at rt for 18 hours. The mixture was basified with 4M aq NaOH (10 mL) and extracted with DCM (2 x 10 mL). The combined organic layers were washed with saturated aqueous sodium bicarbonate (10 mL), dried with magnesium sulfate, filtered and concentrated under reduced pressure to afford the title compound that was used in the next step without purification. LCMS (ESI) mz: 189.2 [M-tBu],Step 3: ((2R,4r.6S)-2,6-dimethyltetrahvdro-2H-pyran-4-yl [hydrazine hydrochloride and ((2R.4s.6S)-2.6-dimethyltetrahydro-2H-pyran-4-yl)hydrazine hydrochloride

[0258] To a stirred solution of tert-butyl 2-(2,6-dimethyltetrahydro-2H-pyran-4-yl)hydrazine-l-carboxylate (950 mg, 3.9 mmol) in 1,4-dioxane (4.0 mL) was added HC1 in dioxane (4M, 4.86 mL, 19.4 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 h Additional HC1 in dioxane (4M, 4.86 mL, 19.4 mmol) w as added and the reaction stirred at rt for 18 h. The mixture was concentrated under reduced pressure to afford the title compound that was used in the next step without purification. 'H-NMR (400 MHz, CDCI3, 2:1 mixture of diastereomers) 37.60 (4H. br s, both isomers, -NHNH3CI), [3.99 (0.66H, m, major isomer, Ha), 3.77 (0.33H. m, minor isomer. Ha)]. 3.66-3.43 (2H, m, Hb). 2.26-2.11 (2H. m, Hc). 1.61-1.39 (2H, m, Hd), [1.26 (4H, d, J=5.6 Hz. major isomer, 2xCH3). 1.20 (2H, d, J = 5.9 Hz, minor isomer, 2. XCH3)]. MS: 145.2. The following intermediates in table D were prepared according to scheme D using the procedures outlined in the synthesis of intermediates D I or D2.Table D(3-cyclopropyl-4-fluorophenyl)hydrazine

[0259] 3-cyclopropyl-4-fluoroaniline (3 g, 19.8 mmol) was added to concentrated HCI (30 mL) at 0 °C, and the mixture was stirred for 10 min. Sodium nitrite (1.37 g, 19.8 mmol) in water (TO mL) '. X as added slowly to over a period of 15 min to this mixture. Then, after stirring for 2 h. tin(II)chloride dihydrate (8.96 g. 39.7 mmol) in concentrated HCI (20 mL) was added drop-wise over a period of 10 min. The resulting mixture was stirred for 12 h at rt. The reaction mixture was filtered and washed with concentrated HCI (20 mL) followed by Et20 (50 mL) and dried under reduced pressure to afford the title compound.!H NMR (DMSO-d6, 400 MHz): 5 10.31 (3H, s), 6.98-7.08 (1H. m), 6.77-6.80 (1H. m). 6.71 (1H, d, J = 6.3 Hz). 1.94-1.99 (1H. m). 0.94 (2H, m), 0.64-0.74 (2H, m).Scheme E

[0260] Intermediate E2 is prepared through an oxidation nitration using sodium nitrite for example in concentrated HCI. Re2is aryl, heteroaryl, linear alkyl, cycloalky I or saturated heterocycle.

[0261] The following intermediates in table E were prepared according to scheme E using the procedures outlined in the synthesis of intermediate E2.Table EIntermediate AA14-fluoro-l-methyl"5"(44.5.5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH"iiidazole

[0262] To a mixture of bis(pinacolato)diboron (670 mg, 2.6 mmol), 5-bromo-4-fluoro-l-methyl-lH-indazole (300 mg, 1 3 mmol) and potassium acetate (390 mg, 3.9 mmol) in dioxane (3.0 mL) was added PdC12(dppf (96 mg, 0.13 mmol) The mixture was stirred at 90 °C for 12 h under an atmosphere of N2. Upon reaction completion, the mixture was filtered and then quenched with H2O (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (20 mL), dried overNa^SCL, filtered, and concentrated under reduced pressure. The crude residue was purified by prep-HPLC (40% to 70% MeCN / H₂O + 0.1 TFA gradient) to provide the title compound. MS (ESI) nVz: 277.3 [M+H]+.1.3.7-trimethyl-6-(4,4.5.5-tetramethyl-1.3.2-dioxaborolan-2-yl)-lH-indazole

[0263] The title compound was made in a similar fashion as Intermediate AA1. MS (ESI) m'z: 287.2 [M +H] + •.(4-Iluoro- 1 -methyl-1 H-indazol-5-yl)boronic acid

[0264] A solution of 5-bromo-4-fluoro-l-methyl-lH-indazole (1.5 g, 6.5 mmol) in THE (35 mL) was cooled to -78 °C. Then a solution of nBuLi (0.46 g, 2.3 molar, 7.2 mmol) in hexane was added dropwise. The reaction mixture was stirred at -78 °C. Then, trimethyl borate (1.0 g, 9.8mmol) was added at -60 °C. After warming to rt, the resulting mixture was quenched by the addition of aq. citric acid (IM) and stirred for 30 min. The pH of the aqueous layer was adjusted to pH 5 and extracted with EtOAc (3 x 40 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to afford the title compound. MS (ESI) m / z: 195.1 [M+H]+.Intermediate AC14-fl uoro- 1 -methyl - 1 H-indazole-5 -carboximidamideStep 1: 4-fluoro-l -methyl- lH-indazole-5-carbonitrile

[0265] To a solution of 5 -bromo-4-fl uoro- 1 -methyl- IH-indazole (100 mg, 0.44 mmol), potassium ferrocyanide (40 mg, 0.1 1 mmol), sodium carbonate (46 mg. 0.44 mmol) in NMP (2.0 mL) was added chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) (22 mg, 0.044 mmol). The resulting mixture was stirred at 80 °C for 18 h. Upon reaction completion, the mixture was quenched with H2O (10 mL) and extracted with EtOAc (3 5 mL). The combined organic extracts were washed with brine (20 mL). dried overNa2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by prep-HPLC (27% to 47% MeCN / H? O + 0.1 TFA gradient) to provide the title compound. MS (ESI) m / z 176.3.Step 2; 4-fluoro-l-methyl-lH-indazole-5-carboximidamideTo a solution of 4-fluoro-l -methyl- lH-indazole-5-carbonitrile (90 mg, 0.51 mmol) in THE (2.0 mL) at 0 °C was added LiHMDS (2.1 mL, 2.1 mmol. IM m THF). The reaction mixture was stirred at 25 °C under an atmosphere of N2 for 16 h. Upon reaction completion, the reaction mixture was quenched with IIC1, then concentrated under reduced pressure. The crude residue was purified by prep-HPLC (0% to 20% MeCN / H2.0 + 0.1 TFA gradient) to proride the title compound. MS (ESI) m / z 192.9.Intermediate ADI Isomer A and Isomer B5-bromo-4-fluoro- 1 -(2-methoxy ethyl )- IH-indazole and 5-bromo-4-fluoro-2-(2-methoxy ethyl )- 2H-indazole

[0266] Procedure: A vial was charged with 5-bromo-4-fluoro- IH-indazole (90 mg, 0.42 mmol), cesium carbonate (0.27 g, 0.84 mmol), and l-bromo-2-(2-methox etho\y)ethane (0.11 g, 0.63 mmol). N-methyl-2-pyrrolidine (NMP) (3 mL) was added and the mixture was heated to 100 °C in a hot plate for 2 hours. Upon reaction completion, the mixture was cooled to room temperature and diluted with ethyl acetate (20 mL) and extracted with water (3 x 50 mL), dried over Na2SO4, filtered then concentrated under reduced pressure. The crude mixture was purified by silica gel chromatography (0-100% EtOAc / liexanes) to afford the title compounds. Data for isomer A (faster eluting): LCMS (ESI) m / z: 275.2 [M+HJ+. 'H NMR (600 MHz, CDCh) ‘H NMR (600 MHz, CDCH) 6 8.05 (s, 1H), 7.43 (dd, J--- 8.7, 6.3 Hz, 1H), 7.17 (d, J- 8.8 Hz, 1H), 4.52 J ------5.3 Hz, 2H), 3.81 (t, J = 5.3 Hz, 2H), 3.27 (s, 3H). Data for isomer B (slower eluting): LCMS (ESI) mA: 275.2 [M+H]+. M NMR (600 MHz, CDCh)3H NMR (600 MHz, CDCh) 5 8.09 (s,1H), 7.38 (d. J = 9.1 Hz. 1H), 7.32 (dd, J= 8.9, 6.5 Hz, 1H), 4.58 (t, J= 5.0 Hz, 2H), 3.87 (t, J = 5.0 Hz. 2H), 3.34 (s, 3H). The following intermediates in table AD were prepared using the procedures outlined in the synthesis of intermediate ADI Isomer A and Isomer B. In cases wherein isomers of the examples were separated via silica gel chromatography, the faster eluting isomer is listed first.Table ADIntermediate AD 11 -cyclopropyl-5-iodo- IH-mdazole

[0267] A mixture of 5-iodo-lH-indazole (2.00 g, 8.20 mmol), cyclopropaneboronic acid (1 41 g, 16.4 mmol), copper diacetate (1.49 g, 8.20 mmol), 2,2’-biyridine (1.28 g, 8.20 mmol) and sodium carbonate (1.74 g, 16.4 mmol) in DCE (41.0 mb) was stirred at 60 °C for 3 h. Then, the mixture was cooled to it. quenched with aq. NH4OH and extracted with DCM (2x). The combined organic layers were dried overNazSC, filtered, and concentrated under reduced pressure. The crude residue was purified by SiOz chromatography (0 to 50% EtOAc / Hex) to provide the title compound.lH NMR (500 MHz, CD'CN) 5 8.15 (d, J = 0.9 Hz, 1H), 7.89 (s, 1H), 7.68 (dd, J - 8.8, 1.5 Hz, 1H), 7.52 (d, J - 8.8 Hz, 1H), 3.67 - 3.60 (m, 1H), 1.15 (d, J === 5.4 Hz. 4H). MS (ESI) m / z: 285.2 [M+HJ+.Intermediate AD2l-(5-bromo-4-fluoro-lH-indazol-l-yl)-2-methylpropan-2-ol

[0268] A vial was charged with 5-bromo-4-fluoro-lH-indazole (200 mg, 0,9 mmol), 2.2-dimethyloxirane (134 mg, 1.86 mmol) and potassium carbonate (386 mg, 2.79 mmol. NMP (6 mL) was added to the vial and the reaction mixture was heated to 180 °C for 45 minutes. The mixture was cooled to room temperature, diluted with EtOAc, arid extracted with water (3 x 20 mL), dried over sodium sulfate, filtered then concentrated in vacuo. The crude mixture was purified by silica gel chromatography (0-100% EtOAc / hexanes) to afford the title compound. MS (ESI) m / z: 271.2 [M-OHJ+Intermediate AD34-fluoro-I -methyl- lH-indazol-5-amineStep 1: tert-butyl (4-fluoro-l-methyl-lH-mdazol-5-yl)carbamate

[0269] To a solution of potassium phosphate tribasic (5.0 g, 26 mmol), 5-bromo-4-fluoro-l-methyl-lH-mdazole (2.0 g, 8.7 mmol) and tert-butyl carbamate (1.5 g, 13 mmol) in dioxane (29 mL) was added dtbpf-Pd-G3 (400 mg. 0.440 mmol) under an atmosphere of N?„ The reaction mixture was stirred at 100 °C overnight, then cooled to rt and filtered with washing with DCM The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel chromatography (0 to 100% EtOAc / Hex) to provide the title compound. MS (ESI) m / z: 266.2 [M+H]+Step 2: 4-fluoro-l-methyl-lH-indazol-5-amine

[0270] To a solution of tert-butyl (4-fluoro-l-methyl-lH-indazol-5-yl)carbamate (500 mg, 1.9 mmol) in DCM (1.9 mL) was added 4M HC1 (24 mL, 9.42 mmol) at rt. After th an additional portion of HC1 was added, and the reaction mixture was stirred for 1 h. To the mixture was added EfoO and the solid precipitate was collected by filtration. The HC1 salt was suspended in DCM and washed with I aq. NaOH. The layers were separated, and aqueous layer was extracted with DCM (2 x). The combined organic layers were dried overNazSOr, filtered then concentrated under reduced pressure to afford the title compound. ’H NMR (500 MHz, CD3CN) 57.84 (s, 1H), 7.15 (d. J = 8.7 Hz, 1H), 7.02 (t, J - 8.4 Hz, 1H), 2.16 (s, 3H) MS (ESI) m / z: 166.2[M+H]+.Intermediate BW-3Step 1: (l-(2,2,2-trifluoroethyl)-lH-mdazol-5-yl)carbamate

[0271] To a mixture of 5-iodo-l-(2,2,2-trifluoroethyl)-lH-indazole (250 mg, 770 pmol, 1 equiv). tripotassium phosphate (488 mg. 2.30 mmol), tert-butyl carbamate (135 mg, 1.15 mmol) and BrettPhos Pd G3 (35 mg. 38 umol) was added 1,4-dioxane (3.0 mL, 0.25 M), and the resulting solution was sparged with argon for 10 min. The vial was then sealed and the mixture heated to 100 °C for 18 h before being cooled, filtered over Ceiite®1, and concentrated in vacuo. Tire crude residue was purified by flash column chromatography (0-100% EtOAc / hexanes) to give tert-butyl (l-(2,2,2-trifluoroethyl)-lH-indazol-5-yl)carbamate. MS (ESI) m / z: 316.2 [M+H]+Step 2: l-(2,2,2-trifluoroethyl)-lH-indazol-5 -amine

[0272] To tert-butyl (l-(2,2,2-trifluoroethyl)-lH-indazol-5-yl)carbamate (314 mg, 996 pmol, 1 equiv) was added HC1 in 1,4-di oxane (4 M,1.2 mL, 5.0 mmol, 5 equiv) and the resulting mixture was stirred at ambient temperature for 18 h. The resulting heterogeneous mixture was then concentrated under reduced pressure before sat. aq NaHCCL (10 mL) and EtOAc (10 mL) were added, and the layers were separated. The aqueous phase was extracted with EtOAc (2 x 5 mL) and the combined organic layers were dried over NazSCfi and concentrated under reduced pressure to provide l-(2.2.2-trifluoroethyl)-lH-indazol-5 -amine. ’H NMR (500 MHz, CDCL,) 8 7.88 (s, 1H), 7.25 (s, 1H), 6.98 - 6.89 (m, 2H), 4.87 (q, J ==:8.5 Hz, 2H).19F NMR (471 MHz, CDCL) 3 -70.84 (t, J = 8.5 Hz). MS (ESI) m / z: 216.2 [M+H]!Intermediate BW-4Step 1: tert-butyl (l-cyclopropyl-lH-indazol-5-yl)carbamate

[0273] To a mixture of 1 -cyclopropyl-5-iodo-lH-indazole (250 mg. 880 jimoi). tripotassium phosphate (560 mg, 2.6 mmol), tert-butyl carbamate (155 mg, 1.32 mmol) and BrettPhos Pd G3 (40 mg, 40 umol) -was added 1,4-dioxane (3 3 mL. 0.25 M) and the resulting solution -was sparged with argon for 10 mm. The vial was then sealed and the mixture heated to 100 °C for 18 h before being cooled, filtered over Ceiite®, and concentrated in vacuo. The crude residue waspurified by flash column chromatography (0-100% EtOAc / hexanes) to give tert-buty l (1-cyclopropyl-lH-indazol-5-yI)carbamate. MS (ESI) m / z: 274.4 [M+H]+Step 2: 1 -cyclopropyl- lH-indazol-5-amine

[0274] To tert-butyl (l-cyclopropyl-lH-indazol-5-yl)carbamate (179 mg, 655 pmol, 1 equiv) was added HC1 in 1,4-dioxane (4 M. 0.8 mL, 3 mmol) and the resulting mixture was stirred at ambient temperature for 18 h. The resulting heterogeneous mixture was then concentrated under reduced pressure before sat. aq. NaHCOi (10 mL) and EtOAc (10 mL) were added, and the layers were separated. The aqueous phase was extracted with EtOAc (2 x 5 mL) and the combined organic layers were dried over Na2SO4and concentrated under reduced pressure to provide titled compound. 1H NMR (500 MHz, CDCh) 87.73 (s, 1H), 7.42 (d, J = 8.7 Hz, 1H), 6.92 (d, J === 1.9 Hz, 1H), 6.88 (dd, J === 8.7, 2.0 Hz, 1H), 3.52 (tt, J - 7.0, 3.6 Hz, 1H), 1.22 - 1.16 (m, 2H), 1.14 - 1.08 (m, 2H). MS (ESI) m / z: 174.4 [M+H]4Intermediate BW-5Step 1: 5-bromo-l-cyclopropyl-4-fluoro-lH-indazole

[0275] To a 100 mL round-bottomed flask was added 5-bromo-4-fluoro-lH-indazole (1.00 g, 31.0 mL, 0 15 molar, 4,65 mmol) copper (II) acetate (845 mg, 4.65 mmol) 2,2'-bi pyridine (726 mg, 4.65 mmol) cyclopropylboronic acid (799 mg 9.30 mmol) sodium carbonate (986 mg. 9.30 mmol) 1,2-DCE (30 mL) and heated to 70 °C for 2 h. Then the mixture was filtered, concentrated under reduced pressure, redissolved in EtOAc (30 mL), and washed twice with sat. aq. CuSCL (2 x 10 mL). Then the organic layer was washed with brine, dried with Na2SO4, and concentrated. The crude mixture was purified by flash column chromatography (40 g S1O2 column, 0 to 100 % EtOAc, 40 mL / min) to provide 5-bromo-l-cyclopropyl-4-fluoro-lH-indazole.]H NMR (500 MHz, CDCI3) 8 7.98 (s, 1H), 7.46 (dd, J--- 8.8, 6.2 Hz, 1H), 7.28 (d, J- 8.8 Hz, 1H), 3.58 (t, J ------70, 3.5 Hz, 1H), 1.26 - 1.15 (m, 4H). MS (ESI) m / z: 257.0 [M+H]4Step 2: tert-butyl (l-cyclopropyl-4-fluoro-lH-indazol-5-yl)carbamate

[0276] To a mixture of 5-bromo-l-cyclopropyl-4-fluoro-lH-indazole (500 mg. 2 mmol, 1 equiv), tripotassium phosphate (1.25 g, 5.88 mmol), tert-butyl carbamate (344 mg, 294 mmol) and BrettPhos Pd G3 (90 mg, 100 umol) was added 1,4-dioxane (7.3 mL. 0.25 M), and the resulting solution was sparged with argon for 10 min. Hie vial w as then sealed and the mixtureheated to 100 °C for 1 h before being cooled, filtered over Celite®, and concentrated in vacuo. The crude residue was purified by flash column chromatography (0-100% EtOAc / hexanes) to provide tert-butyl (l-cycfopropyl-4-fluoro-lH-indazol-5-yl)carbamate. MS (ESI) m / z: 292.2 [M+H]Step 3: l-cyclopropyl-4-fluoro-lH-indazol-5-amine

[0277] To tert-butyl (l-cyclopropyl-4-fluoro-lH-indazol-5-yl)carbamate (403 mg, 1.38 mmol) was added EIC1 in 1,4-di oxane (4 M, 3.5 ml, 14 mmol) and the resulting mixture was stirred at ambient temperature for 18 h. The resulting heterogeneous mixture was then concentrated under reduced pressure before sat. aq. NaHCOa (10 mL) and DCM (10 mL) were added, and the layers were separated. The aqueous phase was extracted with DCM (2 x 5 mL) and the combined organic layers were dried over Na2SC>4 and concentrated under reduced pressure to provide the titled compound.;H NMR (500 MHz, CDC13) 57.88 (s, 1H), 7.23 (d, J = 8.7 Hz, 1H), 7.07 (d, J = 8.5 Hz. 1H), 3.56 - 3.50 (m, 1H), 1.21 - 1.18 (m, 2H), 1.16 - 1.11 (m, 2H).,9F NMR (471 MHz, CDCI3) 6 -140.21. MS (ESI) m / z: 192.2 [M+H]'Intermediate BW-6Step 1: tert-butyl (6-fluoro- 1 -methyl- IH-indazol -5 -yDcarbamate

[0278] To a mixture of 5-bromo-6-fluoro-l-metlryl-lH-indazole (150 mg, 660 pmol), tripotassium phosphate (417 mg, 1.96 mmol), tert-butyl carbamate (115 mg, 982 pmol) and BrettPhos Pd G3 (30 mg, 30 umol) was added 1,4-dioxane (2.5 mL, 0.25 M) and the resulting solution was sparged with argon for 10 min. The vial was then sealed and the mixture heated to 100 °C for 18 h before being cooled, filtered over Celite®, and concentrated in vacuo. The crude residue was purified by flash column chromatography (0-100% EtOAc / hexanes) to provide tertbutyl (6-fluoro-l-methyl-lH-indazol-5-yl)carbamate. MS (ESI) m / z: 266.2 [M+H]+Step 2: l-cvcloproDyl-lH-indazol-5-annne

[0279] To tert-butyl (6-fluoro-l-methyl-lH-indazol-5-yl)carbamate (230 mg, 870 pmol, 1 equiv) was added HCI in 1,4-dioxane (4 M, 2.2 mL. 8.7 mmol, 10 equiv) and the resulting mixture was stirred at ambient temperature for 18 h. The resulting heterogeneous mixture was then concentrated under reduced pressure before sat. aq. NaHCCL (10 mL) and DCM (10 mL) were added, and the layers were separated. The aqueous phase was extracted with DCM (2 x 5 mL) and the combined organic layers were dried over NazSCL and concentrated under reducedpressure to provide title compound. ’H NMR (500 MHz, CDCI3) 87.79 (s, 1H), 7.05 (d. J = 6.7 Hz, 1H), 7.03 (d, J = 4.4 Hz, 1H), 4.00 (s, 3H).!9F NMR (471 MHz, CDCh) 8 -130.65 (dd, J = 10.6, 8.5 Hz). MS (ESI) m / z: 166.2 [M+H]4Intermediate BW-7Step 1: tert-butyl (l-(methyl-d3)-lH-indazol-5-yl)carbamate

[0280] To a mixture of 5-bromo-l-(methyl-d3)-lH-indazole (150 mg, 0.70 mmol), tripotassium phosphate (446 mg, 2.10 mmol), tert-butyl carbamate (123 mg, 1 05 pmol) and BrettPhos Pd G3 (32 mg, 35 pmol) was added 1,4-dioxane (2.6 mL, 0.25 M) and the resulting solution was sparged with argon for 10 min. The vial was then sealed and the mixture heated to 100 °C for 18 h before being cooled, filtered over Celite®, and concentrated in vacuo. The crude residue was purified by flash column chromatography (0-100% EtOAc / hexanes) to provide tert-butyl (I-(methyl-d3)-lI-I-indazol-5-yl)carbamate. MS (ESI) m / z: 251.2 [M+H]4Step 2: l -(methyl-d3)-lH-indazol-5-amine

[0281] To tert-butyl (l-(methyl-d3)-lH-mdazol-5-yl)carbarnate (179 mg, 715 pmol) was added HC1 m 1,4-dioxane (4 M, 0.90 mL, 3.6 mmol) and the resulting mixture was stirred at ambient temperature for 18 h. The resulting heterogeneous mixture was then concentrated under reduced pressure before sat. aq. NaHCO3(10 mL) and EtOAc (10 mL) were added, and the layers were separated. The aqueous phase was extracted with EtOAc (2 x 5 mL) and the combined organic layers were dried over Na2SO4and concentrated under reduced pressure to give 1 -(methyl-d3)-lH-indazol-5-amine as a solid 1H NMR (500 MHz, CDC13) 87.77 (s, 1H). 7.22 (d, J = 8.7 Hz, 1H), 6.93 (d, J = 1.5 Hz, 1H), 6.88 (dd, J = 8.7, 2.1 Hz, 1H). MS (ESI) m / z: 151.2 [M+H]4Intermediate MU-14tert-buty l (S)-3-carbamimidoyl-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-2,4,6,7-tetrahydro-5H- pyrazolo[4,3-c]pyridine-5-carboxylateStep 1: tert-butyl (S)-3-cyano-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-2.4.6.7-tetrahvdro-5H-pyrazolo[4,3-clDyridine-5-carboxylate

[0282] To a solution of tert-butyl (S)-3-bromo-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl- 2.4.6.7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (200.00 mg, 456.27 pmoi), potassium ferricyanide (37.556 mg, 20.06 pL. 114.07 pmol), Naj-CO? (48.360 mg, 456.27 pmol) in NMP (5 mL) was added XPhos Pd G2 (35.900 mg, 0.1 Eq, 45.627 pmol) in a nitrogen filled glovebox, and the resulting mixture was stirred at 100 °C for 16 h. The mixture was diluted with H2O (15 mL) and extracted with EtOAc (10 mL, 3x). The combined organic fraction w as washed with brine (20 mL), dried over anhydrous Na2SCL. filtered and concentrated. The resulting material was purified by prep-HPLC (Column Y: MC-;\ctus Triart C18 150*30mm*5pm.Mobile phase A: water (containing water (0.1%TFA)-ACN), mobile phase B: acetonitrile.Gradient: 27%~47% B, 0-10 min. Flow Rate: 40 mL / min) follo ed by lyophilization, m / z: 385.2 [M+Hty.Step 2: tert-butyl (S)-3-carbannmi doyl-2-(4-fluoro-3,5-dimethylphenyl)-4-methYl-2, 4,6,7-tetrahydro-5H-pyrazolo[4.3-clpyridine-5-carboxylate

[0283] To a solution of tert-butyl (S)-3-cyano-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl- 2.4.6.7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (340.50 mg, 885.66 pmol) in THF (5 mL) was added lithium bis(trimethylsilyl)amide (889.18 mg, 5.31 mL. 1 molar, 5.31 mmol) at 0 °C. The reaction mixture was stirred at 30 °C under N2 for 16 hours. The reaction solution w<as quenched with aq. HC1 (IM), then was concentrated under reduced pressure. The residue w-as purified by prep-HPLC (Column: YMC-Actus Triart Cl 8 150*30mm*5pm. Mobile phase A: water (containing Water (water (0.1%TFA)-ACN), mobile phase B: acetonitrile. Gradient:20%~50% B, 0~l 1 mm. Flow?Rate: 40 niL / mm) followed by lyophilization.[H NMR (400 MHz, chloroform-ri) 8 ppm 2.65 (s, 3 H) 6.62 (dd, J=7.51, 1.79 Hz, 1 H) 7.30 (s, 1 H) 7.50 - 7.66 (m, 2 FI), m / z: 402.1 |M H|.

[0284] The following intermediates in table MU-T1 were prepared using the procedures outlined in the synthesis of intermediate MU- 14.Table MU-T1In termedi ate M (J - 162,3-dimetliylimidazo[l,2-a]pyridine-6-carbonitrile

[0285] To a solution of 6-aminonicotinonitrile (400 mg, 3.36 mmol) in Ethanol (10 ml,) was added 3-bromobutan-2-one (208 g, 13.8 mmol) at 25 °C. Then the reaction mixture was stirred at 100 °C for 16 h. The mixture was concentrated in vacuo and the residue was diluted with water (20 mL) and DCM (30 mL), The resulting mixture 'as adjusted to pH = 10 with NaOH (2M) aqueous solution, then extracted with DCM (30 mL x 2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (EtOAc / Petroleum ether (v / v)::z1 / 10 to 1 / 5 to 1 / 2).NMR (400 MHz, acetonitrile-da) 8 = 8.57 (s. 1H), 7.54 - 7.44 (m, 1H), 7,34 - 7.19 (m, 1H), 2.43 (s, 3H), 2.38 (s, 3H).Intermedi ate MU - 17xXN^"3-methylimidazo[l,5-a]pyridine-7-carbonitrileStep 1: 7-bromo-3-methylimidazo|T,5-a]pyridine

[0286] To a solution of (4-bromopyridin-2-yl)methanamine (1000 mg, 5.35 mmol) in acetic anhydride (3 g. 3 mL, 0.03 mol) was added Ts-OH (1.017 g, 5,346 mmol) at 25 °C Then the reaction mixture was stirred at 100 °C for 16 hours. The mixture was allowed to cool to room temperature, concentrated and poured into water (30 mL). The pH was adjusted pH to 7 with 20%NaOH, and the mixture extracted with dichloromethane (20mL, x3). The organic phase was dried over anhydrous sodium sulfate, concentrated, and the crude product was purified by column chromatography with (EA: PE=0:l). m / z: 211.1 [M+HJTStep 2: 3-methylimidazo| 1.5-a]pyridine-7-carbonitrile

[0287] A solution of zinc cyanide (0.46 g, 0,25 mL, 3.9 mmol), tetrakis(triphenylphosphine) palladium(O) (109.50 mg, 94.760 pmol), 7-bromo-3-methylimidazo[l,5-a]pyridine (200.00 mg, 947.60 pmol) in DMF (3 mL) in a nitrogen filled glovebox, w as stirred at 100 °C under N2 for 16 hours. The mixture w s diluted with H2O (15 mL) and extracted with EtOAc (10 ml,, 3x). The combined organic extracts were washed with brine (20 mL), dried over anhydrous Na2SCL,filtered, and concentrated under reduced pressure. The pH of the aqueous phase was adjusted I 1 with NaOH, then zinc cyanide was quenched with sodium hypochlorite (aq). The residue was purified by prep-TLC(SiO2, Pet. ether: EtOAc = 0: 1), m / z: 158.1 [M+H]+.Intermediate MU-11l,7-dimethyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yi)-lH-indazole

[0288] 6-bromo-l,7-dimethyl-lH-indazole (1.72 g, 7.76 mmol), B2Pin2 (2.32 g, 9.19 mmol), potassium acetate (1.50 g, 15.32 mmol) and 1,4-dioxane (27,35 mL) were added to aflame dried reaction tube. The mixture was purged with argon for 5 minutes after which PdCLfdppf) (168 1 mg, 229.8 pmol) was added, and argon purging was continued for another 5 minutes. The mixture was sealed and placed in an oil bath which was preheated to 95 °C and stirred for 18 hours. The reaction mixture was cooled to room temperature and poured into aq. sat. NaHCO? (100 mL). The mixture was extracted using EtOAc (2x 100 mL) and the combined organic phases were dried overNa^SO.;, filtered, and concentrated. The resulting material was purified using flash column chromatography (80 g silica, DCM injection) eluting with a gradient from heptane: DCM 8:2 to DCM.!H NMR (400 MHz, CDCh) 57.88 (s, 1H), 7.51 (d, J = 8.2 Hz, 1H), 7.46 (d, J = 8.1 Hz, 1H), 4.37 (s, 3H), 3.01 (s, 3H), 1.38 (s, 12H). MS (ESI) m / z: 273.0 [M+H]+.3-bromo- 1 -( 1 -cyanocyclopropyl)- lH-pyrazole-5-carboxylic acid Step 1: methyl 3-bromo-l-(cvanomethyl)-lH-pyrazole-5-carboxylate

[0289] A mixture of methyl 5-broino-lITpyrazole-3-carboxylate (15.5 g, 75.6 mmol), cesium carbonate (61,6 g, 189 mmol) and 2-bromoacetonitrile (18.1 g, 1 1 mmol) in MeCN (180 mL) was stirred at rt for 3h. Then, the mixture was filtered through Cehte® and washed with CH3CN (100 ml) and EtOAc (100 mL). The filtrate was concentrated under reduced pressure. The crude material was purified by SiO2 chromatography (0 to 60% EtOAc / TIex) to afford the titlecompound.!H NMR (400 MHz. CDCI3): 66.91 (s: 1 H); 5.48 (s: 2 H): 3.95 (s; 3 H). MS (ESI) m / z: 244.0, 246.0 [M+H]+.Step 2: methyl 3-bromo-l-(l-cyanocyclopropyl)-lH-pyrazole-5-carboxylate

[0290] Sodium hydride (369 mg. 60% wt, 9.22 mmol) was added with stirring under an atmosphere of Ar to DMSO (10 mL) maintained at rt by use of a water bath. The resulting suspension was stirred for 10 min before the addition of a solution of methyl 3-bromo-l-(cyanomethyl)-lH-pyrazole-5-carboxylate (500 mg, 2.05 mmol) and l-bromo-2-chloro-ethane (735 mg, 5.12 mmol) in DMSO (6.0 mL) slowly (via drop-wise addition over a period of 10-15 min (few pieces of ice was added to water bath to keep the temperature below' room temperature during the addition process). The reaction mixture 'as stirred for 1.5 h in the water bath. Then, sat. aq. NH4CI (32 mL) was added slowly and the resulting mixture was stirred for 15 min. The mixture was extracted with EtOAc (4 x 40 mL). The combined organic layers were washed with brine, dried over a2S€>4, filter and concentrated under reduced pressure. The crude residue was purified by SiO chromatography (0-50% EtOAc / Hex) to provide the title compound. ’H NMR (400 MHz, CDCh): 56.89 (s; 1 H); 3.96 (s; 3 H); 1.93 (t; J = 5.68 Hz; 2 H); 1.86 (t; J = 5.65 Hz; 2 H).Step 3: 3-bromo-l-(l-cyanocyclopropyl)-IH-pyrazole-5-carboxylic acid

[0291] A mixture of methyl 3-bromo-l-(l-cyanocyclopropyl)-lH-pyrazole-5-carboxylate (300 mg, 1.11 mmol) in THF (TO mL) was added aq sodium hydroxide (2.22 mL, 1 molar. 2.22 mmol) at 23 °C. Then, the reaction mixture was stirred at 23 °C for 1 h. Then, the mixture was concentrated under reduced pressure to afford the title compound. ’H NMR (400 MHz, CD3OD): 86.96 (s: 1 H); 1.89 (d; J == 9.54 Hz; 4 H).Intermediate AE24-bromo-2-( 1 -cy anocy cl opropy l)benz.oic acidStep 1: methyl-4-bromo-2-(l-cyanocyclopropyl)benzoate

[0292] To a mixture of methyl-4-bromo-2(cyanomethyl)benzoate (4 g, 15.7mmoL) in DMSO (23 mL) was added 2-(tert-butyl)-l,l,3,3-tetramethylgaunidine (5.4 g, 31.5 mmol) followed by 1-bromo-chloroethane (2.5 g, 17,32 mmol). The mixture was stirred al 23 °C for 18 h then diluted with EtOAc (20 mL), quenched with saturated ammonium chloride (20 mL). extracted withEtOAc (3 x 20 mL), washed with water (15 mL), washed with brine (15 mL), dried over NasSCL, and concentrated under reduced pressure. Ihe crude residue was purified by flash silica gel chromatography (0% to 30% EtOAc / Hex) to provide the title compound. MS (ESI) m / z: 280.1 [M+H]+.Step 2; 4-bromo-2-(l-cyanocyclopropyl)benzoic acid

[0293] To a mixture of methyl 4-bromo-2-(l-cyanocyclopropyl)benzoate (100 mg, 0.36 mmol) in DMSO (1.1 mL) was added sodium hydroxide (0.36 mL, 0.71 mmol, 2 M in water). The mixture was stirred at 23 °C for 10 min then quenched with aqueous HC1 (1 mL, 1 M). The mixture was then diluted with water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over NazSO, filtered, and concentrated under reduced pressure. NMR (499 MHz, CDCl?) 87.49 (d, J 8.2 Hz, 1H), 7.38 (d,. / 28.3 Hz, 1H), 7.23 - 7 18 (m, 1H), 2.20 (s, 1H), 1.34 (s, 2H), 1.05 - 0.66 (m, 3H). MS (ESI) m / z: 2660 [M+H]+.Intermediate AE33-bromo-l-((lS,2S)-l-cyano-2-methyIcj clopropy])-lH-pyrazole-5-carboxylic acid Step 1: methyl 3-bromo- 1 -(( 1 S,2 S )- 1 -cvano-2-methylcy clopropyl)-lH-pyrazole-5-carboxylate

[0294] A solution of methyl 3-bromo-l-(cyanomethyl)-lH-pyrazole-5-carboxylate (66 g, 0.27 mol) and (R)-4-methyl-l,3,2-dioxathiolane 2,2-dioxide (94 g, 67 mL, 0.66 mol) in THF (1.3 L) cooled (0°C) under an inert (Ar) atmosphere was treated with LiHMDS (1.0 M m THF) (0.13 kg, 0.80 L, 0.80 mol) (drop-wise addition over 1 h) and stirred at 0°C for 1 h. The reaction mixture was quenched with a saturated aq NH4CI (1.0 L) at 0°C, then extracted with EtOAc (2 x 1.0 L). The combined organic layers were washed with water (1,0 L) then brine (1000 mL), dried over NacSOr, filtered, and concentrated under reduced pressure. The crude residue was purified by flash silica column chromatography (2: 1 EtOAc / heptane) to afford the product as a mixture of isomers. The mixture was purified by preparative SFC (i-Amylose-3 column, isopropylalcohol (0.1 % NH4OH) as a modifier). The fractions which contained the second eluting diastereomer were combined, concentrated in vacuo and co-evaporated with dichloromethane to afford the title compound.NMR (400 MHz, CDCI3) 86.88 (s, 1H), 3.96 (s, 3H), 2.09 (dd,. / 9.6, 6.5 Hz.1H), 1.94 (ddd. = 9.6. 8.3, 6.3 Hz. 1H). 1.64 - 1 58 (m, 1H), 1.52 (d,. / = 6.3 Hz, 3H) MS (ESI) m / z: 283.9, 285.9 [M+H]+.Step 2: 3-bromo-l-((lS,2S)-l-cvano-2-methylcvdopropyl)-lH-pyrazole-5-carboxylic acid

[0295] A mixture of methyl 3-broino-l-((l S,2S)-1 -cyano-2-methvlcyclopropyl)- 1 H-pyrazole-5-carboxylate (5 g. 17,6 mmol) in THE (50 mL) was added aq lithium hydroxide (886 mg. 21, 1 mmol, 50 mL) at rt. Then, the reaction mixture was stirred at rt for 1 h. The mixture was poured into a solution of 0.5 M HO (500 mL) and extracted with EtOAc (3 x 300 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to afford the title compound.]H NMR (400 MHz. CDCh) 57.02 (s, 1H). 5.71 (s, 1H), 2.12 (dd,.7 = 9.6, 6.5 Hz, 1H), 2.05 - 1.94 (m, 1H), 1.63 (dd, J= 8.2, 6.6 Hz, 1H), 1.51 (d, J = 6.2 Hz, 3H). MS (ESI) m / z: 270.0, 272.0 [M + H]H.Intermediate AE44-bromo-2-(( 1 R.2S)- 1 -cy ano-2-methylcy ciopropyl)benzoic acid or 4-bromo-2-(( 1 S,2S)- 1 -cyano- 2-methylcyclopropyl)benzoic acidStep 1: methyl 4-bromo-2-((l R.2S)-l-cyano-2-methy]cyclopropyl)benzoate

[0296] At 0 °C under an inert (Nz) atmosphere, (R)-4-methyl-l,3,2-dioxathiolane 2,2-dioxide (19.1 g, 139 mmol) and methyl 4-bromo-2-(cyanomethyl)benzoate (17.6 g. 69.3 mmol) were mixed in THF (352 mL). Lithium bis(trimethylsilyl)amide (1.0 in THF) (29.0 g, 173 mL, 173 mmol) was added drop-wise over a period of 1 h and the mixture was subsequently stirred at 0 °C for 1 h. Then, the reaction mixture was poured into saturated aq NH.|C1 (400 mL), water (200 mL) and EtOAc (100 mL) were added. The layers ere separated and the aq layer was extracted with EtOAc (2 x 200 mL). The combined organic layers were washed with brine, dried over Xa SO filtered, and concentrated in vacuo. The cmde residue w as purified using flash silica column chromatography (0 to 35% di-isopropyl ether, eptane) to obtain separated isomers as the titled compounds. Data for the first eluting isomer: *H NMR (400 MHz, CDCh) 5 7.83 (d, J === 8.1 Hz, 1H), 7.59 - 7.51 (m. 2H), 3.98 (s, 3H), 1.54 - 1 41 (m, 5H), 1.41 - 1.32 (m, 1H). LCMS: MS (ESI) m / z: 294.0. 296.0 [M+H]+. Data for the second eluting isomer:JH NMR (400 MHz, CDCh) 87.90 (d, J = 8.4 Hz, 1H), 7.62 - 7.52 (m, 2H), 3.98 (s, 3H), 2,00 (dp, J = 9.0, 6.4 Hz,IH), 1.86 (dd, J = 9.0, 5.5 Hz, 1H), 1.19 (dd. J = 7.0, 5.5 Hz, IH), 0.80 (d, J = 6.3 Hz, 3H). LCMS: MS (ESI) m / z: 294.0, 296.0 [M+H]+.Step 2: 4-bromo-2-((lR,2S)-l-cyano-2-methylcydopropyl)benzoic acid or4-bromo-2-((TS,2S)-l-cyano-2-methylcyclopropyl)benzoic acid

[0297] A solution of methyl 4-bromo-2-((lR,2S)-l-cyano-2-methylcyclopropyl)benzoate or methyl 4-bromo-2-((lS,2S)-l-cyano-2-methylcyclopropyl)benzoate (6.49 g, 22.1 mmol, first eluting isomer from previous step) in THF (130 mL) at rt was added lithium hydroxide monohydrate ( 1.11 g, 26.5 mmol) in water (130 mL). Die resulting mixture was stirred at rt for 3.5 h. Additional lithium hydroxide monohydrate (185 mg, 4.41 mmol) was added and stirring was continued for 18 h. A third portion of lithium hydroxide monohy drate (185 mg, 4.41 mmol) was added and the mixture was stirred for 2 h. Dien, the mixture was poured into aq 0.5 M HC1 (250 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were dried over NasSO / i, filtered, and concentrated in vacuo to obtain the title compound.!H NMR (400 MHz, DMSCMs) 6 13.46 (s, IH). 7.83 - 7.73 (m. 2H), 7.70 (dd, J = 8.3, 2.0 Hz. IH), 1.66 (dd, J = 8.6, 5.4 Hz. IH), 1.59 - 1.46 (m, IH), 1.43 - 1.27 (m, 4H) MS (ESI) m / z: 280.0, 2820 [M+H]!Intermediates AES and AE61-((lS,2S)-l-cyano-2-methylcyclopropyl)-3-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-lH-pyrazole-5-carboxylic acid and I -(( 1 ...

Claims

WHAT IS CLAIMED IS:

1. A compound of Formula (I)or a pharmaceutically acceptable salt thereof,wherein:R1is halogen, CN, OH, aminoalkyl, hydroxyalkyl, diaminoalkyl, dihydroxy alkyl, Ci-C,-, alkyl, Ci-Cs heteroalkyl, Cs-Cs cycloalkyl, 3-10 membered heterocycloalkyl, -C=C-(3-10 membered heterocycloalkyl). -C^C-ICT-Cs cycloalkyl), or -phenyHC -Cs cycloalkyl), wherein R1is substituted with 0 to 5 substituents independently selected from halogen, CN, hydroxyl, Ci-Cf, alkyl, 3-10 membered heterocycloalkyl or Cs-Cs cycloalkyl, wherein the Ci-Ce alkyl, 3-10 membered heterocycloalkyl or Cs-Cs cycloalkyl is substituted with one or more halogen atoms, C1-C2 alkyl, or C1-C0 alkyloxy;R2is H or methyl;R3is H or methyl;R4is hydrogen or Ci-Ce, alkyl;R5is hydrogen or Ci-Ce alkyl, orR4and R5, together with the atoms which they are attached, or R4and Rb. together with the atom which they are attached, form a bridged Cr-Cs heterocyclic ring fused to the pyrazole;each R6is independently H, halo, or Ct-Ce alkyl and each R7is independently H, halo, or Ci-Ce alkyl, orR6and R7together with the atoms to which they are attached, form a C3-C6 cycloalkyl ring or a 3-6 membered heterocycloalkyl ring, wherein the C3-C6 cycloalkyl ring or the 3-6 membered heterocycloalkyl ring is substituted with 0 or 1 instances of R9,provided that if there are two R6and R7then only one set forms a ring and the other R6and R7is each independently H or Ci-Ce alkyl;R9is H, Ci-C'e alkyl, -SO2-(Ci-Ce alkyl), -((Ci-Ce alkylenyl)O)t(Ci-C'6 alkyl), -(Ci-Ce alkylenyl)(C3-Cscycloalkyl), -(C)(O)(Ci-C6alkyl), -(CH2)aryl, C3-Cs cycloalkyl, -(CH2)(C3-C8cycloalkyl), C(O)Ci-C6alkyl. -((Cj-C6alkylenyl)O)t(Ci-C6 alkyl), or S(O)2(Ci-C3alkyl) wherein one or more of the hydrogen atoms of the Ci-Ce alkyl may be substituted with fluoro or hydroxyl, and 0 or 1 of the carbons of the Ci-Ce alkyl form a cyclopropyl ring, and wherein t is 1, 2, 3, 4 or 5;n is 1 or 2;p is 1, 2, 3, 4 or 5;R4, R5, Rband R' are each independently substituted with 0 to 2 substituents independently selected from halogen, NH?„ aminoalkyl, diaminoalkyl, Ci-C« alkyl, and Ci-Cg alkyl substituted with one or more halogen atoms, Ci-6 alkoxy, hydroxy, oxo, CONRwlR"'2, SO2N RW3RW4, SO2RW5, N(RW6)CORW7, NRW8SO2RW9, wherein Rwl. R'v2, R"3. Rw4, R ’ Rw0, RW7, R"8, and Rw9, are each individually selected from H and Ci-Cr, alkyl;A is 5-10 membered heteroaryl or Ce-Cio and;X is O, S, or NRXXwherein Rxxis H or C1-C3 alkyl, wherein C1-C3 alkyl is substituted with 0, 1, or 2 substituents selected from halogen and Ccycloalkyl;on Y is bound to thepyrazole moiety and the righton Y is bound to B,Z is C, CRXor N;Rxis H, halo, hydroxy, Ci-Ce. alkyl, C3-C6 cycloalkyl. Ci-Ce alkoxy, or -O(Cj-C6 cycloalkyl);Ry, and Rz, together with the atoms which they are attached and optionally Rx, form a 5-8 membered heterocycloalkyl ring or a 5-6 membered heteroaryl; orRy, and Rzare each independently H. halo, Ci-Ce alkyl or C3-C6 cycloalkyl; or Rxand Ry. together with the carbon to which they are attached, form a spiro C3-C6 cycloalkyl ring and Rzis H, halo, or Ci-Cg alkyl; orR and Rz, together with the carbon to which they are attached, form a spiro Cs-Cs cycloalkyl ring and Ryis H, halo, or Ci-Cc, alkyl; andB is C3-C8 cycloalkyl. 5-13 membered heterocycloalkyl, aryl or heteroaryl. and B is substituted by 0, 1, 2, or 3 substituents, each independently selected from C1-C3 alkyl, halogen, hydroxyl, heteroalkyl, 5-9 membered heterocycloalkyl, -OfCs-Ce cycloalkyl), C3-CG cycloalkyl, 5-9 membered heteroaryl, 5-9 membered aryl, -0(Ce-Cio aryl), and phosphorus atom substituted with oxo and / or C1-C3 alkyl, wherein one or more of the hydrogen atoms of the C1-C3 alkyl or heteroalkyl may be substituted with deuterium or fluoro, and wherein the 5-9 membered heterocycloalkyl, 5-9 membered heteroaryl or 5-9 membered aryl is substituted with 0, 1, 2, or 3 substituents independently selected from -Ci-C3 alkyl. -C1-C3 haloalkyl, -( / .-( •, cycloalkyl, and oxo;R8is Ci-Ce alkyl, 5-10 membered heterocycloalkyl, heteroaryl, or aryL and R8is substituted by 0, 1, 2, or 3 substituents, each independently selected from C1-C3 alkyl, C3-C6 cycloalkyl, -O(C3-Ce cycloalkyl), phenyl, halogen, -SO2CH3 and oxo, wherein one or more of the hydrogen atoms of the C1-C3 alkyl or Cs-Cg cycloalkyl may be substituted with fluoro or chloro; orR8bis aryl, heteroaryl, 4-10 membered heterocycloalkyl. C3-C10 cycloalkyl, wherein R8bis substituted by 0, 1, 2 or 3 substituents, each independently selected from Ci-C? alky], halogen, and oxo, wherein one or more of the hydrogen atoms of the C1-C3 alkyl may besubstituted with fluoro or chloro; wherein if R8ais L then R8bis heteroaryl or 4-10membered heterocycloalkyl with at least one nitrogen, and R8aforms a bond with the nitrogen of the heteroaryl or 4-10 membered heterocycloalkyl;wherein R8c, when present, is Ci-Ce alkyl, substituted with 0, 1, 2, or 3 substituents independently selected from halogen, C3-C6 cycloalkyl, phenyl or 3-8 membered heterocycloalkyl;wherein at least one of (a)-(h) is true:(a) R8is other than optionally substituted Cg-io aryl and optionally substituted or 5 to 10 membered heteroaryl;wherein the left Y on Y isbound to the pyrazole moiety and the right X on Y is bound to B, and(c) R1is other than optionally substituted 3 to 12 membered heterocycloalkyl and 5 to 10 membered heteroaryl;(d) n is 1 and R6is Ci-Ce alkyl and R7is Ci-Cg alkyl, or(e) n is 1 and R6and R7together with the atom to which they are attached, form a C?-Ce cycloalkyl ring or a 3-6 membered heterocycloalkyl ring;(f) n is 2; andwherein the left X on Y is bound to the pyrazole moiety and the righton Y is bound to B; andthe pyrazole moiety and the right X on Y is bound to B and R20is selected from C1-C3 alky] or cyclopropyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is 6-9 membered heteroaryl or C6-C9 aryl.

3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein A is4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein5. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein A is6 The compound of claim 3. or a pharmaceutically acceptable salt thereof, wherein7. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R1is 6-10 membered heterocycloalkyl or Cs-Cs cycloalkyl, wherein R1is substituted with 0 to 5 substituents independently selected from a halogen, Ci-6 alkyl, Ci-6 alkyl substituted with one or more halogen atoms, and Ci-e alkoxy.

9. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R1is 6-10 membered heterocycloalkyl, wherein R1is substituted with 0 to 2 substituents independently selected from Ci-6 alkyl.

10. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R1is 6-10 membered heterocycloalkyl, wherein R1is substituted with two methyl groups.

11. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R’ is 6-10 membered heterocycloalkyl containing one or two oxygen atoms as ring members, wherein R1is substituted with 0 to 3 substituents independently selected from OH, C1-C6 alkyl, or Ci-C's alkyloxy.

12. The compound of claim 8, or a pharmaceutically acceptable salt thereof wherein R1is C3-C8cycloalkyl, wherein R1is substituted with 0 to 2 substituents independently selected from hydroxyl and Ci-Ce alkoxy.

13. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R1alkyl.

14. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R1halogen, or Ci-Cs alkyl and Rz2is H,halogen or Ci-C'e alkyl, andZZ is N.

15. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R]is tetrahydropyranyl, wherein R1is substituted with 0 or 2 methyl groups.

16. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R117 The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R1halogen, C1-C.5 alkyl, Ci-Ce alkyl substituted with one or more halogen atoms, and C1-C0 alkoxy.

18. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R119. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R120. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R121. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R122. The compound of any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof, wherein R2is H and R3is H.

23. The compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R2is H and RJis methyl.

24. The compound of any one of claims 1 to 23. or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula la:

25. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, whereinR4is hydrogen, methyl, or ethyl;R3is hydrogen or methyl;R4and R5, together with the atom which they are attached, or R4and R6, together with the atom which they are attached, form a bridged C7-8 heterocyclic ring fused to the pyrazole; andR6is H, halo, or methyl, and R7is H, halo, or methyl, orR6and R7together with the atom to which they are attached, form a cyclopropyl ring or a cyclobutyl ring provided that if there are two Rhand Rzthen only one set forms a ring and the other R6and R7is each independently H or methyl,26. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R4is methyl.

27. The compound of any one of claims 1 to 26. or a pharmaceutically acceptable salt thereof, wherein R3is H.

28. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R4is methyl and R' is H.

29. The compound o f any one of claims 1 to 28. or a pharmaceutically acceptable salt thereof, wherein R6is methyl, R7is methyl, and n = 1.

30. The compound of any one of claims 1 to 28, or a pharmaceutically acceptable salt thereof, wherein R6is halo, R7is halo, and n 1.

31. The compound of claim 30, or a pharmaceutically acceptable salt thereof, wherein Rcis fluoro, R7is fluoro, and n:== 1.

32. The compound of any one of claims 1-25, 27 or 29-31, or a pharmaceutically acceptable salt thereof, wherein R4and R6, together with the atom to which they are attached, form a bridged ( ■■-(’.■•; heterocyclic ring fused to the pyrazole.

33. The compound of claim 32, or a pharmaceutically acceptable salt thereof, wherein R4and R6, together with the atom to which they are attached, form a bridged Cy-Cs heterocyclic ring fused to the pyrazole. and n = 1.

34. The compound of any one of claims 1-25 or 28-31, or a pharmaceutically acceptable salt thereof wherein R4and R5, together with the atom to which they are attached, form a bridged Cy-Cs heterocyclic ring fused to the pyrazole.

35. The compound of claim 34, or a pharmaceutically acceptable salt thereof, wherein R4and R5, together with the atom to which they are attached, form a bridged C7-8 heterocyclic ring fused to the pyrazole, and n=l.

36. The compound of any one of claims 1 to 35, or a pharmaceutically acceptable salt thereof, wherein n is 1,37. The compound of any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein n is 2.

38. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof wherein39. The compound of claim 38, or a pharmaceutically acceptable salt thereof, wherein40. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein41. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein42. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, whereinand X° is O or NR9wherein R9is H, C1-C6alkyl, SO2-(Ci-C6alkyl), ((Ci-C6alkylenyl)O)t(Ci-C6 alkyl), -(Ci-C6alkylenyl)(C3-C8cycloalkyl), -(C)(O)(Ci-C6alkyl). -(CH2)aryl, C3-Cg cycloalkyl, -(CH2)(C3-Cs cycloalkyl), or Ci-Cg alkyl, wherein one or more of the hydrogen atoms of the Ci-Cg alkyl may be substituted with fluoro, and t is 1, 2, 3. 4 or 5.

43. The compound of claim 42, or a pharmaceutically acceptable salt thereof, wherein Xcis O, NH, N(CI-C6alkyl), N(C)(O)(CI-C6alkyl), N(SO2-(CI-C6alkyl)), or N((CI-C6alkylenyl)O)t(Ci-C6 alkyl), wherein t is 1, 2. 3, 4 or 5.

44. The compound of claim 42 or 43, or a pharmaceutically acceptable salt thereof, wherein Xcis NR9and R9is -(Ci-Cg alkylenyl)(C3-C«cycloalkyl), C -Cs cycloalkyl, -C(O)Ci-C6 alkyl, -((Ci-Ce alkylenyl)O)t(Ct-C6 alkyl), or -S(O)2(Ci-C6 alkyl) wherein one or more of the hydrogen atoms of the Ci-Cg alkyl may be substituted with fluoro or hydroxyl, and wherein t is 1, 2, 3, 4 or 5.

45. The compound of claim 42 or 43, or a pharmaceutically acceptable salt thereof, wherein Xcis NR9and R9is -(CH2)aryl, -(CH2)(C3-C8cycloalkyl), or Ci-Cs alkyl wherein one or more of the hydrogen atoms of the Ci-Ce alkyl may be substituted with fluoro.

46. The compound of claim 42 or 43, or a pharmaceutically acceptable salt thereof, wherein Xcis NR9and R9is H, -CH2CF3, -CH2CHF2, -CH2C(CH3)2OH, cyclopentyl, phenylmethyl, -C(O)CH3. -C(O)C(CH3)3, -C(O)CHF2, -C(O)CF2CHF2, -(CH2CH2O)4(CH3),47. The compound any one of claims 42 to 46. or a pharmaceutically acceptable salt thereof, wherein48. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, whereinand Xcis O, NH, N(Ci-Cb alkyl), N(C)(O)(Ci-Cs alkyl), N(SO2-(Ci-Ce alkyl)).

49. The compound of any one of claims 1 to 48. or a pharmaceutically acceptable salt thereof, wherein50. The compound of any one of claims 1 to 49. or a pharmaceutically acceptable salt thereof, wherein X is O.

51. The compound of any one of claims 1 to 49, or a pharmaceutically acceptable salt thereof, wherein52. The compound of any one of claims 1 to 51, or a pharmaceutically acceptable salt thereof, wherein R4, R5, R6and R7are each independently substituted with 0 to 2 substituents independently selected from halogen, -NH?„ aminoalkyl, diaminoalkyl, Ci-Cc,alkyl, and Ci-Ce alkyl substituted with one or more halogen atoms, Ci-Cr, alkoxy, and hydroxy.

53. The compound of any one of claims 1 to 52. or a pharmaceutically acceptable salt thereof, wherein Ry. and Rz, together with the atom which they are attached, form a 5-7 membered heterocycloalkyl ring or a 5-6 membered heteroaryl.The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein Rzis H.The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt RyR2RyRzthereof, wherein Y is Z is CRX. and Rxis H, halogen, or CFF.The compound of any one of claims 1 to 52. or a pharmaceutically acceptable salt57. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein58. The compound of and any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, whereinRx, Ry, and Rzare each independently H, halogen, or CH3.

59. The compound of any one of claims 52, 55 or 58. or a pharmaceutically acceptable salt thereof, wherein the halogen is fluoro.

60. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable saltthereof, wherein61. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable saltthereof, whereinRx, Ry, and Rzare each independently H, halogen, or CH?; or Rxand Ry. together with the carbon to which they are attached, form a spiro C?,-Ce cycloalkyl ring and Rzis H. halo, or Ci-Cc alkyl.

62. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable saltthereof, whereinRx, Ry, and Rzare each independently H, halogen, or CH?,.

63. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, whereinX1is N or C(H);X2is N or C(H);Xais N or C(H);Xb is N or C(H): andXc is N or C(H).

64. The compound of claim 63, or a pharmaceutically acceptable salt thereof, wherein at least one of X1or X2is N.

65. The compound of claim 63, or a pharmaceutically acceptable salt thereof, wherein at least one of Xa, Xb, and Xcis N66. The compound of any one of claims 1 to 52. or a pharmaceutically acceptable saltremaining are C or C(H).

67. The compound of claim 66, or a pharmaceutically acceptable salt thereof, wherein one or two of Xd, Xd, Xe, Xf, Xg, and Xh, are nitrogen and the remaining are C or C(H).

68. The compound of any one of claims 1 to 52. or a pharmaceutically acceptable salt thereof, wherein Y is:

69. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt70. The compound of any one of claims 1 to 52. or a pharmaceutically acceptable salt thereof, wherein Y is:

71. The compound of any one of claims 1-20 or 22-52, or a pharmaceutically acceptable salt thereof, wherein Y is:

72. The compound of claim 68, or a pharmaceutically acceptable salt thereof, wherein Yis:

73. The compound of claim 68, or a pharmaceutically acceptable salt thereof, wherein Y74. The compound of claim 68. or a pharmaceutically acceptable salt thereof, wherein Yis:

75. The compound of claim 68, or a pharmaceutically acceptable salt thereof, wherein Yis:

76. The compound of claim 70. or a pharmaceutically acceptable salt thereof, wherein Y77. The compound of claim 68, or a pharmaceutically acceptable salt thereof, wherein Yclaim 68, or a pharmaceutically acceptable salt thereof, wherein Y79. The compound of claim 71, or a pharmaceutically acceptable salt thereof, wherein Yd of claim 71, or a pharmaceutically acceptable salt thereof, wherein Y81. The compound of claim 68, or a pharmaceutically acceptable salt thereof, wherein Y82. The compound of claim 68, or a pharmaceutically acceptable salt thereof, wherein Y83. The compound of claim 68, or a pharmaceutically acceptable salt thereof, wherein Y84. The compound of claim 68. or a pharmaceutically acceptable salt thereof, wherein Y85. The compound of any one of claims 72 to 80, or a pharmaceutically acceptable salt thereof whereinR' is H and R3is H or methyl,R4is hydrogen, methyl, or ethyl:R3is hydrogen or methyl;R4and R5, together with the atom which they are attached, or R4and R6, together with the atom which they are attached, form a bridged C7-8 heterocyclic ring fused to the pyrazole; andR6is H, halo, or methyl, and R7is H, halo, or methyl, orR" and R7together with the atom to which they are attached, form a cyclopropyl ring or a cyclobutyl ring provided that if there are two R6and R7then only one set forms a ring and the other R6and R7is each independently H or methyl.86 The compound of claim 85, or a pharmaceutical ly acceptable salt thereof, wherein B isR8is:

87. The compound of any one of claims 1 to 71, or a pharmaceutically acceptable salt thereof, wherein B is 5-13 membered heterocycloalkyl, aryl or heteroaryl, and B is substituted by 0, 1 or 2 substituents, each independently selected from C1-C3 alkyl, halo. -O(C1-C3alkyl), -C1-C6alkylenyl-O-(C1-C3alkyl), C1-C5alkylenyl-O-C1-C3alkylenyl-O-C1-C3alkyl, -NH(C1-C3alkyl), -O(C3-C6cycloalkyl), and -O(C6-C10aryl), wherein one or more of the hydrogen atoms of the -C1-C3 alkyl or -O(Ci-C3alkyl) may be substituted with fluoro.

88. The compound of any one of claims 1 to 71, or a pharmaceutically acceptable salt thereof, wherein B is substituted by 1 or 2 substituents, each independently selected fromfluoro, methyl, -CHF₂, cyclopropyl, -OCF2CF3,89. The compound of any one of claims 1 to 71, or a pharmaceutically acceptable saltthereof, whereinsubstituted by0, 1 or 2 substituents, as recited in claim 1.

90. The compound of claim 89, or a pharmaceutically acceptable salt thereof, wherein B is substituted by 1 or 2 instances of C1-C3 alkyl.

91. The compound of any one of claims 1 to 71. or a pharmaceutically acceptable saltone of Rbbor Rbcis C1-C3 alkyl or heteroalkyl, and the other is not present, Rbdis hydrogen or halogen,wherein one or more of the hydrogen atoms of the C1-C3alkyl or heteroalkyl may be substituted with fluoro.

92. The compound of claim 91, or a pharmaceutically acceptable salt thereof, wherein the heteroalkyl is -O(C1-C3alkyl).

93. The compound of claim 87, or a pharmaceutically acceptable salt thereof, wherein Bthird is CH, CH2, N or NH, and Rberepresents one, or two optional ring substituents, which can be the same or different at each occurrence and wherein each occurrence of Rbeis independently selected from C1-C3 alkyl, halo, -O(C1-C3alkyl), -O(C3-C6cycloalkyl), -O(C6-C10aryl) and phosphorus atom substituted with oxo and / or C1-C3 alkyl, wherein one or more of the hydrogen atoms of the -C1-C3 alkyl or -O(Ci-C3 alkyl) is optionally substituted with fluoro.

94. The compound of any one of claims 1-71 or 87-93, or a pharmaceutically acceptable salt thereof, wherein B is substituted with C1-C3 fluoroalkyl.

95. The compound of any one of claims 1-71 or 87-93, or a pharmaceutically acceptable salt thereof, wherein B is substituted by 1 or 2 substituents, each independently selected from fluoro, methyl, -CHF2, CF3, -CH2CF3. -OCF2CF3. -CH2CH2-O-CH2CH2-O-CH3, -96. The compound of any one of claims 1-71 or 87-93, or a pharmaceutically acceptable salt thereof, wherein B is substituted by 1 or 2 substituents, each independently selected from fluoro, methyl, -CHF2, CF3, -CH2CF3, -OCF2CF3, -CH2CH2-O-CH2CH2-O-CH3, -97 The compound of any one of claims 1 to 71, or a pharmaceutically acceptable salt thereof, wherein B is98. The compound of any one of claims 1 to 71. or a pharmaceutically acceptable salt thereof, wherein B is99. The compound of claim 98, or a pharmaceutically acceptable salt thereof, wherein B100. The compound of any one of claims 1-85 or 87-96, or a pharmaceutically acceptable salt thereof, wherein R8is substituted by 1 or 2 substituents, each independently selected from fluoro, methyl, CF₃. cyclopropyl, and oxygen.

101. The compound of any one of claims 1 to 99, or a pharmaceutically acceptable saltthereof wherein if R8ais then R8bis heteroaryl or 4-10 membered heterocycloalkylwith at least one nitrogen, and R8aforms a bond with the nitrogen of the heteroaryl or 4-10 membered heterocycloalkyl.

102. The compound of any one of claims 1 to 99, or a pharmaceutically acceptable salt thereof, wherein R8is:

103. The compound of claim 100 or 101, or a pharmaceutically acceptable salt thereof, wherein R8is:104, The compound of claim 102, or a pharmaceutically acceptable salt thereof, wherein R8is:

105. The compound of any one of claims 1-71 or 87-104, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the formula II. Ila, III, IV, IV a, IVb, V. Va, Vb, VI, Via, Vlb, VII, Vila, or VIII and Rzlis H or Ci-C6alkyl and Rz2is H or Ci-C6alkyl,- 98fr -106. The compound of any one of claims 1-71, 87-98 or 100-104, or a pharmaceutically acceptable sail thereof, wherein the compound of Formula I has the formula IX. IXa or IXb:

107. The compound of any one of claims 1-71 or 87-104, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the formula X, Xa or Xb:

108. The compound of any one of claims 1-71, 87-98 or 100-106, or a pharmaceutically acceptable salt thereof, wherein109. The compound of any one of claims 1-71, 87-98, 100-106 or 108, or a pharmaceutically acceptable salt thereof, wherein110. A compound selected from:3-((lS,2S)-l-(2-((S)-3-(3-(4-fluoro-l -methyl- lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-iniidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetraliydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazoi-5(4H)-one;3-((lS,2S)-l-(2-((S)-3’-(3-(4-fluoro-l-methyl-lH-mdazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazoIo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethy]phenyl)-4-methyl-2,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(5-((S)-2,2-dimetliyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-l-methyl- lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l -yl)-2-(4-f!uoro-3,5-dimethylphenyl)-4-methyl-2,4,5,6,7.8-hexahydropyrazolo[4,3-c]azepine-5-carboiiyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;ethyl 2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazo]-l-yl)-4-methy!-5-(l-((l S.2S)-2-methyl-l-(5-oxo-4.5-dihydro-L2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-! H-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)acetate;(S)-3-(l-(5-bromo-2-(3-(3-(4-fluoro-l-methyI-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3f5-dimethylphenyl)-4-methyl-4.5?6?7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)cyclopropyl)-L2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-benzyl-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahy ro-2H-pyrazolo[4.3-c]pyri ine-5-carbonyI)-5-(tetrahy dro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methy Icy clopropyl)- 1.2.4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((S)-l-cyclopropylethyl)-3-(3-(4-fiuoro-l -methyl- IH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcy clopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((R)-l-cyclopropylethyl)-3-(3-(4-fluoro-l -methyl -IH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-inndazoi-l-yl)-4-methyI-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yi)-lH-mdoJ-l-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-2-(2-methyl-2-(methylsulfonyl )propyl)-4, 5, 6, 7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(l,l-dioxidotetrahydro-2H-thiop ran-4-yl)-3-(3-(4-fluoro-l-methyl-lII-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(3-(4-fluoro-l -methyl- lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-2-((3-methyl-l,l-dioxidothietan-3-yl)methyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyndine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(( 1 S,2S)- 1 -(5-((S)-2,2-dimethyltetrahy dro-2H-pyran-4-yl)-2-((S)-3'-(3-(4-fluoro- 1 -methyI-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2'-(4-fiuoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo 4.3-c]py ridine]-5'-carbonyl)-lH-indol-l-yl)-2 -methylcyclopropyl)-!, 2, 4-oxadi azol -5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indoI-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;(4'S)-5'-(5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-lH-indole-2-carbonyl)-3'-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclobutane-l,7'-pyrazolo[4,3-c]pyridin]-r-ium;3-((l S,2S)-l-(2-((S)-3'-(3-(4-fluoro-l -methyl- lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2'-(4-fIuoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclobutane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(telrahydro-2H-pyran-4-yr)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-I-(5-(2,2-dimethyltetraliydro-2H-pyran-4-yl)-2-((S)-3'-(3-(4-fluoro-l-(2-methoxyethyl)-lH-inda oI-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2'-(4-fluoro-3,5-dimethylphenyi)-4'-methyl-2',4',5,?6'-tetrahydrospiro[cyclopropane-L7'-pyrazoIo[4,3-c]pyridine]-5'-carbonyl)-lH-mdol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3'-(3-(4-fluoro-2-(2-methoxyethyl)-2H-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidaz.ol-l-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5'.6'-tetrahydrospiro[cyclopropane-L7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-1.2,4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3'-(3-(4-fluoro-l-(2-(2-methoxyethoxy)ethyl)-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2'-(4-fluoro-3.5-dimethylphenyl)-4'-methyl-2',4',5\6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo|4,3-c Ipyri dine ]-5'-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyI)-l?2,4-oxadi azol-5(4H)-one:3-((lS,2S)-l-(2-((S)-3'-(3-(4-fluoro-l -methyl-1 H-indazol-5-yl)-2-oxo-2,3-dihydro-lH-iniidazol-l-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2,2',3,4'.5.5’,6,6'-octahydrospiro[pyran-4,7'-pyrazolo[4.3-c|pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropy])-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((S)-l-cyclopropyi-2,2,2-trifluoroethyl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyI)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-metbylcjclopropyJ)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((R)-l-cyciopropyl-2,2,2-trifluoroethyl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((R)-l-cyclopropylethyl)-3-(3-(4-fluoro-l-methyl-lH-mdazol-5-yl)-2-oxo-2,3-dihydro-lH midazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.,3-c]pyridine-5-carbonyl)-5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-l-y1)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((l S,2S)-l-(2-((S)-2-((S)-l-cyclopropylethyl)-3-(3-(4-fluoro-l -methyl- IH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyI)-5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-metliylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-I-(2-((S)-2-((R)-l-cyclopropylethyI)-3-(3-(4-fluoro-l-tnethyI-lH-mdazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l -yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((S)-2.2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-l -yl)-2-methylcy clopropyl)-!, 2.4-oxadiazol-5(4H)-one;3-(( 1 S,2S )- 1 -(2-((S)-2-((S )- 1 -cy clopropy lethy 1 )- 3 -(3 -(4-fluoro- 1 -methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-l-y1)-2-methylcy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-((S)-l,l-dioxidotetrahydro-2H-thiopyran-3-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)- IH-indol- l-yl)-2-methylcy clopropyl)- l,2,4-oxadiazol-5(4H)-one;3-((! S,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yi)-2-((S)-2-((R)-l,l-dioxidotetrahydro-2H-thiopyran-3-yl)-3-(3-(4-fluoro-! -methyl- lH-indazol-5-yl)-2-oxo-2, 3-dihy dro-lH-imidazol-l-yl)-4-methy 1-4,5, 6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)- IH-indoi- 1 -y l)-2-methylcy clopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-((S)-l,l-dioxidotetrahydro-2H-thiopyran-3-yl)-3-(3-(4-fluoro-l-methyl-! H-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imid zol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo|4.3-c|pyridine-5-carbony 1)- 1 H-indol- 1 -y l)-2-methylcy clopropyl)-!, 2, 4-oxadiaz.ol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyitetrahydro-2H-pyran-4-yl)-2-((S)-2-((R)-J,1-dioxidotetrahydro-2H-thiopyran-3-yl)-3-(3-(4-fluoro-l-methy!-rH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)- IH-indol- 1 -yl )-2-methylcy clopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((S)-l,l-dioxidotetrahydrothiophen-3-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6.7-tetraliydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-metbylcy clopropyl)- 1, 2, 4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-2-((R)-l,l-dioxidotetrahydrothiophen-3-yl)-3-(3-(4-fluoro-l-methyl-lH-mdazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4.5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indo1-l-yl)-2-methy Icy clopropy I)- 1,2, 4-oxadi azol-5 (4H)-one;3-((lS,2S)-l-(2-((S)-2-((S)-l,l-dioxidotetrahydrothiophen-3-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-y1)-lH-indol-l -yl)-2-methylcy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((l S.2S)- l-(2-((S)-2-((R)-l, 1 -dioxidoteirahydrothiophen-3-yl)-3-(3-(4-fluoro-l-methyI-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6;7 -tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((4S,7R)-3-(3-(4-fluoro-l-methy]-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-355-dimethylphenyl)-2 5.6,7,8-hexahydro-4,7-epiniinocyclohepta[c]pyrazole-9-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-ll-I-indol-l-yI)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(( 1 S,2S)-1 -(2-((4R, 7S)-3-(3-(4-fluoro- 1 -methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-2,4,5,6,7,8-hexahydro-4,7-epiminocyclohepta[c]pyrazole-9-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((4S,7R)-3-(3-(4-fluoro-l -methyl- lH-indazol-5-yl)-2-oxo-2, 3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-2,4,5,6,7,8-hexahydro-4,7-epiminocyclohepta[c]pyrazole-9-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((4R,7S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-2,4,5,6,7,8-hexahydro-4,7-epiminocyclohepta[c]pyrazole-9-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcydopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yI)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((2R,4s,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-d!hydro-lH-imidazol-l-yl)-4-methyl-4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyndine-5-cartionyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-2-((2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(3-(4-fluoro-1 -methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imida ol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yr)-lH-indol-l-vl)-2-methylcycIopropyI)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-((2R,4s,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-rH-imidazol-l-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-IH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(l-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazo]o[4,3-c]pyridine-5-carbonyl)-5-(ietrahydro-2H-pyran-4-yl)-! H-mdol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((! S,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(l-(4-fluoro-l -methyl- lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-! H-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yi)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-(l -( 1 -methyl-1 H-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-(l-(l-methyl-lH-indazol-5-yl)-6-oxo-l,6-dihydropyrimidin-5-yl)-4,5,6,7-tetraliydro-2H-pyrazoloi4,3-c]pyridine-5-carbonyl)-lH-indol-l-yI)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(l-(l-(difluoromethyl)-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetraliydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((! S,2S)-I-(2-((S)-3-(l-(2-(difluoromethyl)-2H-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyJ)-l,2,4-oxadiazoI-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3, 5-dimethylphenyl)-4-methyl-3-( 1-(1 -methyl- 1H-indazol-5-yl)-2-oxo-1.2-dihydropyridin-3-yl)-4.5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)- 1.2.4-oxadiazol-5(4H)-one;3-((! S,2S)-l-(2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-3-(l-(2-methyl-2H-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-! H-indol-l -yl)-2-methy1cyclopropyl)- 1.2.4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-3-(l-(l,3-dimethyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6T7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(( 1 S.2S)-l-(2-((S)-2-(4-fluoro-3.5-dimethylphenyl)-4, 7, 7-trimethyl-3-(l-(l -methyl-lH-mdazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-4,5.6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropy])-1,2?4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-3'-(l-(1.3-dimethyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro| cyclopropane-l,7'-pyrazolo|4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-3'-(l-(2-melhyl-2H-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2',4',5'?6'-tetrahydrospiro[cyclopropane-l '-pyrazolo[4,3-c]pyridine]-5'-carbony])-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(l-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4.7.7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-y])-lH-indol-l -yl)-2-methylcydopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetraliydro-2H-pyran-4-yl)-2-((S)-3-(l-(4-fluoro-l-methyl- 1 H-indazol-5-yl)-2-o o-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5f6.7-tetraliydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)- 2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-3-(l-(2-(difluoromethyl)-2H-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dirnethylphenyI)-4,7.,7-trirnethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-3-(l -(l-methyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin- 3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazoI-5(4H)-one;3-((lS,2S)-l-(2-((S)-2'-(4-fIuoro-3,5-dimethylphenyl)-4'-methyl-3'-(l -(1-methyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2',4',5',6'-tetraliydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2.4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-(2-oxo-l-(2-(trifluoromethyl)imidazo[l,2-a]pyridin-6-yl)-l,2-dihydropyridin-3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyi)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l -yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(l-(2-cyclopropyl-[ l,2,4]triazolo[l,5-a]pyridin-6-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-(2-oxo-l-(3-(trifluoromethyl)imidazo[l,5-a]pyridin-7-yl)-l,2-dihydropyridin-3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(l-(l-(dif]uoromethyl)-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fliioro-3,5-diniethylphenyI)-4-methyl-4,5,6,7-tetrahydro-2H-pyi'azolo[4,3-c]pyridine-5-carbonyl)-5-(tetraliydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4Il)-one;3-((lS,2S)-l-(2-((S)-3-(l-(l-(difluoromethyl)-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl )-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-rnethyIcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-(2'-methyl-2-oxo-2H-| l,4'-bipyridin]-3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-3-(l-(imidazo| l,5-a|pyridin-6-yl)-2-oxo-L2-dihydropyndin-3-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbony1)-! H-indol-l -yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3'-(2'-cyclopropoxy-2-oxo-2H-[l,4'-bipyridin]-3-yr)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l -yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(2'-cyciopropoxy-2-oxo-2H-[l,4'-bipyridin]-3-y3)-2-(4-fluoro- 3.5-dimethylphenyl)-457,7-trimethyl-4,5.6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methyicyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-3-(2'-cyclopropoxy-2-oxo-2H-[I,4'-bipyridin]-3-yl)-2-(4-fluoro- 3.5-dimethylphenyl)-4,7,7-trimethyl-4.5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyndine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(( 1 S,2S)-1 -(2-((S)-3'-(2'-cy clopropoxy-2-oxo-2H-[ 1,4'-bipyridin] -3 -y l)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo|4,3-c|pyridine]-5'-carbonyl)-5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-1 -yi)-2-methylcydopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(2'-cyclopropoxy-2-oxo-2H-[l,4'-bipyridin]-3-yl)-2-(4-fluoro- 3.5-dimethyIphenyl)-4-methyl-4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-lH-indol-l-y1)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(2'-cyclopropoxy-2-oxo-2H-[l,4'-bipyridin]-3-yl)-2-(4-fluoro- 3.5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c|pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-mdol-l-y])-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one 3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-3-(l-(isoquinolin-6-yl)-2-oxo-l,2-dihydropyridin-3-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-inethylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-3-(l-(4-(diethylphosphoiyl)-3-(methylammo)phenyl)-2-oxo-1.2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indo1-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-(l-(4-morpholinophenyl)-2-oxo-l,2-dihydropyridin-3-y1)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyI)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-7,7-difluoro-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-(l-(l-methyl-lH-mdazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyi)-5-((S)-2.2-dimethyltetrahydro-2H-pyran-4-yl)-]H-indol-1 -yl)-2-methylcyclopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethvl-3-(l-(l-methyl-lH-indazoi-5-yI)-6-oxo-l,6-dihydropyrimidin-5-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbony1)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-tluoro-3,5-dimethylphenyl)-4-methyl-3-(l -(l-methyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepine-5-carbonyl)-lH-indol-l-yl)-2-methyicyclopropyl)-l,2,4-oxadiazoI-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-3-(l-(3-methoxyphenyl)-2-oxo-l,2-dihydropyridin-3-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbony l)-5 -(tetrahy dro-2H-py ran-4-y 1)- 1 H-indol- 1 -yl)-2-methy Icy clopropy 1)- 1,2,4-oxadiazol-5(4H)-one:3-((lS,2S)-I-(2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methy]-3-(2-oxo-l-(l-(2,2,2-trifluoroethyl)-rH-indazol-5-yl)-l,2-dihydropyridin-3-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(l-(l-cyc]opropyl-lH-indazo]-5-y])-2-oxo-l,2-dihydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)- 1.2.4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-3-(2-(4-fluoro-l-methyl-lH-indazol-5-yl)-3-oxo-2,3-dihydropyridazin-4-yl)-2-(4-fluoro-3,5-dimethyiphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3, 5-dimethylphenyl)-4-methyl-3-(2-( 1 -methyl- 1H-indazol-5-yl)-3-oxo-2.3-dihydiopyridazin-4-yl)-4,5.6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbony!)-5-( tetrahy dro-2H-pyran-4-yl)-lH-indol- l-yl)-2-methylcy clopropyl)- 1.2.4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3, 5-dimethylphenyl)-4, 7, 7-trimethyl-3-(2-(l -niethyl-lH-indazol-5-yl)-3-oxo-2,3-dihydropyridazin-4-yl)-4,5,6,7-tetrahydro-2H-pyrazolo|4,3-c]pyridine-5-carbonyI)-5-(tetrahydro-2H-pyran-4-yl)-! H-indol-l-yl)-2-methy1cy clopropyl)- 1.2.4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-3'-(2-( I -methyl- 1H-indazol-5-yl)-3-oxo-2,3-dihydropyndazin-4-yl)-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo|4,3-c|pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(( 1 S.2S)- 1 -(2-((S)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-3-( 1 -( 1 -methyl- 1 H-indazol-5-yl)-6-oxo-1.6-dihydropyrimidin-5-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyI)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropy])-1,2,4-oxadiazol-5(4II)-one:3-((lS,2S)-l-(2-((S)-3'-(l-(4-fluoro-I-methyl-lH-indazol-5-yl)-2-oxo-l,2-dihydropyridin-3-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5,-carbonyl)-5-(tetrahydro-2H-pyran -4-yl)- lH-indol-l-yl)-2-methylcyclopropyl)-l, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltelraliydro-2H-pyran-4-yl)-2-((S)-3-(l-(4-Iluoro-l-methyl-lH-mdazol-5-yl)-6-oxo-l,6-dihydropyrimidin-5-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(4-(4-fluoro-l-methyl-lH-indazol-5-yl)-5-oxo-4,5-dihydro-lH-l,2,4-lriazol-l-yl)-2-(4-fluoro-3.5-dimethylphenyl)-4,7,7-trimethyl-4.5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-y])-lH-indol-l -yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(4-(4-fluoro-l-methyl-lH-indazol-5-yl)-5-oxo-4.5-dihydro-lH-l,2,4-triazol-l-yl)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-4.,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2.4-oxadiazol-5(4H)-one;(S)-3-(l-(2-(3-(4-(4-fluoro-l -methyl-lH-indazol-5-yl)-5-oxo-4,5-dihydro-lH-l,2,4-triazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)cyclopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3'-(4-(4-fluoro-l-methyl-lH-indazol-5-yl)-5-oxo-4,5-dihydro-lH-l,2,4-triazol-l-yl)-2'-(4-fluoro-3,5-dimetbylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran -4-yl)- lH-indol-l-yl)-2-methylcyclopropyl)-l, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(4-(4-fluoro-l-methyl-lH-indazol-5-yl)-5-oxo-4,5-dihydro-lH-l,2,4-triazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4.5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyi)-lH-indol-1 -yl)-2-methylcyclopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3'-(4-(4-fluoro-l-methy{-lH-indazol-5-yl)-5-oxo-4,5-dihydro-lH-l,2,4-triazol-l-yl)-2'-(4-fluoro-3 -dimethylphenyl)-4'-methyl-2',4',5'.6'-tetrahydrospiro[cyclopropane-L7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-1.2,4-oxadiazol-5(4H)-one:N-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4?5,6,7-tetrahydro-2H-pyrazolo[4,3-c|pyndin-3-yl)acetamide;2-((4'S)-5'-(5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-l-((lS,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-lH-indo1e-2-carbonyl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5'.6’-tetrahydrospiro[cyclobutane-l,7'-pyrazolo[4,3-c]pyridin | -3'-yl)-N-(4-fluoro-l -methyl- lH-indazol-5-yl)acetamide;N-(4-fluoro-l -methyl-lH-indazol-5-yl)-2-((S)-2'-(4-fluoro-3,5-dimethy]phenyl)-4'-methyI-5’-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyraii-4-yl)-lH-indole-2-carbonyl)-2',4',5',6'-tetrahydrospiro[cyclobutane-l,7'-pyrazolo[4,3-c]pyridin|-3'-yl)acetanude;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2 -methyl- 1 -(5-oxo- 4.5-dihydro-1.2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(isochroman-7-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyI)-4;5,6,7-tetraliydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(4-(3-methyl-2-oxoimidazolidin- 1 -yl )phenyl)acetamide:2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-l,2?4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-y1)-N-(l -methyl -1H-benzo[d]imidazol-6-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l -(5-oxo- 4.5-dihydro-l,2.4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yI)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-( I -methyl-1 H-benzo[d][l,2,3]triazol-5-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((] S,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-l,2T4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-mdole-2-carbonyI)-4.5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(l-isopropyl-lH-indazol-5-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methy]-l -(5-oxo- 4.5-dihydro-1.2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyI)-45,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-y3)-N-(4-morpholinophenyl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-mdole-2-carbonyl)-4,5,6,7-tetra}iydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(2-methyl-2H-indazol-5-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-melhyl-5-(l-((iS,2S)-2-melhyl-l-(5-oxo- 4.5-dihydro-1.2.4-oxadiazol-3-yl)cyclopropyl)-5-(tetraliydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyri din-3-yl)-N-(2-methylpyndin-4-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-1.2.4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-y])-lH-indole-2-carbonyl)-4,5,6,7-letrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-((lr,4S)-4-hydroxycyclohexyl)acetamide;N-((lr,4S)-4-cyclopropoxycyclohexyl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-mdole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c|pyndin-3-yl)acetamide;N-(4,4-difluorocyclohexyl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yi)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[43-c]pyridin-3-yljacetamide2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methy]-5-(l -((1 S,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-l,2,4-oxadiazol-3-yl)cyc1opropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(4-(2-methoxyethoxy)cyclohexyl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylpheny])-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-1.2,4-oxadiazol-3-yI)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyD-4.5.6.7-teirahydro-2H-pyra olo[4,3-c]pyridin-3-yJ)-N-(trans-4-methoxycyclohexyl)acetamide:2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-l,2.4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridm-3-yl)-N-( I -methyl- lH-indazol-5-yl)acetamide;2-((4S)-5-(5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-l-((l S,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-lH-indole-2-carbonyl)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyI-4,5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(4-fluoro-l-methyl-lH-indazol-5-yl)acetamide;N-cyclohexyI-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyI-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetaniide;N-(dibenzo[bd?]furan-2-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-(( 1 S,2S)-2-methyJ-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indoIe-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazoIo[4.3-c]pyri din-3-yl)acetamideN-(4-(diethylphosphoryl)-3-(methylamino)phenyl)-2-((S)-2-(4-fluoro-3?5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4?5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4.5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetaniide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-L2.4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-mdole-2-carbonyl)-4:5,6,7-tetrahydro-2H-pyrazolo[4.3-c|pyridin-3-yl)-N-((R)-4,5.6;7-tetrahydropyrazolo[l,5-a]pyridin-5-yl)acetamide or 2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((l S,2S)-2-methyl-l -(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropy])-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4.5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-((S)-4,5,6,7-tetrahydropyrazolo| l,5-a]pyridin-5-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((l S,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-((R)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyridin-5-yl)acetamide;2-((S)-2-(4-fluoro-3.5-dimethylpheny])-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-1.2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyD-4.5,6,7-teirahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-((S)-4,5,6>.7-tetrahydropyrazolo[l,5-a]pyridin-5-yl)acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo- 4.5-dihydro-l,2.4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyi)-4,5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-(4-(4-methyl-lH-imidazol-I -yl)phenyl)acetamide;3-((lS,2S)-l-(2-((S)-3-(5-(4-fluoro-l-methyl-lH-indazol-5-yl)-lH-l,2,4-triazol-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yr)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(5-(4-fluoro-l-methyl-lH-indazol-5-yl)-lH-l,2.4-triazol-3-yl)-2-(4-fluoro-3,5-dimethylphenyI)-4-methyl-4.5,6,7-lelrahydro-2H-pyrazolo[4,3-c]pyndme-5-carbonyl)-lH-mdol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;(S)-3-(l-(2-(3-(5-(4-fluoro-l-methyJ-lH-indazol-5-yl)-lH-l,2,4-triazol-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)cyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((l S,2S)-l-(2-((S)-3'-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-lH-pyrazol-l -yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3'-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-lH-pyrazol-l-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetraliydrospiro|cyclopropane-l,7'-pyrazolo|4,3-c]pyridine]-5'-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-lH-pyrazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5.6,7-tetrahydro-2H-pyrazolo|4,3-c]pyridme-5-carbonyl)-5-(tetrahy dro-2H-pyran-4-y 1 )- 1 H-indol- 1 -yl)-2-methylcy clopropyl)- 1,2,4-oxadiazol-5(4H)-one;(S)-3-(l-(2-(3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-lH-pyrazol-l-yl)-2-(4-fkioro- 3.5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-y1)cyclopropyl)-l,2,4-oxadiazol-5(4H)-one;2.2-difluoro-2-(4-fluoro-l -methyl- lH-indazol-5-yl)-N-((S)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5.6,7-tetrahydro-2H-pyrazolo|4,3-c|pyridin-3-yl)acetamide:2.2-difluoro-2-(4-fluoro-l -methyl- lH-indazol-3-yl)-N-((S)-2-(4-fluoro-3.5-dimethylphenyI)-4-methyl-5-(l-((lS.2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetamide;N-((S)-5-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-l-((lS,2S)-2-methyl-l-(5-oxo-4?5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-lH-mdole-2-carbonyl)-2-(4-fluoro-3,5-dimethylphenyI)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyri din-3-yl)-2,2-difluoro-2-(4-fluoro-l-methyl-l H-indazol-5-yI)acetamide;(S)-2-(4-fluoro-l-methyl-IH-indazol-5-yl)-N-(2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-5-(l-(l-(5-oxo-4,5-dihydro-l,2,4-oxadiazoi-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4?3-c]pyridin-3-yl)acetamide;2-(4-fluoro-l -methyl- lH-indazol-5-yl)-N-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyI-5-(l-((l S,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-N-methylacetamide;3-((lS,2S)-l-(2-((S)-3-((lS,5R)-4-(4-fluoro-l-methyl-lH-indazol-5-yi)-3-oxo-2,4-diazabicycIo[3.1.0]hexan-2-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-! H-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-I-(2-((S)-3-((lR,5S)-4-(4-fluoro-l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1,0]hexan-2-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyndine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-3-((l S, 5R)-4-(4-fluoro-l -methyl- lH-indazo1-5-yl)-3-oxo-2, 4-diazabicyclo[3.1.0]hexan-2-yl)-2-(4-fluoro-3,5-dimethy1phenyl)-4,7,7-trimethy1-4,5.6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yi)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-((lR,5S)-4-(4-fluoro-l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-IH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3'-((lS,5R)-4-(4-fluoro-l-methyl-lH-indazol-5-yl)-3-oxo-2.4-diazabicyclo[3.1.0]hexan-2-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,254-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3'-((lR,5S)-4-(4-fluoro-l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo| 3.1.0]hexan-2-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetraliydrospiro[cyclopropane-l,7,-pyrazolo[4,3-c]pyridiiie]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yi)-lH-mdol-l-yl)-2-methylcyciopropyi)-l,2,4-oxadiazoI-5(4H)-one:3-((lS,2S)-l-(2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-((lS,5R)-4-(l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyc1o[3.1.0]hexan-2-yI)-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((l S,2S)-l-(2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methy]-3-((l R, S)-4-(l-methyI-rH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3 1.0]hexan-2-yl)-4,5>6,7-tetrahydro-2H-pyi'azolo[4,3-c]pyridine-5-carbonyl)-5-(tetraliydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!, 2, 4-oxadiazol-5(4Il)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-((lS,5R)-4-(l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-! H-indol-l-yl)-2-methylc clopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylpheny!)-4-methyl-3-((lR,5S)-4-(l-methyl-lH-indazol-5-yl)-3-oxo-2.4-diazabicyclo[3.1.0]hexan-2-yl)-4,5,6,7-tetrahydro-2H-pyrazoIo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-((lS,5R)-4-(4-fluoro-l-methyl-! H-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-IH-indol-l -yl)-2-methyIcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyraii-4-yl)-2-((S)-3-((lR,5S)-4-(4-fluoro- 1 -methyl- lH-mdazoI-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0 ]hexan-2-yl)-2-(4-fluoro-3, -dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((l S?2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3'-((l S.5R)-4-(4-fluoro-l-methyl-lH-indazol-5-yr)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2'-(4-fluoro- 3.5-dimethyIphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro|cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(( 1 S.2S)- 1 -(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-y3)-2-((S)-3'-((lR.5S)-4-(4-fluoro-l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2'-(4-fluoro- 3.5-dimethyIphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-lH-indol-l-yl)-2-methyicyclopropyl)-L2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3'-((lS,5R)-4-(4-(diethylphosphoryl)-3-(methylamino)phenyl)-3-oxo-2.4-diazabicyclo[3.1.0]hexan-2-yl)-2'-(4-fluoro-3.5-dimethyIphenyl)-4'-methyl-2',4',5',6'-tetraliydrospiro|cyclopropane-l,7'-pyrazolo|4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-3'-((lR,5S)-4-(4-(diethyiphosphoiyl)-3-(methylamino)phenyl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-1.2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3'-((lR,5S)-4-(4-fluoro-l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5'.6'-tetrahydrospiro[cyclobutane-l,7'-pyrazolo[4,3-c]pyridine|-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methy3cycIopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS?2S) -(2-((S)-3'-((lS,5R)-4-(4-fluoro-l -methyl- lH-indazol-5-yl)-3-oxo-2.4-diazabicyclo[3.1.0]hexan-2-yl)-2'-(4-fluoro-3.5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclobutane-l;7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yI)-lH-indol-l-yl)-2-methylcycIopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(5-((S)-2,2-dimethyltetraliydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-((lS,5R)-4-(l-methyl-lH-indazol-5-yl)-3-oxo-2,4-diazabicyclo[3.1.0]hexan-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-IH-indol-l -yl)-2-methyIcyclopropyl)-l,2,4-oxadiazoI-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-((lR,5S)-4-(l -methyl- lH-indazol-5-yl)-3-oxo-2, 4-diazabicycio[3.1.0]hexan-2-y])-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-3-(l-(4-fluoro-l-methyi-lH-indazol-5-yl)-2-oxo-l,2,5,6-tetraliydropyridin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetraliydro-2H-pyrazolo|4,3-c|pyridine-5-carbonyl)-5-(tetraliydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)- -(3-(4-fiuoro-l-methyl-lH-indazo]-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(2-(6-fluoro-3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyi)-4-methyl- 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(3-(4-fluoro-I-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-inndazol-l-yl)-4"methyl-2-(2-oxo-2-(4-azaspiro[2.6]nonan-4"yi)ethyl)-4,5?6,7-tetrahydro-2H-pyrazolo|4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-mdol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(2-(4-azadispiro[2.1.25.33]decan-4-yl)-2-oxoethyl)-3-(3-(4-fluoro- 1 -methyl- 1 H-indazol-5 -yl)-2-oxo-2, 3 -dihydro- 1 H-imidazol- 1 -y l)-4-methyl-4.5.6.7 -tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(2-((lR,5S)-8-azabicyclo[3.

2. l]octan-8-yl)-2-oxoethyl)-3-(3-(4-fIuoro-l-methyl-lH-indazol-5-y])-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-2-(2-((lR,4R)-7-azabicyclo[2.2.1]heptan-7-yl)-2-oxoethyI)-3-(3-(4-fluoro-l-niethyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyI- 4.5.6.7-tetraliydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-I-(2-((S)-2-(2-((2S;5R)-2,5-dimethylpyrrolidin-l-yl)-2-oxoethyl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yI)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyndine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one:3-((lS,2S)-l-(2-((S)-2-(2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl)-3-(3-(4-fhroro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazoI-l-yl)-4-methyl-4,5,6,7-tetraliydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yr)-lH-indol-l-yl)-2-methylcycIopropyl)-l,2,4-oxadiazol-5(4H)-one;N-benzy]-N-(cyclopropylmethyl)-2-((S)-3-(3-(4-fluoro-l-methyl-lH-in azol-5-yJ)-2-oxo-2, 3-dihydro-lH-imidazol-l-yl)-4-methyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-1.2.4-oxadiazol-3-yl)cy clopropyl )-5-(tetrahydro-2H-pyran-4-yl)-IH-indole-2-carbonyl)-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)acetamide;3-((lS,2S)-l-(2-((S)-2-(2-(4,4-difluoropiperidin-l-yl)-2-oxoethyl)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-4-methyl-4,5,6,7-letrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyI)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l -yl)-2-methylcy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(3-(4-fluoro-l-methyI-lH-indazol-5-yl)-2-oxo-2,3-dihydro- lH-imidazol-l-yl)-4-methyl-2-(2-oxo-2-(4-azaspiro[2.5]octan-4-yl)ethyl)-4,5,6,7-tetraliydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one;2-((S)-3-(3-(4-fluoro- 1 -methyl- lH-indazol-5-yl )-2-oxo-2,3-dihydro-! H-imidazol-l-yl)-4-methyl-5-(l-((l S,2S)-2-methyl-l -(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-mdole-2-carbonyl)-4,5,6,7-letrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)-N-(3-(trifluoromethyl)oxetan-3-yl)acetamide:N-(bicyclo[2,2.2]octan-l -yl)-2-((S)-3-(3-(4-fluoro-l -methyl- lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-iniidazoi-l-yl)-4-niethyl-5-(l-((lS.2S)-2-methyl-l-(5-oxo-4,5-dihydro- 1.2.4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)acetamide;3-((lS,2S)-l-(2-((S)-3'-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxoimidazolidin-l-yl)-2'-(5-fluoro-4,6-dimethylpyrimidin-2-yl)-4'-methyl-2,,4',5'.6'-tetrahydrospiro[cyclopropane-l,7'-pyrazoIo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS?2S)- 1 -(2-((S)-3'-(3-(4-fluoro- 1 -methyl- lH-indazol-5-yl)-2-oxoimidazolidiii-l-yl)-r-(5-tluoro-4,6-dimethylpyrimidin-2-yl)-4'-methyl-r,4',5'.6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridine]-5'-carbonyl)-5-(tetrahydro-2H-pyran -4-yl)- lH-indol-l-yl)-2-methy ley clopropyl)-!, 2, 4-oxadiazoi-5(4H)-one,(S)-3-(l-(5-(3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-inndazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-3-(isochroma -6-yl)-iH-pyraz.ol-l-yl)cy clopropyl)- 1.2.4-oxadiazol-5(4H)-one;3-(l-(5-((S)-2.2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4, 5, 6, 7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)phenyl)cy clopropyl)- 1.2.4-oxadiazol-5(4H)-one;3-(l-(5-((R)-2.2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4, 5, 6, 7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)phenyl)cy clopropyl)- 1.2.4-oxadiazol-5(4H)-one;(S)-3-(l-(5-(3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-3-((tetrahydro-2H-pyran-4-yl)ethynyl)-lH-pyrazol-l-yl )cy clopropyl)- 1,2.4-oxadiazol-5(4H)-one;(S)-3-(l-(5-(3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-3-(4-(l -methoxy cyclobutyl)phenyl)-lH-pyrazol-l-yl)cy clopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-(l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-mdazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3.5-dimethylphenyl)-4-methyl-4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridme-5-carbonyl)-5-((3aR,6aR)-hexahydro-lH-cyclopenta[c]furan-5-yl)phenyl)cyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((3aS,6aS)-hexahydro-lH-cyclopenta[c]furan-5-yl)phenyl)cy clopropyl)- l,2,4-oxadiazol-5(4H)-one;(S)-3-(l-(2-(3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-5-(2-oxaspiro[3.5]nonan-7-yl)phenyl)cy clopropyl)- 1.2.4-oxadiazol-5(4H)-one;3-(l -(2-((S)-3-(3-(4-fluoro-l -methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyndine-5-carbonyl)-5-((3aR.6aR)-hexahydro-lH-cyclopenta[c]furan-5-yl)-lH-indol-l-yl)cy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one:3-(l-(2-((S)-3-(3-(4-fluoro-l-rnethyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-JH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((3aS,6aS)-hexahydro-lH-cyclopenta[c]furan-5-yl)-! H-indol-l-yl)cyclopropyl)-1,2,4-oxadiazol-5(4H)-one;3-(l -(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yi)-2-(4-fluoro-3,5-dimethylphenyl)-4-niethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-((R)-2,5-dioxaspiro[3.5]nonan-7-yl)-lH-indol-l-yl)cyc!opropyl)-l,2,4-oxadiazol-5(4H)-one;3-(l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazo]o[4,3-c]pyridine-5-carbonyl)-5-((S)-2.5-dioxaspiro[3.5]nonan-7-yl)-lH-indol-l-yl)cyclopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-(l-(2-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydio-2II-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(2-hydroxybicyclo[3.2.1]octan-6-yl)-lH-indol-l-yl)cycIopropyl)-L2,4-oxadiazol-5(4H)-one;(S)-3-(l-(2-(3-(3-(4-fluoro-l -methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyndine-5-carbonyl)-5-(4-methoxycyclohexyl)-lH-indol-l-yl)cyclopropyl)-l,2,4-oxadiazol-5(4H)-one:N-(4-fluoro-l -methyl-lH-indazol-5-yl)-2-((S)-2'-(4-f]uoro-3,5-dimethylphenyl)-4'-methyI-5'-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetraliydro-2H-pyraii-4-yl)-lH-indole-2-carbonyl)-2',4',5',6'-tetraliydrospiro[cyclopropaiie-l,7'-pyrazolo[4,3-c]pyridin|-3'-yl)acetanude;2-((S)-5'-(5-((S)-2,2-dimethy]tetrahydro-2H-pyran-4-y])-l-((lS,2S)-2-methyl-l -(5-oxo-4, 5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-lH-indole-2-carbonyl)-2'-(4-fluoro-3,5-dimethylphenyl)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridin|-3'-yl)-N-(4-fluoro-l-methyl-lH-indazol-5-yl)acetamide,2-((S)-5'-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-lH-indole-2-carbonyl)-2'-(4-fluoro-3,5-dimethylphenyi)-4'-methyl-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazolo[4,3-c]pyridin]-3'-yl)-N-(l-methyl-lH-indazol-5-yl)acetamide,2-((S)-2'-(4-fluoro-3,5-dimethylphenyI)-4'-methyl-5'-(l-((lS,2S)-2-methyl-l -(5-oxo-4.5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-2',4',5',6'-tetrahydrospiro[cyclopropane-l,7'-pyrazo]o[4,3-c]pyri din]-3'-yl)-N-(l-methy 1- 1 H-indazol -5-yl )acetamide;2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-tnmethyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyri in-3-yI)-N-(l -methyl- IH-indazoI-5-yl)acetamide;N-(4-fluoro-l -methyl-! H-indazol-5-yl)-2-((S)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-5-(l-((lS,2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5.6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetamide;2.2-difluoro-N-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-((S)-2-(4-fluoro-3.5-dimethylphenyI)-4-methyl-5-(l-((lS.2S)-2-methyl-l-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl)cyclopropyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indole-2-carbonyl)-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)acetamide;3-((lS,2S)-l-(2-((S)-3-(l-(4-fluoro-l-methyl-lH-indazol-5-yl)-5-oxo-l,5-dihydro-4H-l,2,4-tnazol-4-yl)-2-(4-fluoro-3,5-dimethy]phenyl)-4-methyl-4.5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-((S)-l-(4-fluoro-l -methyl- lH-indazol-5-yl)-2-oxopiperidin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-y1)-2-methylcyclopropyl)- 1.2.4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-((R)-l-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxopipendin-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4- ethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methyl cyclopropyl)- 1.2.4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-((lS,6S)-3-(4-fluoro-l-methyl-lH-mdazol-5-yl)-2-oxo-3-azabicydo[4.1.0]heptan-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2.4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-((lR,6R)-3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-letrahydro-2H-pyrazolo[43-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-!?2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-((lR,6R)-3-(4-fluoro-1 -methyl-lH-indazol-5-yI)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5.6.7-tetraliydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2 -methylcyclopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-((l S,6S)-3-(4-fluoro-l-methyl-lH-indazol-5-yI)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl)-2-(4-fiuoro-3,5-dimethylphenyi)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazoIo[4,3-c]pyridine-5-carbonyi)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-((lR,6R)-3-(4-fluoro-1 -methyl- lH-indazol-5-yI)-2-oxo-3-azabicy clo[4.1.0]heptan-l-yl)-2-(4-fluoro-3, 5-dimethylphenyl)-4-methyl-4.5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-((lS,6S)-3-(4-fluoro-1 -methyl-lH-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-((lR,6R)-3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-trimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyndine-5-carbonyi)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyciopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-((l S,6S)-3-(4-fluoro-l-metbyl-lH-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,7,7-tnmethyl-4,5,6,7-tetraliydro-2H-pyrazolo[4.3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yi)-lH-indol-l-yl)-2-methy]cyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-((lR,6R)-3-(4-fluoro-l-methyl-lH-indazol-5-y])-2-oxo-3-azabicyclo[4.1 0]heptan-l-yl)-2-(4-fluoro-3.5-dimethylphenyl)-4,7,7-trimethyl-4,5,6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one,3-((lS?2S)-l-(2-((S)-3-((lS,6S)-3-(4-fluoro-l -methyl- IH-mdazol-5-yi)-2-oxo-3-azabicyclo[4.1 0|heptan-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4.7,7-tnmethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((lS.2S)-l-(2-((S)-3-(5-(4-fluoro-l-methyl-lH-indazol-5-yl)-lH-pyrazol-3-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5.6,7-tetrahydro-2H-pyrazolo|4,3-c]pyridme-5-carbonyl)-5-(tetrahy dro-2H-pyran-4-y 1 )- 1 H-indol- 1 -yl)-2-methylcy clopropyl)- 1,2,4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((Z)-((S)-3-(3-(4-fluoro-l-methyl-lH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yI)-2-(4-fluoro-3,5-dimethylphenyI)-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)(methylimino)methyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-((l S,2S)- l-(2-((Z)-(ethylimino)((S)-3-(3-(4-fluoro- 1 -methyl-IH-indazol-5-yl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-2,4,6.7-tetrahydro-5H-pyrazolo|4,3-c]pyridm-5-yl)methyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-mdol-l-yl)-2-methylcyclopropyl)-l,2,4-oxadiazol-5(4H)-one;3-(( 1 S.2S)- 1 -(2-((Z)-((cy clopropylmelhy l)imino)((S)-3-(3-(4-fluoro- 1 -methyl- 1H-indazol-5-yl)-2-oxo-2.3-dihydro-lH-imidazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)methyl)-5-(tetrahydro-2H-pyran-4-y l)-lH-indoi-l-yl)-2-methylc clopropyl)-!, 2, 4-oxadiazol-5(4H)-one;3-((lS,2S)-l-(2-((S)-3-(4-(4-fluoro-l-methyl-lH-indazol-5-yl)-IH-pyrazol-l-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2H-pyran-4-yl)-lH-indol-l-yl)-2-methy icy clopropyl)- 1,2,4-oxadiazol-5(4H)-one;(2S,4S)-2,5,12-lrihydroxy-7-methoxy-4-(((lS,3R,4aS,9S,9aR,10aS)-9-methoxy-l-methyloctahydro-lH-pyrano[4',3':4,5]oxazolo[2,3-c]| l,4]oxazin-3-yl)oxy)-6.11-dioxo-N-(pyrrolidin-3-yl)-l,2,3,4,6,l l-hexahydrotetracene-2-carboxamide:3-((lS,2S)-l-(2-((S)-3-(l-(4-fluoro-l-methyl-lH-indazol-5-yl)-lH-pyrazol-4-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyndine-5-carbonyl)-5-(tetrahydro-2H-py ran -4-yl)-lH-indol- l-yl)-2-methy Icy clopropyl)- 1,2,4-oxadiazol-5(4H)-one; and3-((lS,2S)-l-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-l-methyl-lH-mdazol-5-yl)-2-oxopyridin-l(2H)-yi)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl- 4.5.6.7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-lH-indol-l-yl)-2-methylcy clopropyl)-!, 2, 4-oxadiazol-5(4H)-one,or a pharmaceutically acceptable salt thereof.Ill, A compound selected from;3-[(lS.2S)-l-[5-[(4S -2,2-dimethyltetrahydropyraii-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[3-(3-methylbenzimidazol-l-ium-5-yl)-2-oxo-imidazol-l-yl]- 4.6.7.8-tetrahydropyrazo1o[4,3-c]azepine-5-carbonyl]indo1-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[3-(l-methylbenz.otriazol-5-yl)-2-oxo-imidazol-l-yl]-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-l -ium-5-carbonyl]indol- l-yl]-2-methyl -cyclopropyl] -4H- 1.2.4-oxadiazol-5-one;3-[(lS.2S)-l-[2-[(4S)-3-[3-(2,3-dimethylimidazo[1.2-a]pyridin-l -ium-6-yl)-2-oxo-imidazol-l-yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4.6,7.8-tetrahydropyrazolo[4.3-c]azepine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[2-[(4S)-3-[3-[2-(difiuoromethyl)indazol-5-yl]-2-oxo-imidazol-l -yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-1-ium-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cyclopropyl] -4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[3-(2,3-dimethylpyridin-l-ium-4-yl)-2-oxo-imidazol-l-yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4.6,7,8-tetrahydropyrazolo[4.3-c]azepine-5-carbonyl]-5-[(4S)-2.2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-c clopropy]]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimelhylteirahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[3-(l-methylisoquinolin-2-ium-6-yl)-2-oxo-imidazoi-l-yl|- 4.6.7.8-tetrahydropyrazo]o[4,3-c]azepine-5-carbonyl]indo]-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-mdazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c] azepin- l-ium-7 '-cyclopropane]-5-carbonyl]indol-l-yl]-2-methyl-cyciopropyl]-4H-l,2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-|(4S)-2,2-dimethyItetrahydropyran-4-yl]-2-|(4S)-2-(5-fluoro-4,6-dimethyl-pyridin-l-ium-2-yl)-3-|3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l -yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-4-methyI-3-[2-oxo-3-[2-(2,2,2-trifiuoroethyl)indazol-5-yl]imidazol-l -yl]- 4.6.7.8-tetrahydropyrazolo[4,3-c]azepin-l-ium-5-carbonyl]indol-I-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[3-(l-methylindazol-5-y])-2-oxo-imid zoI-l -yl]-4,6,7,8-tetrahydropyrazolo[4.3-c]azepin-l-ium-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol -5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethy]tetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-diniethyl-phenyI)-4-methyl-3-[2-oxo-3-[l-(trideuteriomethyl)indazol-5-yl]imidazol-l-yl]-4.6.7.8-tetrahydropyrazoJo[4,3-c]azepin-l-ium-5-carbonyl]indoI-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[3-(l-cyclopropylindazol-5-yl)-2-oxo-iniidazol-l-yl|-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c] azepin-l-ium-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cyclopropy]]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|3-(4-fluoro-l-methyl-indazoI-5-yl)-2-oxo-imidazol-l -yl|-4,7,7-tnmethyl-6,8-dihydro-4H-pyrazolo[4,3-c]azepine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one:3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-4-methyl-3-[2-oxo-3-[l-(2,2,2-trifluoroethyl)indazol-5-yl]imidazol-l -yl]- 4.6.7.8-lelrahydropyrazolo[4.3-c]azepiii-l-iuni-5-carbonyl]indol-l-yl]-2-melhyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one:3-[(l S,2S)-l-[5-(2,2-dimethylmorpholin-4-ium-4-yl)-2-[(4S)-4-ethyl-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-mdazol-5-yI)-2-oxo-imidazol-l-yl]-4.6,7,8-tetraliydropyrazolo[4,3-c]azepine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl|-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimelhy]tetrahydropyran-4-yl]-2-[(4S)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-2-[5-(trifliioromethyl)-3-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,4'-tetrahydropyran]-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;calcium 3-[(lS,2S)-l-[5-[(4S)-2,2-dimetliyltetraliydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[l-(2-methyl-6-quinolyl)-2-oxo-3-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-l-oxa-2-aza-4-az.anidacyclopent-2-eii-5-one;3-[( 1 S,2S)-1 -[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[ 1 -(2-methyl-6-quinolyl)-2-oxo-3-pyridylj-6,7-dihydro-4H-pyrazo]o[4,3-c]pyridine-5-carbonyl]-5-[(2S)-2-methylmorpholin-4-yl]jndol-l-y]]-2-methyl-cyclopropy]]-4H-l,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-3-[l-(2-methyl-6-quinolyl)-6-oxo-pyrimidin-5-yl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl|indol-l-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-diniethyl-phenyr)-3-[l-(4-fluoro-l-methyl-indazol-5-yl)-6-oxo-pyrimidin-5-yl]-4-methyl-4, 6.7, 8-tetrahydropyraz.olo|4,3-c| azepin- l-ium-5-carbonyl]indoI-l-yl]-2-methyl-cyclopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyi-3-| l-(l-methylisoqumolm-2-ium-6-yl)-2-oxo-3-pyridyl|-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]indol-l-yl|-2-rnethyl-cyclopropyl|-4H-l,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-3-[1-[2-(cyclopropoxy)pyridin-1-ium-4-yl]-2-oxo-3-pyridyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4.6.7.8-tetrahydropyrazolo[4.3-c]azepine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methy]-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l-(4-fluoro-l-methyl-mdazol-5-yl)-2-oxo-3-pyridyl]-4-methyl-4.6,7,8-tetrahydropyrazolo[4,3-c]azepin-l -ium-5-carbony l]indol-l -yl]-2-methyl -cyclopropyl] -4H- 1.2.4-oxadiazol-5-one;3-[ (lS,2S)-l-[2-| (4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3- 1 l-(4-fluoro-l -methyl-indazol-2-ium-5-y!)-2-oxo-3-pyridyl] -4-methyl-spiro[4,6-dihydropyrazolo|4,3-c]pyridine-7,r-cyclobutane]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-l-yl]-2-methyl-cyclopropyl]-4H-1.2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-3-[l-(5-fluoro-2-methyl-6-quinolyI)-2-oxo-3-pyridyl]-4-melhyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridiiie-5-carbonyl]mdol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l-(4-fluoro-l-methyl-indazol-5-yI)-2-oxo-3-pyridyl]-4-methyl-r-(2,2,2-trifluoroethyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-l-ium]-5-carbonyl]indol-l-yl]-2-methyl-cyclopropylj-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethy]tetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l-(5-fluoro-l-niethyl-isoquinoliii-2-ium-6-yl)-2-oxo-3-pyridyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimetliyl-phenyl)-3-[l-(4-fluoro-l-methyl-indazol-2-iuni-5-yl)-2-oxo-3-pyridyl]-4-methyl-spiro[4,6-dihydropyrazolo[4.3-c]pyridme-7 / l'-cyclobutane]-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;N-(l -cyclopropyl-4-fluoro-indazol-5- l)-2-[(4S)-5-[5-[(4S)-2,2-dimethyitetrahydropyian-4- l]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihy dro-4H-pyrazolo[4, 3-c] azepin- l-ium-7,l'-cyclopropane]-3-yI] acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c]azepin-l-ium-7,r-cyclopropane]-3-yl]-N-(l-methyIindazol-5-yl)acetamide:2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6.8-dihydro-4H-pyrazolo[4, 3-c] azepin- l-ium-7,r-cyclopropane] -3-yl] -N-(6-fluoro-l-methyl-indazol-5-yl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c]azepin-l-ium-7,r-cyclopropane]-3-yl] -N-(4-fluoro-l-methyl-indazol-5-yl)acetamide;N-(l-methylindazol-5-yl)-2-[(4S)-4,7,7-trimethyl-5-[l-[(lS,2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazoI-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-2-| 1-methyI-5-(trifluoimnethyl)pyrazol-3-yl]-4,6-dihydropyraz.o!o|4,3-c]pyridin-I-ium-3-yl] acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4,7,7-trimethyl-2-[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]-4,6-dihydropyrazolo[4,3-c]pyridin-1-ium-3-yl]-N-(1-methylindazol-5-yl)acetamide;2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-[(IS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(2-methylquino]in-l-ium-6-yl)acetamide;2-[(4S)-2-(4-fluoro-3,5-diniethyl-phenyD-4,7,7-trimethyl-5-[5-[(2S)-2-methylmorpholin-4-yl]-l-[(l S,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-N-(2-methylquinolin- 1 -iurn-6-y I (acetamide;2-[(4S)-2-(4-fluoro-3.5-dimethyl-phenyl)-4.7.7-trimethyl-5-[5-[(2S)-2-methylmorpholin-4-ium-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-N-(l-methylindazol-5-yl)acetarnide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyi-l-(5-oxo-4H-l,2,4-oxadiazoi-3”yl)cyclopropyl]mdoie-2"Carbonyi]-2-(4”fluoro-3,5"dimethyI-phenyl)- 4.7.7-trimethyI-4,6-dihydropyrazolo|4,3-c]pyridin-l-ium-3-yl]-N-(4-fluoro-l -methyl-indazol-5-yl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimelhyheirahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazoI-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)- 4,7,7-trimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-N-(2-methylquinolin-1-ium-6-yl)acetamide;2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-|(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l -ium-3-yl]-N-(4-methoxy-l-bicyclo[2.2.2]octanyl)acetamide:2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4.7.7-trimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(l-methylmdazol-5-yl)acetamide;2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[5-[(2S)-2-methylmorpholin-4-ium-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-1-methyl-indazol-5-yl)acetamide;2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[5-[(2R)-2-methylmorpholin-4-ium-4-yl]-l-[(l S,2S)-2-methy1-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indo1e-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)acetamide;N-[4-(cyclopropoxy)cyclohexyl]-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyI]-2-(4-fluoro-3.5-dimethyl-phenyl)-4,7.7-trimethyl-4,6-dihydropyrazolo[4.3-c]pyridin-l-ium- 3-yl]acetamide;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[4-(4-fluoro-l-methyl-indazol-5-yI)-3-oxo-2,4-diazabicyclo[3. l,0]hexan-2-yl]-4-methyl-4,6,7.8-tetrahydropyrazolo[4,3-c]azepin-l -ium-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-1.2,4-oxadiazol-5-one;3-[l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo- midazol-l-yl]-4-methyl-6,7-dihydro-4II-pyrazolo[4,3-c]pyridine-5-carbon r|-5-[(lS,5R)-6-hydroxy-2-bicyclo[3.2.1]octanyi]indol-l-yl]cyclopropyl]-4H-1.2.4-oxadiazol-5-one;3-[l -[2-[(4S)-2-(4-fluoro-3.5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyri dine-5-carbonyl]-5-[(lS,5R)-6-hydroxy-2-bicyclo[3.2.1]octanyl]indol-l-yl]cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(4-f1uoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]-5-(4-oxa-7-azoniaspiro|2.5]octan-7-yl)indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4.,3-c]azepine-5-carbonyr|-5-[(2S)-2-methylmorpholin-4-ium-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(1S,2S)-1-[5-(2,2-dimethylmorpholin-4-ium-4-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one,3-[l-[3-(4,4-difluoroisochroman-6-yl)-5-[(4S)-2-(4-fluoro-3.5-dimethyI-phenyl)-3-|3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]pyrazoI-l-yl]cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[3-(l,7-dimethylindazo3-2-ium-6-yl)-5-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yr)-2-oxo-iniidazol-l-yl]-4-methyl-6.7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]pyrazol-]-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c|pyridin-3-yr|-2,2-difluoro-N-(4-fluoro-l -methyl-indazol-5-yl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methy 1-4, 6, 7, 8-tetraliydropyrazolo[4,3-c] azepin- l-ium-3-yi]-N-(4-fluoro-l -methyl-indazol-5-yl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-1'-(2,2,2-trifluoroethyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-1-ium]-3-yl]-N-(4-fluoro-1-methyl-indazol-5-yl)acetamide;3-[(lS,2S)-l-[5-[(4S)-2,2-dimelhyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|(lS.6S)-3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-3-azabicyclo[4, 1.0]heptan-l-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,r-cyclopropane]-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[(1R,6R)-3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-1-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,1'-cyclopropane]-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l -yl]-4-methyl-4,6,7.8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyI]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one:3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-1-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-4-methyl-5-[l -[(IS, 2S)-2 -methyl- 1 -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(l-methylindazol-5-yl)cyclopropanecarboxamide;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[l-(l -methylmdazol-5-yl)-2-oxo-pyrrolidin-3-yl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5- 59^carbonyl]-5-tetrahydropyran-4-yl-indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3.5-dimethyl-phenyI)-4-methyl-3-[(lS,6S)-3-(2-methyl-6-quinolyl)-2-oxo-3-az.abicyclo[4.1.0]heptan-l-y1]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cydopropyl]-4H-l,2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[(lS,6S)-3-(l-methyl-6-isoquinolyl)-2-oxo-3-azabicydo[4.1.0]heptan-l-yl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl|-2”methyl-cyclopropyl]-4H-1.2,4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-3-[(1S,6S)-3-[2-(cyclopropoxy)-4-pyridyl]-2-oxo-3-azabicyclo[4.1.0]heptan-1-yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-I-[2-[(4S)-3-[l-[4-(cyclopropoxy)cyclohexyI]-6-oxo-pyrimidin-5-yl]-2-(4-fiuoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4.3-c]pyridine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyI-cydopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[1-(4-methoxycyclohexyl)-6-oxo-pyrimidin-5-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-1-ium-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-1'-(2,2-dimethylpropanoyl)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-1'-(2,2-difluoroacetyl)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-r-(2.2-difluoropropanoyl)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-ylJ-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyI-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-mdazol-5-yr)-2-oxo-imidazol-l-yl]-4-methyl-r-(2,2,3,3-tetrafluoropropanoyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]indol-l-yI]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiaz.oI-5-one,3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyJtetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyr)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-r-(2,2,2-trifluoroacetyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyI]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-r-acetyl-2-(4-fluoro-3,5-dimethyi-phenyl)-3-[3-(4-fluoro-l-methyi-mdazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimelhylteirahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxO"imidazoI-l-yl]-4-methyl-r-(2,2,2-trifluoroethyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3,-azetidin-l-ium]-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazo3-l-yl]-4-methyl-r-(2,2,2-trifluoroethyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidme]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-l -yl]-2-methyl-cyclopropyl]-4H-l,2.4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-1'-(2,2-difluoroethyl)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-1-ium]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-y1]-r-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethyl]-4-methyI-spiro[4,6-dihydropyrazolo[4.3-c]pyridine-7,3'-azetidin-I-ium]-5-carbonyl]-5-tetrahydropyran-4-yl-mdol-l-yl]-2-methyl-cyclopropyl]-4H-1.2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-r-benzyl-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyI-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-spiro[4,6-dihydropyrazo1o[4,3-c]pyridine-7,3'-azetidin-l-ium]-5-carbonyl]-5-tetraliydropyran-4-yl-indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethy]tetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-T-(2-hydroxy-2-methyl-propyl)-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-1-ium]-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2 (4S)-r-cyclohexyl-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l - l]-4-methyI-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-l-ium]-5-carbonyl]-5-letrahydropyran-4-yl-indol-l-yl]-2-methyI-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(1S,2S)-1-[2-[(4S)-1'-(cyclopropylmethyl)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-1-ium]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-y1]-4-methyl-r-methylsulfonyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-l-yl]-2-methyl-cyclopropyl|-4H-1.2.4-oxadiazol-5-one;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4-methyl-2-[5-(trifIuoromethyl)-3-pyridyl]-6,7-dihydro-4H-pyrazolo[4?3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)acetamide;2-[(4S)-2-(3-cyclopropyl-4-fluoro-phenyl)-5-[7-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-3-[1-(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]indolizine-2-carbonyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-1-methyl-indazol-5-yl)acetamide;3-[l-|2-[(4S)-2-(3-cyclopropyl-4-fluoro-phenyl)-4-inethyl-3-[l-(l-methyIindazol-5-yl)-2-oxo-3-pyridyl]-6.7-dihydro-4H-pyrazolo[4.3-c]pyridine-5-carbonyl]-7-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indolizin-3-yl]cyclopropyl]-4H-l;2;4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-4-methyl-3-[5-(3-methylimidazo[l,5-a]pyridin-7-yl)-lH-l,2.4-triazol-4-ium-3-yl]-6,7-dihydro-4H-pyrazolo[4.3-c]pyridme-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[5-(4-fluoro-l-methyl-indazol-5-yI)-lH-l,2.4-triazol-4-ium-3-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[5-(2,3-dimethylimidazo[l,2-a]pyri din-6-yl)-lH-l,2,4-triazol-4-iiini-3-yI]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyi]-5-[(4S)-2.2-dimethyltetrahydropyran-4-yl]indol-l-yi]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-|(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetraliydropyran-4-yl-indole-2-carbonyl]-6,7-dihydro-4H-pyraz.olo[4.3-c]pyridin-3-yl]-N-(4-fluoro-]-methyI-indazo1-5-yl)cyclopropanecarboxamide:l-[(4S)-5-[5-|(4S)-2,2-dimethyltetraliydropyr n-4-yl]-l-[(l S,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluofo-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(l-methylindazol-5-yl)cyclopropanecarboxamide;N-[2-(cyclopropoxy)pyridin-l-ium-4-yl]-l-[(4S)-5-[5-|(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-Huoro-3,5-dimethyl-phenyr)-4-methyl-6.7-dihydro-4H-pyrazolo|4,3-c]pyridin-3-yl | cyclopropanecarboxamide;N-[4-(cyclopropoxy)cyclobexyl]-l -[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo|4.3-cjpyridin-l-ium-3-yl]cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyr zolo[4,3-c]pyridin-l-ium-3-yl]-N-(2-fluorophenylicyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(2-fluoroph eny l)cy cl opropanecarboxamide;1-[(4S)-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-5-[5-[(2S)-2-methylmorpholin-4-ium-4-yl|-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyI-indazol-5-yl)cyclopropanecarboxamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyi-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(4-fluoro-l -methyl-indazol- 5-yl)propanannde;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyi-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo|4,3-c|pyridin-l-ium-3-yl]-N-(4-fluoro-l-methyl-indazol- 5-yl)propan amide;N-(l-methy1indazol-5-yl)-2-[rac-(4S)-5-[5-(2,2-dimeihy1tetrahydropyran-4-yl)-l-[rac-(lSt2S)-2-metliyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyI-phenyi)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]propanamide;N-(l-methylindazol-5-yl)-2-[rac-(4S)-5-[5-(2.2-dimethyltetrahydropyran-4-yl)-l-[rac-(lS?2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyI|-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazo1o[4,3-c|pyri din-3-yl]propan amide;N-(2-fiuorophenyl)-2-[rac-(4S)-5-[5-(2,2-dimethyltetrahydropyran-4-yl)-l-[rac- (15.25)-2-methyl-l-(5-oxo-4H-l,2?4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl|-2-(4-fluoro-3,5-di ethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazoIo[4,3-c]pyri din-3-yl]propanamide;N-(2-fluorophenyl)-2-|rac-(4S)-5-[5-(2,2-dimethyltetraliydropyran-4-yl)-l-[rac- (15.25)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4:3-c]pyridin-3-yl]propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4.3-c]pyridin-l-ium-3-yl]-N-(4-methoxy-l-bicyclo[2.2.2]octanyl)propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS;2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fIuoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(4-methoxy-l-bicyclo|2.2.2|octanyl)propanannde:N-[4-(cyclopropoxy)cyclohexyI]-2-[rac-(4S)-5-[5-(252-dimethyItetrahydropyran-4-y])-l-[rac-(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yI)cy opropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c] py ridin-3 -y I] propanamide;N-[4-(cyclopropoxy)cyclohexyl]-2-[rac-(4S)-5-[5-(2,2-dimethyltetrahydropyran-4-yl)-l-[rac-(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6.7-dihydro-4H-pyrazolo[4.3-c]pyndin-3-yl]propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-flii0ro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)propanamide;2-[(4S)-5-[5-|(4S)-2,2-dimethyltetraliydropyran-4-yl]-l-[(l S,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)propanamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methy 1-4, 6, 7, 8-tetrahydropyrazolo[4,3-c] azepin- l-ium-3-yl]-N-(4-fluoro-l -methyl-indazol-5-yl)cyclopropanecarboxamide:N-( 1,3-benzothiazol-3-ium-6-yl)-l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo|4,3-c|azepin-3-yl]cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4, 6,7, 8-tetraliydropyrazolo[4,3-c] azepin- 1 -ium-3-yl]-N-(2-methylindazol-5-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-l-ium-3-yl]-N-(l-methylindazol-5-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazoIo[4,3-c]azepin-l-ium-3-yl]-N-[l-(trideuteriomethy])indazol-5-yl]cydopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyi-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-l-ium-3-yl]-N-(6-fluoro-l -methyl-indazol-5-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yS,2S)-2-methyi-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methy 1-4,6, 7, 8-tetrahydropyrazolo[ 4, 3-c] azepin- 1 -ium-3 -yl] -N-(l -ethylindazol-5 -yl)cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl ]-2-(4-fluoro-3, 5-dimethy l-phenyl)-4-methy 1-4,,7,8-tetrahy dropyrazolo[4, 3-c ]azepin- 1 -ium-3 -yl] cyclopropanecarboxamide;N-(l-cyclopropylindazol-5-yl)-l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]- 1-[(lS,2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-l-ium-3-yl]cyclopropan ecarboxamide;l-[(4S)-2-(4-fluoro-3,5-dimethyl-pheiiyl)-4-methyl-5-[l-[(lS,2S)-2-melhyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-4,6,7,8-tetrahydropyrazol o[4, 3-c] azepin- l-ium-3-yl]-N-(4-fluoro-l -methyl-indazo]-5-yl)cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-5-j 1-[(1 S,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiaz.ol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-l -ium-3-yl] cyclopropanecarboxamide;N-[4-(cyclopropoxy)cyclohexyl]-l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]- 2-(4-fluoro-3.5-dimethyl-pheiiyl)-4-methyl-4.6,7,8-tetrahydropyrazolo[4.3-c]azepiii-l-ium- 3-yl]cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indaznl-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-5-[5-[(2S)-2-methylmorpholin-4-ium-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H- 1,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4.6,7,8-tetrahydropyrazolo[4.3-c]azepin-3-yl]cyclopropanecarboxamide;l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[5-[(2S)-2-methylmorpholin-4-ium-4-yl]-l-[(l S,2S)-2-methy1-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indo1e-2-carbonyl]-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4, 6,7, 8-tetrahydropyrazolo[4,3-c]azepin-l-ium-3-yi]-N-[l -(2,2,2-tnfltJoroethy!)indazol-5-yl]cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-mdazol-5-yl)-l-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-5-[5-|(2S)-2-methylmorphoIin-4-ium-4-yl]-l-[(lS,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropy]]mdole-2-carbonyl]spiro[6,8-dihydro-4H-pyrazolo[4,3-c]azepine-7,l'-cyclopropane]-3-yl]cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl ]-l-|(l S,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl]-N-isoquinolin-2-ium-6-yl-cyciopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-niethyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl]-N-(l-methylisoqumolin-2-ium-6-yljcyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl|-N-(5,6,7,8-tetrahydroquinolin-l-ium-6-yl)cyclopropanecarboxamide:l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c] zepin-3-yl]-N-(5,6,7,8-tetrahydroisoquinolin-7-yllcyclopropanecarboxamide;1-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yl]-N-(5,6,7,8-tetraJhydroisoquinolin-7-y l)cy cl opropanecarboxamid e;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)-2-hydroxy-propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyi-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazo1o[4,3-c]pyridin-3-yl]-2-fluoro-N-(4-fluoro-l -methyl-indazol-5-yl)propanamide;2-CT'clopropyl-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yi]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c|pyridin-3-yr|-N-(4-fluoro-l-methyl-indazol-2-ium-5-yl)-2-hydroxy -acetamide;2-cyciopropyl-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyI-indazol-2-ium-5-yl)-2 -hydroxy-acetamide;2-cyclopropyl-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyI-l-(5-oxo-4H-L2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyI)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-2-fluoro-N-(4-fluoro-1 -methyl -indazoI-5-yl)acetamide;2-cyciopropyl-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl- l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl|-2-(4-fluoro-3, 5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyri din-3-yl]-2-fluoro-N-(4-fluoro-l-methyl-indazol-5-yl)acetamide:2-cyclopropyl-2-|(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3?5-dimethyl-phenyl)-4-metbyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-2-fluoro-N-(l-methyl-6-isoquinolyl)acetamide;2-cyclopropyl-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl|-l-[(lS,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-2-fluoro-N-(l-methyl-6-isoquinolyl)acetamide;[l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-2-[(4-fluoro-l-methyl-indazol-2-ium-5-yl)amino] - 1 -methy l-2-oxo-ethyl]-dimethyl-ammomum;[l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridm-3-yl]-2-[(4-fluoro-l-methyI-mdazol-2-ium-5-yl)amino]-l-methyI-2-oxo-ethylj-dimethyl-ammonium;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2.4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)-2-methoxy-propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,24-oxadiazol-3-yl)cycIopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-y])-2-methoxv-propanamide;3-[(lS,2S)-l-[2-[(4S)-2-(l-cyclopropylpyrazol-4-yl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l -yl|-4-methyl-spiro[4,6-dihydropyraz.olo[4,3-c]pyridine-7,r-cyclopropane]-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indoi-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-3-[3-(4-fluoro-l -methyI-indaz.ol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-2-[l-methyl-5-(lrifluoromethyl)pyrazol-3-yI]-6,7-dihydro-4H-pyrazolo[4.3-c]pyridme-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl|-4H-1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-3-[3-(4-fluoro-l-methy I-indazol-5 -yl)-2-oxo-imidazol- 1 -yl] -4-methy l-2-[ 1 -methyl-5 -(trifluoromethyl)pyrazol-3-yl]spiro[4,6-dihydropyrazolo|4,3-c|pyridine-7,r-cyclopropane|- 5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one:3-[(lS,2S)-l-[5-[(4S)-2,2-dimelhy]tetrahydropyran-4-yl]-2-[(4S)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-2-[5-(trifluoromethyl)-3-pyridyl]spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7.r-cyclopropane]-5-carbonyl]indol-l-yl]-2-methyl-cycIopropyl|-4H-1.2.4-oxadiazol-5-one;3-[(lS?2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[5-(2-methyl-4-pyridyl)-lH-I.2,4-tnazol-4-ium-3-yl]-6,7-dihydro-4H-pyrazolo[4,3-c|pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazo1-5-one;3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yi]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|3-(4-fluoro- 1 -methyl-indazol-5-yl)-2-oxo-3-azabicy clo| 3.

1. OJhexan- 1 -y]]-4-methyl-6;7-dihydro-4H-pyrazolo[4,3-c]pyrjdirie-5-carbonyl]indol-l -yl]-2-methyi-cy clopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethy!-phenyl)-3-[3-(4-fluoro-l-methy!-indazol-5-yl)-2-oxo-3-azabicyclo[3.1,0]hexan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyI-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[5-(4-fluoro-l-methyl-indazol-2-ium-5-yl)-6-oxo-pyridazin-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl|-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;1-[(4S)-5-[7-(2,2-dimethyltetrahydropyran-4-yl)-3-[l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indolizine-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methy 1-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyI-indazol-5-yl)cyclopropanecarboxamide;3-[l-[7-(2,2-dimethyltetraliydropyran-4-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-pyrrolidin-3-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indolizin-3-yl] cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[l-[7-(2,2-dimethyltetrahydropyran-4-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-| l-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-pyrrolidin-3-yl|-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indo1izin-3-yl]cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[5-(4-fluoro-l-methyl-mdazoI-5-yl)-6-oxo-pyrimidin-l-yr|-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-5-carbonyl]indol-l -yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethy 1-pheny l)-3-[5-(4-fl uoro-l-methyl-indazol-5-yl)-6-oxo-pyri midin- l-yl]-4-methyl-4,6,7,8-tetraliydropyrazolo[4,3-c]azepme-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fIuoro-3,5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-I-ium-3-yl]-4-(4-fluoro-l-methyl-indazol- 5-yl)-2-methyl-morpholin-3-one;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl]-4-(4-fiuoro-l-methyl-indazol- 5-yl)-2-methyl-rnorpholin-3-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-diniethyl-phenyI)-4-methyl-3-[4-(l-methylindazol-2-ium-5-yl)-5-oxo-l,2,4-triazol-l-yl]-4,6,7,8-tetrahydropyrazoJo[4,3-c]azepine-5-carbonyl]indoJ-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(3-cyclopropyl-4-fluoro-phenyl)-3-[4-(4-fluoro-l-methyl-indazol-2-iiim-5-yl)-5-oxo-l,2,4-triazol-l-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c] azepine-5-carbonyl]-5-[(4S)-2.2-dimethyitetrahydropyran-4-yl]indo3-l-y]]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazoI-5-one;2-[(4S)-5-[5-|(4S)-2,2-dimethyltetraliydropyran-4-yl]-l-[(l S,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-2-ium- 5-yl)-2-methyl-propanamide;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-y1]-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidine]-5-carbonyl]-5-tetrahydropyran-4-yl-indol-l-yl]-2-methyl-cyclopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-y3]-2-[(4S)-4-ethyl-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4,6,7,8-tetraliydropyrazolo[4,3-c]azepin-l-ium-5-carbonyl]indol-l-yl]-2-methyi-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[5-(2,2-dimethyltetrahydropyran-4-yl)-2-[(4S)-2-(4-fluoro-3,5-diniethyl-pheny!)-3-[l-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-pyrrolidin-3-yl]-4-methyl- 6.7-dihydro-4H-pyrazolo|4,3-c]pyridin-l-ium-5-carbonyl]mdol-l-yl]-2-methyl-cy clopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS,2S)-I-[5-(2,2-dimethyltetrahydropyran-4-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l-(4-fluoro-l-methyl-indazol-5-yi)-2-oxo-pyrrolidin-3-yl]-4-methyl- 6.7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-5-carbonyl]indol-l-yl|-2-methyl-cyc1opropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[2-[2-(cyclopropoxy)-4-pyridyl]-3-oxo-pyridazin-4-yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-6,7-dihydro-4H-pyrazolo 4,3-c]pyridine-5-carbonyl]-5-[(4S)-2,2-dimethyItetrahydropyran-4-yl]indol-i-y]]-2-methyl-cyclopropyl]-4H-l,2,4-oxadi azol-5 -one;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyi-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4-methyI-2-[5-(trif!uoroinethy])-3-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-f!uoro-l -methyl-indazol-5-yl)propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyi-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-4-methyl-2-[5-(trifluoromethyl)-3-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)propan amide:N-(4-fluoro-l-methyl-indazol-5-yl)-2-[(4S)-4.7,7-trimethyl-5-[5-[(2S)-2-methy lmorpholin-4-yl] - 1 - [(I S,2S)-2-methyl- 1 -(5 -oxo-4H- 1,2,4-oxadiazol-3 -yl)cy clopropyl]indole-2-carbonyI]-2-[5-(trifluoromethyl)pyridin-l-ium-3-yl ]-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]propanamide;N-(4-fluoro-l-methyl-indazol-5-yl)-2-[(4S)-4.7.7-trimethyl-5-[5-[(2S)-2-methyImorpholin-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-L2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-[5-(trifluoromethyl)pyridin-l-ium-3-yl]-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]propanamide;1-[(4S)- -[5-[(4S)-2,2-dimelhylteirahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indoIe-2-carbonyi]-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-l '-(2?2,2-trifluoroethyl)spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-l -ium] -3-y 1] -N -(4-fluoro- 1 -methyl-mdazol-5 -y l)cy clopropanecarboxamide;3-[(lS,2S)-l-[2-[(4S)-2-(5-cyclopropylpyri din- l-ium-3-yl)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-yl]-4-methyl-6.7-dihydro-4H-pyrazolo[4.3-c]pyridine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS,2S)-l-[2-|(4S)-3-[l-|4-(cyclopropoxy)cyclohexyl]-6-oxo-pyrimidin-5-yl]-2-(4-fluoro-3,5-dimelhyl-phenyl)-4-meth l-4,6,7 8-tetraliydropyrazolo[4,3-c]azepin-l -ium-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fIuoro-3,5-dimethyl-phenyl)-4.7,7-trimethyl-6,8-dihydro-4H-pyrazolo[4.3-c]azepin-l-ium-3-yl]-N-(4-fiuoro-l-methyl-indazol-5-yl)acetamide;l-[(4S)-r-(2,2-difluoroethyl)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(1 S,2S)-2-methy1-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indo1e-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)-4-metliyl-spiro[4,6-diliydropyrazolo[4.3-c]pyndme-7,3'-azeti din- l-ium]-3-yl]-N-(4-tluoro-l-methyl-indazol-5-yl)cy clopropanecarboxamide;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[2-(l -methylindazol-5-yl)-3-oxo-pyridazin-4-yl]spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,r-cyclopropane] -5-carbonyl]-5-[(2S)-2-methylmorpholm-4-ium-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[l-[2-(difluoromethyl)indazol-5-yl]-2-oxo-3-pyridyl]-2-(5-fluoro-4,6-dimethyl-py ri din- l-iom-2-yl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyri dine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]indoI-l-yl]-2-metbyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|2-(4-fluoro-l -methyl-indazol-5-yl)-3-oxo-pyridazin-4-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-5-[(2S)-2-methylmorpholin-4-ium-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one:3-[(lS,2S)-l-[5-(2,2-difluoromorpholin-4-ium-4-yl)-2-|(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-3-[l-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-3-pyridyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]mdoi-l-yl]-2-melhyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(l S,2S)-l-[2-[(4S)-2-(4-fluoro-,5-dimethyl-phenyl)-3-[l -(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-3-pyridyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridme-5-carbonyl] -5 -morpholin-4-ium-4-yl-indoI- 1 -yl] -2-methyl-cy clopropyl] -4H- 1,2, 4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l -(4-fluoro-l -methyl-indazol-5-yl)-6-oxo-pyrimidin-5-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyndine-5-carbonyl]-5-[(2S)-2-methylmorpholin-4-ium-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1.2.4-oxadiazol-5-one;3-[(lS?2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l -(4-fluoro-l -methyl-indazol-5-yl)-6-oxo-pyrimidin-5-yl]-4-niethyl-6,7-dihydro-4H-pyrazolo|4.3-c]pyridine-5-carbony l]-5-morpho!in-4-ium-4-yl -indol- 1-yl] -2-methyl-cy clopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[l-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-3-pyridyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-5-[(2S)-2-methylmorpholin-4-ium-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl- henyl)-4,7,7-tnmethyl-3-[l-(l-methylindazol-5-yl)-2-oxo-3-pyridyl]-4,6-dihydropyrazolo[4,3-c]pyridine-5-carbonyl]-5-[(2S)-2-methylmorpholin-4-ium-4-yl]indol-l -yl]-2-methyl-cy clopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS.2S)-l-[2-[(4S)-3-[l-[2-(cyclopropoxy)-4-pyridyl]-2-oxo-3-pyridyJ]-2-(5-fluoro-4,6-dimethyl-pyridm-l-ium-2-yl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyndine-5-carbonyl]-5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]mdol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one; and3-[(lS.2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[(lS,6S)-3-(4-fluoro-l-methyl-indazol-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl|-5-[(2S)-2-methylmorpholin-4-ium-4-yl]indol-l-yl]-2-methyl-cyclopropyl|-4H-l,2,4-oxadiazol-5-one?or a pharmaceutically acceptable salt thereof.

112. A compound selected from:2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-[(l S,2S)-2-methyl-l-(5-oxo- 4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4?3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-2-ium-5-yl)-2-methyl-propanamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2"Carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-3-yr|-2-fluoro-N-(l-methyl-6-isoquinolyl)propanamide:3-[(lS,2S)-l-[5-[(4S)-2.2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|3-fluoro-l-(4-fluoro-l-methyl-indazol-2-ium-5-yl)-2-oxo-pyrrolidin-3-yl]-4-methyl-6,7-d!hydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-1.2.4-oxadiazol-5-one:3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3.5-dimethyl-phenyl)-3-[3-fluoro-l-(4-fluoro-l-methyl-indaz.ol-2-ium-5-yl)-2-oxo-pyrrolidin-3-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbony1]indol-l-yl]-2-methyl-cyclopropyl]-4H-L2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2?2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethy1-phenyl)-3-[3-(4-fluoro-l-methy1-indazol-2-ium-5-y1)-2-oxo-3-azabicyclo[3, 1.0]hexan-l-yl]-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethy]tetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[3-(2-methylquinolin-l-ium-6-yl)-2-oxo-3-azabicyclo[3.1.0]hexan-l-yi]-6,7-dihydro-4H-pyrazoio[4,3-c]pyridine-5-carbonyi]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;2-[(4S)-2-(4-fluoro-3,5-dimethyl-plienyl)-4,7,7-trimethyl-5-[l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)-2-methyl-propananude;2-[(4S)-5-[5-|(4S)-2,2-dimethyltetraliydropyran-4-yl]-l-[(l S,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4.7.7-trimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)- 2-methyl-propanamide;3-[(lR,2S)-l-|5-(2;2-dimethyltetrahydropyran-4-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-y1]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-iuiii-5-carbonyl]phenyl]-2-methyl-cyclopropyl]-4H- l,2?4-oxadiazol-5-one;2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[2-[(lS,2S)-2 -methyl- 1 -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-(l,3,7-trimethylmdazoI-6-yi)pyrazole-3-carbonyl]- 6.7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazoi-5-yl)acetamide;N-( l-cyclopropyl-4-fluoro-indazoI-5-yl)-l- (4S)-5-[5-(3.3-dimethyl-2-oxo-indolin-5-yl)-2-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]pyrazole-3-carbonyI]-2-(4-fltJoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]cyclopropanecarboxamide;N-(l-cycIopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[2-[(lS,2S)-2-methyl-l-(5-oxo-4H-lf2.4-oxadiazol-3-yl)cyclopropyl]-5-[l -methyl- 3-(tnfluoromethyl)pyrazol-5-yl]pyrazole-3-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]cyclopropanecarboxamide;1 -[(4S)-5-[5-(l,7-dimelhylindazol-6-yl)-2-[(lS,2S)-2-methy1-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]pyrazole-3-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)-4-methyl-6T7-dihydro-4H-pyrazoio[4,3-c]pyridin-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)cyclopropanecarboxamide;N-(l -cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[5-[4-(3-methyloxetan-3-yl)phenyl]-2-[(lS?2S)-2-methyl-l-(5-oxo-4H- 1.2.4-oxadiazol-3-yl)cyclopropyl]pyrazole-3-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyri din-3-yl]cyclopropan ecarboxamide;l-[(4S)-5-[5-(l, 7-dimethylindazoi-6-yl )-2-[( IS.2S)-2-methyl-l-(5-oxo-4H- 1.2,4-oxadiazol-3-yl)cyclopropyl]pyrazole-3-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro|4,6-dihydropyrazolo[4,3-c]pyridine-7,r-cyclobutane]-3-yl]-N-(4-fluoro-l-methy I-indazol -5-y 1 )cy clopropanecarboxarnide;N-(l-cyclopropyl-4-fluoro-indazo1-5-yl)-l-[(4S)-5-[5-(1.7-dimethyIindazol-6-yl)-2-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]pyrazole-3-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]cy clopropanecarboxarnide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-5-[5-[4-(l -methoxy cyclobutyl)phenyl|-2-|(lS,2S)-2-methyl-l-(5-oxo-4H-l, 2, 4-oxadiazol-3-yl)cyclopropyl]pyrazole-3-carbonyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]cy clopropanecarboxarnide;3-[(lS,2S)-l-[5-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l -methyl-indazol-5-yl)-2-oxo-imidazol-l-yl|-4-methyl-6.7-dihydro-4H-pyrazolol4.3-c|pyridine-5-carbonyl]-3-(5-methyl-6-isoquinolyl)pyrazol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;5-[4-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-l-methyl-indazol-2-ium-5-yl)-2-oxo-inridazoI-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-5-carbonyl]-3-[(lR.2S)-l-(5-hydroxy-l,2,4-oxadiazole-2,4-diium-3-yl)-2-methyl-cydopropyl]phenyl]-3,3-dimethyl-indolin-2-one;N-(2,3-dimethyl-4-pyridyl)-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(1 S,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyI]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c] azepin-3-yl] acetamide;N-(l-cycIopropylindazol-5-yl)-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-o o-4H-l,2,4-oxadia ol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6.8-dihydro-4H-pyrazolo[4,3-c]azepin-l-ium-7,r-cyclopropane]-3-yl]acetamide;N-(l -cyclopropylindazol-2-ium-5-yl)-2-[(4S)-5-[5-[(4S)-2,2-dimethy1tetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]iiidole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4,7,7-trimethyl-6,8-dihydro-4H-pyrazoloj4,3-c]azepin-3-yl]acetamide;N-(l-cyclopropylindazol-5-yl)-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-1 -[(1 S,2S)-2-methyl- 1 -(5-0X0-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-pheny0-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7.r-cyclobutane] -3-yl] acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c]azepin-l-ium-7,r-cyclopropasie]-3-yl]-N-(4-fluoro- l-methyl-mdazol-5-yl)acetamide;2-[(4S)-5-[5-|(4S)-2,2-dimethyltetrahydropyran-4-yl]- ]-[(! S,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c]azepine-7,r-cyclopropane]-3-yl]-N-(l-methylisoquinolm-2-ium-6-yl)acetamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-[(l S,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-mdole-2-carbonyl]spiro[4,6-dihydropyrazolo[4,3-c]pyndine-7.1'-cyclobutane]-3-yl]acetamide;N-(4,6-difluoro-l-methyl-indazol-5-yl)-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-5-[l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetraliydropyran-4-yl-indole-2-carbonyl]spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,r-cy cl obutane] -3-yl] acetamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS.2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl|-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,r-cyclobulane]-3-yl] acetamide;N-(4?6-difluoro-l-methyl-indazol-5-yl)-2-[(4S)-5-[5-[(4S)-2.2-dimethyltetrahydropyran-4-yl]-l-|(lS,2S)-2-methyl-l-(5-oxo-4H-l,2:4-oxadiazol- -yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c]az.epin-l-ium-7,r-cyclopropane]-3-yl] acetamide:2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2T4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c]azep e-7,r-cycloproparie]-3-yi]-N-(3-methyli soquinolin-2-ium-6-yi)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[6,8-dihydro-4H-pyrazolo[4,3-c]azepine-7,r-cyclopropane]-3-yl]-N-(2-methylquinolin-l-ium-6-yl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S.2S)-2-methyi-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyl]-2-(4-fluoro-3.5-dimethyl-phenyl)-4,7,7-trimethyl-6,8-dihydro-4H-pyrazolo[4,3-c|azepin-l-ium-3-yT|-N-(4-fluoro-l-methyl-indazol-5-yl)acetamide;3-[(lS.2S)-l-[2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-3-[3-(l-methylisoquinolin-2-ium-6-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl|-5-[(2S)-2-methylmorpholin-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H- 1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(7-fluoro-l-methyl-isoquinolin-2-ium-6-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cycIopropyl]-4H-l.,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimelhylteirahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-|3-(5-fluoro-l-methyl-isoquinolin-2-ium-6-yl)-2-oxo-3-azabicyclo[4, 1.0]heptan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4, -c]pyridine-5-carbonyl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(7-fluoro-2-methyl-quinolin-l-ium-6-yl)-2-oxo-3-azabicyclo[4.1,0]heptan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbony l]indol- 1 -yl] -2-methy 1-cy clopropy 1] -4H- 1,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[2-|(4S)-3-|3-(l-cyclopropyl-4-fluoro-indazol-2-ium-5-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-inethyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-5-[(4S)-2.2-dimethyltetrahydropyran-4-yl]indol-l-yl]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-3-[(l S,6S)-3-(4-hydroxycyclohexyl)-2-oxo-3-azabicyclo[4.1.0]heplan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]mdol-l-yl]-2-methyl-cy clopropy l]-4H-l,2,4-oxadiazol-5-one;3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(6-fluoro-l-methyl-indazol-2-ium-5-yl)-2-oxo-3-azabicyclo[4J.0]heptan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbony l]indol-l-yl] -2-methyl-cy clopropy 1J-4H-1, 2, 4-oxadiaz.ol-5-one;3-[(lS,2S)-l-[2-[(4S)-3-[(lS,6S)-3-[4-(cyclopropoxy)cyclohexyl]-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyi]-5-[(4S)-2.2-dimethyltetrahydropyran-4-yl]indol-l-yi]-2-methyl-cyclopropyl]-4H-l,2,4-oxadiazol-5-oneN-(4-chloro-l-methyl-indazol-5-yl)-l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyi]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl]cyclopropanecarboxamide;l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l -[(IS, 2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,l'-cyclobutane]-3-yl]-N-(l-methylisoquinolin-2-ium-6-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(6-fluoro-l-methyl-indazol- 5-yl)cyclopropanecarboxaniide;l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c|pyridin-l-ium-3-yl]-N-(6-fluoro-l-methyl-indazol-5-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methy[-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-N-(5,6,7,8-tetrahydroisoquinolin-2-i u rn-7-y 1 )cy cl opropanecarboxami de;N-(4,6-difluoro-l-methyl-indazol-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[l-|(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-y 1] cy cl opropanecarboxamid e;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydiopyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridm-3-yl]-N-(5,6,7,8-tetrahydroisoquinolin-2-ium-7-yl)cycl opropanecarboxami de;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-5-[5-[(4S)-2,2-dimethylietrahydropyran-4-yi]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropy]]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyI-6.7-dihydro-4H-pyrazolo[4,3-c]pyridin-l-ium-3-yl] cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-y 1]-1-[(1 S.2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]mdole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo|4,3-c]pyridin-3-yl]-N-(2-methylquinolin-l-ium-6-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4.7.7-trimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(l-methylindazol-5-yl)cyclopropanecarboxamide;l-[(4S)-2-(4-fluoro-3.5-dimethyl-phenyl)-4-metliyl-5-[l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-tetrahydropyran-4-yl-indole-2-carbonyl]spiro[4,6-dihydropyrazolo[4,3-c]pyridin-l-iuni-7 '-cyclobutane]-3-yl]-N-(l-inethylindazol-5-yl)cyclopropanecarboxamide;N-(4,6-difluoro-l-melhyl-indazol-5-yl)-l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS.2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indol e-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-tetrahydropyrazolo[4,3-c]azepin-l-ium-3-yl] cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4.7.7-trimethyl-46-dihydropyrazolo[4,3-c]pyridin-l-ium-3-yl]-N-(4-fluoro-l -methyl-indazol-5-yl)cyclopropanecarboxamide;l-[(4S)-5-[5-|(4S)-2,2-dimetliyltetrahydropyran-4-yl]-l-|(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7.8-tetrahydropyrazolo[4,3-c]azepin-l-ium-3-yl]-N-(7-fluoro-2-methyl-indazol-5-yl)cyclopropanecarboxamide;N-(4,6-difluoro-l- ethyl-indazol-5-yl)-l-[(4S)-5-[5-[(4S)-2.2-dimethyltetrahydropyran-4-yl]S,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyr)-4-methyl-6.7-dihydro-4H-pyrazolo|4,3-c]pyri din- l-ium-3-yl] cyclopropanecarboxamide;l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(] S,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridin-l-ium-7,r-cyclobutane]-3-yl]-N-(4-fluoro-l-methyl-indazol-5-yl)cyclopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-5-[2-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]-5-(4-morpholinophenyl)pyrazole-3-carbonyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]cy clopropanecarboxamide;N-(4-chloro-l-niethyl-indazol-5-yl)-l-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS.2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)c clopropyl]indole-2-carbonyi]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-4,6,7,8-teirahydropyrazolo[4,3-c] azepin- l-ium-3-yl] cyclopropanecarboxamide;1-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-4-methyl-5-|5-[(2S)-2-methylmorpholin-4-yl]-l-[(l S,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indoIe-2-carbonyl]spiro[4,6-dihydropyrazolo[4.3-c]pyridine-7,r-cyclobutane]-3-yl]-N-(l-methyiisoquinolm-2-ium-6-yl)cy clopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazol-2-ium-5-yl)-2-[(4S)-5-[5-|(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(l S,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-nuoro-3,5-dimethyl-phenyl)-4,7,7-trimethyl-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-2-hydroxy-propanamide;2-cycIopropyI-2-[(4S)- -[5-[(4S)-2,2-dimethy]tetrahydropyran-4-yl]-I-[(lS,2S)-2-methyI-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]-2-fluoro-N-(l-methyIindaz.ol-5-yl)acetamide;1-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-r-[(l-methylcyclopropyl)methyl|spiro|4,6-dihydropyrazolo[4,3-c]pyridine-7,3'-azetidin-l-iuni]-3-yl] -N-(4-fluoro-l-methyI-indazol-5-yl)cyclopropanecarboxamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,r-cyclobutane]-3-yl]-N-(5-fluoro-l-metbyI-6-isoquinolyl)acetamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-5-[4-(3.3-dimethyI-2-oxo-indolin-5-yl)-2-| (1 R,2S)-2-methyl-l-(5-oxo-4H-l,2?4-oxadiazol-3-yl)cy cl opropyl] benzoyl | -2-(4-fluoro-3,5-dimethyl-phenyl)-4-niethyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-y 1 ] cy clopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-mdazol-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-5-[4-isochroman-6-yl-2-[(lR,2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cyclopropyl]benzoyl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]cy clopropanecarboxamide;N-(l-cyclopropyl-4-fluoro-indazol-5-yl)-l-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-5-[4-(6-isoquinolyl)-2-[(lR,2S)-2-methyl-l-(5-oxo-4H-1.2,4-oxadiazol-3-yl)cy clopropyl] benzoyl] -4-methyl-6.7-dihydro-4H-pyrazolo| 4, 3-c|pyridin-3-yl]cyclopropanecarboxamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spiro[4,6-dihydropyrazolo[4,3-c]pyridine-7,l'-cyclobutane]-3-yl]-N-(7-fluoro-l-methyl-6-isoquinolyl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)- 4.7.7-trimethyI-4,6-dihydropyrazolo|4,3-c]pyridin-3-yl]-N-(5-fluoro-2-methyi-6-quinolyljacetamide;2-[(4S)-5-[5-[(4S)-2,2-dimelhyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyij-2-(4-fluoro-3.5-dimethyl-phenyl)- 4.7.7-trimethyi-4,6-dihydropyrazolo[4,3-c]pyridin-3-yl]-N-(5-fluoro-l -methyl-6-isoquinolyl)acetamide;2-[(4S)-5-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-l-[(lS,2S)-2-methyl-l-(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-spjro[4,6-dihydropyrazolo[4,3-c]pyridine-7,r-cyclobutane]-3-yl]-N-(5-fluoro-2-methy 1 -6 - qum oly 1) ac etami de;l-[(4S)-5-[5-|(4S)-2,2-dimetliyltetrahydropyran-4-yl]-l-|(lS,2S)-2-methyl-l -(5-oxo-4H-l,2,4-oxadiazol-3-yl)cyclopropyl]indole-2-carbonyl]-2-(4-fluoro-3,5-dimethyl-phenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4.3-c]pyridin-3-yl]-N-(5-fluoro-2-methyl-quinohn-l-ium-6-yl)cyclopropanecarboxamide; and3-[(lS,2S)-l-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyI)-3-[3-(5-fluoro-2-methyl-quinolin-I-ium-6-yl)-2-oxo-3-azabicyclo[4.1.0]heptan-l-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one,or a pharmaceutically acceptable salt thereof.

113. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 112, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

114. A method for treating obesity or non-insulin-dependent di betes mellitus (Type 2 diabetes) which comprises administering to a subject in need of such treatment (i) a therapeutically effective amount of a compound according to any one of claims 1 to 112, or a pharmaceutically acceptable salt thereof, or (ii ) a pharmaceutical composition according to cl aim 113.

115. Use of a compound according to any one of claims 1 to 112, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating obesity or non-insulm-dependent diabetes mellitus (Type 2 diabetes).

Images